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ABSTRACT
Angiogenesis is the process of generating new blood microvessels. In adults,
angiogenesis is fundamental to tumor biology and also to tissues rendered ischemic from
vascular occlusion. Despite a promising appeal, strategies designed to simulate or
otherwise modify the angiogenic process in adult tissues have yet to realize significant
therapeutic potential. Importantly, understanding the structure and function of new
microvascular networks formed in adult, diseased tissues is limited. In fact, it remains
unknown if a new or regenerated microcirculation can effectively deliver oxygen to the
tissue. The purpose of this thesis was to seek out novel determinants of functional
angiogenesis and microvascular regeneration.
Using a novel real-time microscopy strategy for imaging red blood cells (RBCs), I
interrogated microcirculatory architecture and perfusion in mouse renal cell carcinomas. I
found that the tumor microvasculature was devoid of hierarchy, microvessel
specification, and vasoreactivity. Furthermore, I found that fibroblast growth factor 9 can
productively reconfigure the tumor microvasculature into a hierarchical network of
arteriole-capillary-venular units, with vasomotor competence. Together, these findings
revealed important microvascular abnormalities in tumors and established that attainment
of a physiologically advanced microcirculation in tumors is achievable.
I next interrogated the structure and function of the regenerated microvasculature
that forms in skeletal muscle following ischemic injury. I discovered that despite
extensive angiogenesis, there are profound flaws in microvascular network geometry,
hierarchy, RBC transit, flow control by hypoxia, and smooth muscle cell wrapping
around arterioles. Thus, the neo-microvasculature in regenerated skeletal muscle does not
recapitulate the anatomy and physiology of a normal microvasculature and is ineffective
at controlling the delivery of oxygen.
Finally, I examined the early-stage events by which new microvascular networks
form following skeletal muscle infarction. I discovered that vascular regeneration entails
the abrupt appearance of metastable primordial microvessels with ultra-low blood flow. I
ii

further discovered that primordial microvessels rapidly transform into an extensive
microvasculature via intraluminal endothelial cell protrusion and intussusceptive
angiogenesis. This non-sprouting angiogenesis cascade was determined by differential
endothelial cell VEGFR2 activation.
In summary, this thesis provides novel insights into adult angiogenesis and the
workings of microvascular systems that have been injured by disease. These findings
have relevance to strategies for restoring oxygen content in pathological tissues.

Keywords: angiogenesis, microcirculation, ischemia, intravital microscopy, skeletal
muscle, cancer, microcirculatory function, endothelial cell, VEGFR2, intussusceptive
angiogenesis
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CHAPTER 1
General Introduction
Critical limb ischemia and myocardial infarction are major causes of morbidity
and mortality. This is despite substantial advances in medical and surgical therapy for
vascular diseases. Accordingly, there has been considerable interest in capitalizing on the
natural, biological processes that underlie the formation of new blood vessels. Blood
vessel formation has been extensively studied in the context of embryogenesis and organ
development. However, new blood vessels can also be stimulated to form in adult tissues.
This can occur in response to hypoxia, and as part of the repair and regeneration of
damaged tissues.
The neovascularization response to ischemic injury includes the process of
angiogenesis, whereby new microvessels form from pre-existing vessels within the tissue
(Carmeliet, 2000). Angiogenesis can be stimulated by exogenous factors and,
accordingly, there has been extensive effort to therapeutically enhance the process in
ischemic tissues. However, although “therapeutic angiogenesis” strategies have appeared
promising in animal models, carefully performed human studies have shown no benefit to
the patient in terms of improving perfusion (Annex, 2013, Simons et al., 2003, Tongers et
al., 2008).
For a new vascular network to function it must have the ability to exquisitely
control blood flow and oxygen delivery in order to meet the local tissue needs, needs that
vary in space and time. This matching process requires the formation of a hierarchical
microvascular network, with vasoreactive arterioles, capillaries with single-file red blood
cell transit, and draining venules. Whether such a network forms during angiogenesis in
ischemic tissues is currently unknown. Moreover, the pathways by which a microvascular
network forms in ischemic tissue in the adult are poorly understood.
A central premise of my thesis is that current understanding of adult angiogenesis
is compromised by a lack of tools to investigate the regenerated microcirculation at a
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network level, and with the required spatial and temporal resolution. Accordingly, the
broad goals of my thesis were to develop strategies to interrogate the process of
angiogenesis in adult tissues at a network level, and to utilize these strategies to
determine i) the physiological attributes of a regenerated microcirculation, and ii) the
steps by which that microvasculature forms.
To address these overarching goals, I have studied angiogenesis in two adult
tissue environments: tumors and ischemic skeletal muscle.
My specific objectives were:
1. To develop high-resolution, real-time intravital microscopy-based strategies to
elucidate the architecture and function of a newly formed microcirculation in
diseased tissue, specifically renal tumors and injured skeletal muscle.
2. To determine the extent to which the architecture and function of the
regenerated microcirculation in the mouse hindlimb recapitulates that of the
normal muscle microcirculation.
3. To determine the architectural and cellular processes by which the early
vascular network forms in regenerating skeletal muscle following ischemic
injury.

1.1
1.1.1

Human Cardiovascular Disease
Ischemic Cardiovascular Disease
One of the greatest burdens of human disease and mortality globally is

cardiovascular disease (Yusuf et al., 2001). Particularly devastating are the
cardiovascular diseases that involve the narrowing or blockage of arterial vessels. This is
because they can diminish or prevent blood flow into organs, which causes ischemic
tissue injury and necrosis. This is manifested in human diseases including, but not limited
to, atherosclerosis, peripheral arterial disease, coronary artery disease, hypertension, and
stroke.
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Feeder arteries are a particularly vulnerable component of the vasculature, and are
the major type of vessel within the vascular tree affected by these diseases. Because of
this, intensive preclinical research and human studies have been ongoing for decades, in
order to unravel the cellular mechanisms regulating arterial health, disease, and repair.
However, to successfully combat the clinical burden imparted by ischemic cardiovascular
disease, the advancement of existing therapies and the development of new therapeutic
strategies are required.
1.1.2

Peripheral Arterial Disease
Peripheral arterial disease (PAD), also known as peripheral vascular disease, is an

ischemic cardiovascular disease affecting the legs, arms, and neck. PAD is caused by the
development of systemic atherosclerosis. Atherosclerosis results in the narrowing and
occlusion of feeder artery lumens, and restricts the supply of blood flow to the
extremities (Annex, 2013). Restriction of blood flow induces ischemic injury in tissues
downstream of the obstruction. In severe cases, total arterial blockage will result in
marked tissue hypoxia and necrosis.
PAD is an important global health problem being the third leading cause of
cardiovascular mortality, after coronary artery disease and stroke (Fowkes et al., 2013).
The prevalence of PAD increases with age, affecting up to 20% of individuals over 70
years of age (Roger et al., 2011). Patients with diabetes are at a higher risk of developing
PAD, and other causative risk factors for the development of PAD include hypertension,
hypercholesterolemia, obesity, and smoking (Roger et al., 2011). The clinical
manifestations of PAD include impaired limb function and reduced quality of life, as a
consequence of reduced blood flow to the legs at rest or during exercise (Hankey et al.,
2006).
Critical limb ischemia (CLI) is the most severe form of PAD. This is associated
with pain at rest and can also be associated with skin ulcers and gangrene. Patients with
CLI have a 25-40% risk of limb amputation and an annual mortality rate of 20% (Roger
et al., 2011).
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Peripheral human limbs are comprised mainly of skeletal muscle and thus muscle
tissue is the most affected organ in PAD. Skeletal muscle is a metabolically active tissue
composed of tightly arranged myofiber bundles that generate longitudinal contraction
(Bach et al., 2004). As skeletal muscle requires a large amount of blood flow during both
rest and exercise to support its metabolic activity, it is particularly vulnerable to ischemic
injury and necrosis following arterial occlusion (Hurme et al., 1991). PAD restricts blood
flow into expansive capillary networks embedded within skeletal muscle, and reduces
tissue oxygen content.

1.2
1.2.1

The Microcirculation
Role of the Microcirculation
The microcirculation contains the smallest blood vessels within the cardiovascular

system, ranging from 5 µm to ~150-200 µm in diameter (Levy et al., 2001). The main
role of the microcirculation is to transport oxygen (O2) and nutrients to every living cell
of an organism through a series of interconnected tubes (Pries et al., 1995, Segal, 2005).
The microcirculation is a highly organized tree-like network of arteries, arterioles,
capillaries, venules, and veins. These microvessels are structurally arranged to optimize
O2 transport within a given organ.
Arteries and arterioles have a straight and slender morphology and are blood flow
feeder channels. They control systemic vascular resistance and regulate the magnitude of
O2-rich blood flow into downstream capillaries (Segal, 2005). Capillaries are the smallest
microvessels wherein RBCs transit in single file. Moreover, capillaries are the site of
effective O2 exchange from RBCs into the surrounding tissue, and are interconnected in
distinct meshwork patterns that are specific to the host organ. Venules and veins are
irregular-shaped and dilated channels with low blood pressure. They drain RBCs that
have flowed through capillaries and have delivered their O2 and return the RBCs to the
heart and lungs for reoxygenation.
A functional microcirculation must exert dynamic control over tissue
oxygenation, despite the short diffusion distance of O2 from the blood into surrounding
cells (Ellis et al., 2005). For this to occur, the microvasculature must be highly responsive
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to dynamic changes in metabolic demand and adjust blood flow accordingly (Segal,
2005). This is crucial for preventing ischemia in tissues such as skeletal or cardiac muscle
that have high metabolic requirements. If a microvasculature is dysfunctional and has an
impaired ability to control flow, the tissue is rendered hypoxic as a result of a
maldistribution of blood flow and O2 delivery (Ellis et al., 2005). This is a consequence
of diminished arterial vessel tone regulation via impaired communication between
different segments of the microvascular tree (Segal, 2005, Ellis et al., 2005).
1.2.2

Cellular Anatomy of the Microcirculation

1.2.2.1 Arteries and Arterioles
The healthy artery in humans and mice is characterized by a three-layer
multicellular arrangement (Lusis, 2000, Balint et al., 2015). The innermost layer is called
the intima and is comprised of endothelium that makes direct contact with blood. The
intima is separated from the second layer – the media, by a sheet of elastin fibers called
the internal elastic lamina. The media is composed of one or more collectivized layers of
vascular smooth muscle cells (SMCs), which contain contractile machinery and regulate
vessel tone (Balint et al., 2015). The adventitial layer is the third and outermost layer and
is comprised of loosely layered collagen, fibroblasts, immune cells, scattered SMCs, and
progenitor cells (Passman et al., 2008). Small arteries and arterioles, including terminal or
precapillary arterioles, are characterized by a two-layer arrangement. They are comprised
of a monolayer of endothelial cells (ECs) that is tightly wrapped by one or two layers of
SMCs (Figure 1.1)
The endothelium lines every blood vessel, not just arteries, and is composed
exclusively of a monolayer of ECs (Sumpio et al., 2002, Ross, 1993) (Figure 1.1). ECs
arise from a primordial vasculature that invades a developing organ in the embryo. ECs
sustain normal microcirculatory function. This includes modulating vascular tone,
controlling vessel permeability, and controlling immune responses by regulating the
adherence of monocytes, platelets, and leukocytes to the inner vessel wall (Sumpio et al.,
2002). The endothelium is also a paracrine and endocrine organ that influences the
activity of ECs, perivascular cells, and circulating blood cells (Sumpio et al., 2002). ECs
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Figure 1.1 Anatomy of the microcirculation
The microcirculation is comprised of a network of arteries, arterioles, capillaries,
venules, and veins. Illustrated in this schematic is the cellular composition of the different
vessel types in the microcirculation. Arteries are comprised of endothelial-lined channels
that are fully wrapped by circumferential SMCs. As arteries branch into smaller arterioles
and precapillary or terminal arterioles, the endothelium remains wrapped by SMCs but
the wrapping orientation is altered. SMCs extend more longitudinally along the vessel
and individual SMC processes circumferentially wrap the vessel. Capillaries are mainly
comprised of ECs with scattered wrapping pericytes. Venules and veins are the largest
endothelial tubes within the microcirculation and are invested by SMCs in a patchworklike pattern.
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form powerful adhesions with their neighbours with VE-Cadherin adherens junctions and
tight junctions, in order to maintain vessel stability and form a tight barrier (Li et al.,
2012). In disease or following injury, the EC monolayer becomes perturbed and the
contact between neighbouring ECs is weakened.
SMCs and SMC processes circumferentially wrap the endothelium in arterial
vessels (Figure 1.1). A circumferential arrangement provides structural integrity to the
vessel, and allows SMCs to effectively constrict and relax in a coordinated manner to
regulate vessel diameter (Clark et al., 1985). The embryological origins of SMCs vary
depending on vessel size and location, but SMCs within the microvasculature appear to
be derived locally within the organ parenchyma (Majesky, 2007). As a result, SMCs in
different arteries may respond differently and have a spectrum of phenotypes. SMCs are
identified by their expression of SM-α-actin and SM myosin heavy chain, among other
markers (Owens et al., 2004). In some tissues such as bone, SMCs can express SM-αactin and also the pericyte cell marker neural glial antigen 2 (NG2) (Kusumbe et al.,
2016).
Although the circumferential wrapping pattern of SMCs is intrinsic to healthy
arteries, SMCs can adopt specific orientations depending on their position within the
arterial tree (Hill et al., 2015). There is a shift in SMC wrapping orientation from fully
circumferential in arteries, to more parallel and spanning longer distances longitudinally
as the vessel size decreases in arterioles near capillaries. However both orientations
envelop the entire vessel circumference (Hill et al., 2015). In contrast to healthy arteries,
disordered SMC wrapping arrangements characterize diseased arteries (Gown et al.,
1986, Pickering et al., 1996). Furthermore, vasomotor competency and EC survival in
arteries is not possible without the circumferential wrapping of ECs with SMCs (Hill et
al., 2015).
1.2.2.2 Capillaries
Capillaries are 3-7 µm-diameter microvessels (Birbrair et al., 2014). They are
positioned between arterioles and venules and have the thinnest walls of any vessel in the
circulatory tree. Capillaries are comprised mainly of ECs, with scattered wrapping
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pericyte cells (Birbrair et al., 2014) (Figure 1.1). ECs within capillaries are elongated and
aligned to the direction of flow, and are positioned in series along the length of the
microvessels. Most capillaries are completely continuous with tightly joined ECs,
however some specialized capillaries contain fenestrations between ECs that enable a
high level of vascular permeability.
Pericytes have recently become recognized as widespread components of the
microvascular cellular architecture. By definition, they have short and thin cellular
processes that project for hundreds of microns longitudinally and orthogonally to the
vessel, but rarely wrap the entire vessel circumference (Hill et al., 2015). They make
direct physical contact with ECs via longitudinal cytoplasmic processes that penetrate the
EC basement membrane. Their abundance of coverage on the abluminal side of the
capillary endothelium ranges from 10-50% depending on the organ (Armulik et al.,
2005). In skeletal muscle, the pericyte to EC ratio has been estimated to be approximately
1:100, whereas in the retina the ratio is closer to 1:1 (Shepro et al., 1993).
Pericytes play critical roles in capillary development, stabilization, maturation,
and remodeling (Armulik et al., 2005). Pericytes have been shown to have progenitor-like
properties by having the ability to give rise to a variety of mesenchymal cell types
(Farrington-Rock et al., 2004, Dellavalle et al., 2007, Brachvogel et al., 2005). Pericytes
are also important for the tissue repair process and have been shown to participate in
skeletal muscle regeneration and myogenesis (Birbrair et al., 2013). However, very little
is known about their function in the skeletal muscle microcirculation. Pericytes are
distinguished from other perivascular cell types by their expression of NG2, plateletderived growth factor receptor β (PDGFRβ), desmin, and sometimes SM-α-actin
(Lindblom et al., 2003). The fact that they express contractile elements including SM-αactin indicates that they may be involved in regulating vessel tone. However, there is a
substantial amount of controversy surrounding this idea. Recently, it was demonstrated in
the brain microvasculature that pericytes do not regulate vessel diameter and blood flow
(Hill et al., 2015). Whether this is the case for all microvascular beds has not fully been
elucidated. This is partially because the distinction between pericyte and SMC
morphology, surface markers, and location is not absolute. There is a continuum of
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phenotypes ranging from the classical description of SMCs to that of pericytes,
distributed along the entire vascular tree (Armulik et al., 2005, Herman et al., 1985).
1.2.2.3 Venules and Veins
Venules and veins are endothelium-lined conductance channels covered by
pericytes and SMCs (Holley et al., 1983, Baumann et al., 1981). However, the SMC
wrapping of venous vessels is less extensive and ordered compared to that in arterial
vessels. The SMC wrapping pattern is circumferential and band-like, but individual cells
cover larger surface areas of the vessel and exhibit a looser patchwork-like appearance
(Hill et al., 2015) (Figure 1.1). While arteries and arterioles regularly dilate and contract,
venules and small veins rarely change their diameter. Moreover, extensive distension of
veins is a pathological feature of a diseased microvasculature (Raffetto et al., 2007)
1.2.3

Network Architecture and Hierarchy
The architecture of a microvascular network refers to the organization and

patterning of individual microvessel segments within a tree-like arrangement. Normal
network architecture is exquisitely organized in an artery-arteriole-capillary-venule-vein
vessel hierarchy (Arpino et al., 2017) (Figure 1.1). A hierarchical architecture is essential
for optimizing O2 delivery to tissues.
The architecture of a microvascular network is pre-determined by genetic factors
at birth and renders organ-specific patterns (Pries et al., 1995, Jones et al., 2006).
Following the initial development of network architecture, further modification to
network branching patterns and vessel caliber is induced by hemodynamic factors and
local environmental signals (Pries et al., 1995, Jones et al., 2006).
Capillaries must be positioned between terminal arterioles and postcapillary
venules in order to optimize O2 delivery. Moreover, capillaries must be properly
interconnected and dispersed in order to optimize the distribution of oxygenated RBCs
from terminal arterioles into downstream individual capillaries (Ellis et al., 1994, Less et
al., 1991, Pries et al., 1989). This also permits an intrinsic and diverse heterogeneity of
RBC perfusion throughout individual capillaries that are fed by the same arteriole, which
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is fundamental for tightly matching the delivery and distribution of blood flow to the
localized requirements of tissues (Duling et al., 1987, Ellis et al., 1994).
1.2.3.1 Network Architecture in Skeletal Muscle
The skeletal muscle microvasculature is one of the most elegant examples of a
normal and highly organized network architecture (Ellis et al., 1994, Arpino et al., 2017).
Feeder arteries penetrate deep within the tissue, and arterioles and terminal arterioles
symmetrically branch off from feeders at regular intervals and in orthogonal orientations
to the muscle fibers. Each terminal arteriole branches into and supplies a dense meshwork
of capillaries. Capillaries in skeletal muscle are aligned parallel to the muscle fibers and
are 4 - 6 µm in diameter (Baum et al., 2013). They course for approximately 0.5 – 1 mm
in length between individual muscle fibers, with many anastomoses between parallel
segments (Emerson et al., 1997). Postcapillary venules are positioned between two
terminal arterioles and collect blood from the parallel capillary beds. They dive into the
tissue and drain blood into larger veins positioned deeper within the muscle.
In mouse skeletal muscle, the most distal arterioles (7-20 µm in diameter) have a
single layer of circumferentially oriented SMCs, with some discontinuity in wrapping
along the vessel length in the form of spaces between individual cells and processes
(Holley et al., 1983). The entire SMC body spirals around the circumference of the vessel
in 1-2 turns in larger caliber arterioles (Figure 1.1). However, in precapillary arterioles,
SMCs extend over a longer distance with the nucleus oriented to the long axis of the
vessel, and individual cell processes circumferentially wrap the vessel (Holley et al.,
1983) (Figure 1.1).
In 1919, August Krogh first described the significance of the strategic positioning
of capillaries between individual muscle fibers - to maximize the effectiveness of O2
delivery (Krogh, 1919). He generated a mathematical model that proposed that each
capillary supplies O2 to a cylindrical volume of tissue surrounding the vessel segment.
Furthermore, the model demonstrated that simply delivering O2 in bulk to an organ is
ineffective, and that O2 must be distributed properly within the tissue to minimize O2-free
zones. Krogh’s model highlights the impact of gas diffusion limitations on tissue
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oxygenation, and explains why the density of capillaries is elevated in tissues with high
O2 demand and consumption such as skeletal muscle.
Because of these physical principles, capillaries are widely distributed through the
muscle tissue volume and every skeletal myocyte must be less than ~25 µm from a
capillary O2 supply (Ellis et al., 2012). Moreover, aerobic slow-twitch muscle fibers are
surrounded by more capillaries compared to anaerobic fast-twitch muscle fibers (Kusters
et al., 2016). It has recently been shown that capillaries are embedded within grooves of
muscle fibers in order to maximize the contact surface area between myocytes and
capillaries, and that mitochondria line these grooves in order to minimize the O2 diffusion
distance (Glancy et al., 2014).
1.2.3.2 Network Architecture in Tumors
Like all solid organs, tumors that have reached a threshold size will have their
own microvasculature. However, the microvascular network architecture in tumors is
abnormal and highly disordered. Tumor vessels are seemingly oriented at random within
the tissue, and network branching patterns are haphazard (Yin et al., 2015). The diameter
of the channels in tumors is notably wider than that of normal microvessels (Tong et al.,
2004, Less et al., 1991). Moreover, there are avascular and poorly vascularized regions
scattered throughout tumors.
An organized microvascular network architecture is largely missing in the tumor
vasculature (Yin et al., 2015). Instead, the network is characterized by disordered loops
and meshworks (Tong et al., 2004, Jain, 1988, Less et al., 1991). Both asymmetrical
arteriolar branching and supernumerary branching are also features of the disordered
tumor microvasculature (Fukumura et al., 2010, Less et al., 1991).
Tumor vessel walls are sparsely covered by pericytes and SMCs and the specific
wrapping orientation of these cells is not understood (Nagy et al., 2009, Fukumura et al.,
2010). Although growing tumours can surround and co-opt native arteries, the ability of
vessels within the tumor to respond to vasomotor signals and regulate vessel tone has not
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been identified. Together, these features of the aberrant tumor microvascular architecture
render a hypoxic tissue environment (Helmlinger et al., 1997, Yin et al., 2015).
1.2.4

Molecular Specification and Hierarchical Differentiation of Vessels
The physiologic specification of vessels into arteries, capillaries, and veins is

required for a vascular network to function properly. The endothelium does not consist of
a globally homogeneous EC population, but instead a variety of molecules and pathways
differentially mark the ECs that line arteries, capillaries, and veins. ECs express distinct
arterio-venous (AV)-specific surface markers and proteins depending on their home
vessel type and organ (Cines et al., 1998, Nunes et al., 2011).
In the embryo, distinct EC phenotypes contribute to the AV specification and
differentiation of vessels. Embryonic ECs express different AV-specific markers even
before the onset of a heartbeat or blood flow (Wang et al., 1998). This results in the
formation of a hierarchical microvascular tree that develops from a primitive capillary
plexus (Rocha et al., 2009). The first identified AV-specific markers were Ephrin-B2,
which is expressed only in arterial ECs, and its receptor EphB4, which is expressed only
in venous ECs (Wang et al., 1998). Since then, several pan-EC markers and specialized
AV markers have been identified.
Pan-EC markers that are expressed by the endothelium in all types of vessels
include cluster of differentiation 31 (CD31)/PECAM-1, VE-Cadherin, and vascular
endothelial growth factor receptor 2 (VEGFR2) (Simons et al., 2015). Von Willebrand
factor (vWF) is often considered to be a pan-EC marker but in fact is more strongly
expressed in the endothelium of large vessels compared to microvessels (Kumar et al.,
1987, Turner et al., 1987).
Arterial ECs specifically express the gap junction proteins Connexin-37 and
Connexin-40, the transcription factor Sox18, the vascular endothelial growth factor
(VEGF) co-receptor neuropilin-1 (NRP1), and EphrinB2 (Rocha et al., 2009). The
crosstalk between Ephrin-B2 expressed by arterial ECs, and EphB4 expressed by mural
cells is required for mural cell recruitment to arterial vessels (Korff et al., 2008). Venous
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ECs express neuropilin-2 (NRP2), vascular endothelial growth factor receptor 3
(VEGFR3), and EphB4 (Rocha et al., 2009).
Interestingly, capillary ECs express a mosaic of the aforementioned AV-specific
markers, depending on whether they are located at the arterial (upstream) or venous
(downstream) end of a capillary bed. In addition, Dll4 and Notch are expressed mainly in
capillary and arterial ECs (Shutter et al., 2000). Furthermore, the ECs in capillaries and
veins express endomucin, but endomucin is not expressed in ECs in arteries (dela Paz et
al., 2009). VEGFR2 is expressed more in the capillary ECs towards to the arterial end of
a microvascular network, whereas VEGFR3 is restricted in the capillary ECs towards the
venous end of the network (Rocha et al., 2009).
During adult neovascularization, AV specification is considerably plastic. ECs
can change phenotypes during the generation and differentiation of new microvessels and
microvascular networks (Nunes et al., 2011). This indicates that while AV specification
is pre-determined in the embryo, it can be influenced by environmental cues during active
vessel growth and remodeling.
Microvessels can also acquire organ-specific specialization in response to locally
derived signals. This results in specific morphological and function features of the
endothelium. In the intestine, liver, and kidney, capillaries contain small pore-like
openings, called fenestrations, which allow high local permeability and rapid exchange of
solutes between the blood and surrounding tissue (Stan et al., 2004). In contrast, in the
central nervous system, the ECs must form a tight barrier so that trans-endothelial
transport can be tightly regulated (Engelhardt, 2003).

1.3

Regulation of Blood Flow in the Microcirculation
The vascular tree does not act as an inert set of blood flow channels but, instead,

as an intricately coordinated vasomotor system that controls the magnitude and
distribution of blood flow into tissues as required (Segal, 2005). Vascular tone at the
arterial level determines blood pressure and flow magnitude, and represents the
interaction between the myogenic contraction of SMCs and the vasodilatory influence of
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ECs (Segal, 2005). Several control systems regulate vascular tone throughout the
circulation including neural impulses, circulating hormonal factors, local myogenic
responses, and retrograde conducted vascular signaling (Segal, 2005, Clifford, 2011).
In order to tightly match microvascular blood flow with local requirements,
vasomotor regulatory signals must be highly integrated throughout the entire
microvasculature (Duling et al., 1987, Segal et al., 1989, Segal, 2005). The endothelium
plays a pivotal role in this process. ECs integrate and conduct local chemical and
mechanical stimulatory cues throughout vessel walls via electrical communication
between ECs, and between ECs and SMCs (Segal et al., 1987, Segal et al., 1989, Dietrich
et al., 1992, Koller et al., 1991).
Intriguingly, skeletal muscle has the largest capacity of any organ to alter arterial
tone and microcirculatory blood flow, and can increase blood flow 100-fold as needed
(Thomas et al., 2004).
1.3.1 Flow-Mediated and Conducted Vasomotor Responses
One of the important mediators of vascular tone is blood flow. Muscle activity
stimulates an increase in blood flow and RBC velocity through arteries, which induces
the enlargement of the vessel diameter (Segal, 2005). Arterial vasodilation in response to
flow is mediated in part by the release of soluble vasodilatory agents such as nitric oxide
(NO) and prostacyclin from stimulated ECs (Clifford, 2011). These agents instruct SMCs
to relax, which locally decreases arterial tone and flow resistance. In turn, this increases
blood flow and transmural pressure in proximal feeder arteries. Proximal arteries then
consequently vasodilate and maintain the increased delivery of blood flow into distal
arteries where the response originated.
In addition, locally initiated vasomotor responses can be conducted to distant
arms of the arterial tree. This enables the vasculature to coordinate the magnitude and
distribution of blood flow between separate arterial branches within vascular networks at
the organ-level (Welsh et al., 1998). Moreover, conducted signaling determines whether
vasodilation or vasoconstriction prevails. At high levels of metabolic demand, the locus
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of regulating blood flow shifts from dilated terminal arterioles to upstream resistance
arteries in a process called conducted or ascending vasodilation (Hilton, 1959).
The mechanism controlling conducted vasomotor responses occurs via the spread
of electricity throughout the walls of blood vessels. This response can initiate in
capillaries and venules before spreading to arteries. The electrical signal originates in the
endothelium, wherein charged ions travel rapidly through gap junctions (Segal, 2005).
When endothelial cells are stimulated, they become hyperpolarized and internally release
Ca2+. Ca2+ spreads through gap junctions between neighbouring ECs and this promotes
the hyperpolarization of SMCs, via the production of hormones that stimulate SMC K+
efflux and relaxation. As well, the activation of K+ channels in ECs can hyperpolarize and
relax SMCs, via electrical coupling through heterocellular myoendothelial coupling
(Welsh et al., 1998, Emerson et al., 2000). An influx and spread of intracellular Ca2+ and
the activation of α–adrenoreceptors within SMCs mediates SMC contraction (Segal,
2005).
Therefore, electrical conduction through vascular cell gap junctions provides an
efficient and rapid pathway for coordinating vasomotor tone amongst different branching
orders of the arterial tree. Impaired endothelial conduction likely occurs in a variety of
diseases including diabetes and sepsis, which are associated with a compromised control
of vasomotor tone (Bateman et al., 2008, Frisbee, 2005).
1.3.2 Blood Flow Shear Stress and Mechanotransduction
For ECs to properly conduct and transmit vasomotor signals, they require an
intrinsic ability to directly sense blood flow. Specifically, ECs can sense blood flow shear
stress and transmit the signal to the cell interior (Ando et al., 2009, Traub et al., 1998,
Resnick et al., 2003). The transmission of blood flow shear stress forces into the EC
interior is known as mechanotransduction.
Shear stress is defined as the dragging frictional force imparted by blood on the
endothelium in the direction of flow (Al-Khazraji et al., 2016). Shear stress is the product
of blood viscosity and vessel wall shear rate, the latter being the tangential flow velocity
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gradient at the vessel wall (Al-Khazraji et al., 2016). Under normal conditions in large
arteries, blood flow has a parabolic velocity profile and the magnitude of shear stress
ranges from 10-40 dynes/cm2 (Traub et al., 1998).
The interplay between flow sensing and flow regulation is critical for maintaining
normal vascular function. Moreover, the proper alignment of ECs is critical for proper
EC function and regulation of vasomotor tone. The sensing of shear stress by the
endothelium induces changes in EC morphology, function, and gene expression (Ando et
al., 2009, Traub et al., 1998). In response to laminar shear stress, ECs become spindleshaped and elongate their main axis parallel to the direction of blood flow (Tzima et al.,
2001). At the genetic level, shear stress influences the expression of many genes through
the activation of transcriptional factors (Ohura et al., 2003). Shear stress induces the
expression of the gene transcription factor Krüppel-like factor 2 (KLF2), which mediates
the cell alignment to flow and is essential for the formation of actin filament shear fibers
(Boon et al., 2010).
In contrast, ECs lining vessels with stagnant or turbulent flow have a cobblestonelike appearance and lack a uniform orientation (Langille et al., 1981). This impairs EC
function and leads to the development of vascular diseases including hypertension and
atherosclerosis (Zhou et al., 2014).
Several studies have attempted to clarify the mechanisms by which the
mechanical signals are transduced into the endothelium. However, this process remains
not well understood and controversial (Ando et al., 2013). Multiple candidates have been
suggested to sense shear stress including EC ion channels, receptor-tyrosine kinases
including VEGFR2 and angiopoietin receptor (Tie-2), GTP binding protein-coupled
receptors, adhesion molecules, glycocalyx, primary cilia, caveolae, and the cytoskeleton
(Ando et al., 2013).
Furthermore, shear stress sensing is critical for the remodeling and optimization
of vascular network architecture and lumen diameter. It is interesting that tyrosine kinase
receptors can be phosphorylated by shear stress, since these receptors play major roles in
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regulating hierarchical differentiation, EC specification, morphology, and migration
(Davies, 1995).
1.3.3

Regulation of Capillary Perfusion and the Local Oxygen Content Control
Loop
Dynamic regulation of terminal arteriole tone is fundamental for optimizing the

delivery and distribution of O2-carrying RBCs into capillaries (Bloch et al., 1982, Arpino
et al., 2017). Fine-tuning of terminal arteriole tone is necessary to optimize O2 transport
directly at the site of oxygen delivery. The field’s understanding of perfusion at the
capillary level has shifted from the regulation of RBC delivery in individual capillaries,
to the regulation of RBC delivery throughout entire capillary networks.
A single terminal arteriole and its downstream capillary mesh constitute a
microvascular unit (Bloch et al., 1982,Emerson, 1997 #906). The architecture of a
microvascular unit dictates its ability to effectively regulate capillary perfusion. The
fractal and hierarchical branching pattern of normal microcirculation is critical for
ensuring the proper distribution of O2-carrying RBCs into individual capillaries within a
microvascular unit, and reduces plasma skimming at bifurcations (Ellis et al., 1994,
Koller et al., 1987, Pries et al., 1989, Frame et al., 1993). In contrast, fractal branching
patterns are not replicated in abnormal microvasculatures like the ones found in tumors,
rendering a hypoxic tissue environment (Baish et al., 2000).
Heterogeneity in RBC delivery throughout capillaries supplied by the same feeder
arteriole is necessary for tightly matching the delivery of O2 to highly localized metabolic
requirements (Duling et al., 1987, Ellis et al., 1994). This is particularly important in
skeletal muscle, as individual muscle fibers within skeletal muscle have a variety of
metabolic requirements at rest (Kusters et al., 2016). In the case of increased blood flow
demand, a higher and more uniform RBC distribution is supplied to the capillaries. Once
a terminal arteriole has maximally dilated, perfusion into its downstream capillaries is no
longer controlled at the arteriole level. Instead, it is determined by passive rheological
parameters of the RBC flow path including branching angles, flow path length, and flow
resistance (Sarelius, 1986).
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Importantly, the local and temporal regulation of capillary perfusion is intricately
linked to local tissue O2 content, independent of mechanical forces (Segal, 2005).
Hypoxia is a powerful stimulus for enhancing delivery of RBCs in skeletal muscle (Jia et
al., 2011, Parthasarathi et al., 1999). Regulatory mechanisms that rely on flow-mediated
and hormonal responses do not directly sense O2 levels and are thus alone insufficient to
regulate the local supply of O2 at the site of delivery (Ellis et al., 2012).
Interestingly, in addition to their role as the primary O2 carriers in the blood,
RBCs can regulate their own delivery and distribution (Ellis et al., 2012, Clifford, 2011,
Ellsworth et al., 2012, Ellsworth et al., 2009). When RBCs enter a tissue region with high
O2 demand, O2 will diffuse from the blood into the tissue and decrease the O2 saturation
of hemoglobin. This decrease in O2 saturation stimulates the rapid release of ATP from
the RBC from pannexin 1 channels in a linearly proportional manner (Ellsworth et al.,
1995, Ellsworth, 2004). Since RBCs are in very close proximity to the endothelium in
capillaries (<1 µm), the released ATP can diffuse across the short distance between the
RBC and the endothelium, and interact with purinergic receptors on the surface of ECs
(Ellis et al., 2012).
This interaction induces the release of NO and prostacyclin, as well as conducted
Ca2+ signaling and hyperpolarization via K+ efflux in the endothelial cells. These
vasodilatory signals are conducted upstream, resulting in increased blood flow and
oxygen supply to the regions of increased O2 demand (Ellis et al., 2012). Thus, the
density of the capillary bed and surface area for RBCs to signal with the endothelium
may play a crucial role in regulating the distribution of RBCs within microvascular units.

1.4
1.4.1

Blood Vessel Growth
Developmental Vasculogenesis and Angiogenesis
In the embryo, de novo blood vessels form from primordial blood islands in a

process called vasculogenesis (Flamme et al., 1997). The first blood islands arise from
hemangioblasts between two mesoderm germ layers around E7-E7.5 in the mouse
embryo (Patan, 2000). Blood islands harbor EC precursors called angioblasts, as well as
hematopoietic precursors. Angioblasts accumulate and build de novo primitive tubes that
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form the primitive vascular plexus (Figure 1.2). De novo tubes initially form as separate
units that end up joining together. Moreover, angioblasts also migrate inside the embryo
to form primitive vascular plexuses in distant organs.
The primitive vascular plexus is believed to expand into an extensive circulatory
network by sprouting angiogenesis (Adams et al., 2007). Angiogenesis is defined as the
process by which new blood vessels develop from a pre-existing vasculature. Over time
this network remodels into a differentiated network of arteries, capillaries, and veins.
1.4.2

Sprouting Angiogenesis
Sprouting angiogenesis is the best-understood and most extensively studied

process of neovascularization. The majority of the field’s knowledge regarding the
processes and mechanisms regulating sprouting angiogenesis arise from studies in
developing zebrafish embryos or mouse retinas. Sprouting is the dominant mode of
neovascularization in these systems.
The main purpose of sprouting angiogenesis is to generate new microvessels and
capillaries in tissue regions with insufficient blood flow. Vessel sprouts are ECcontaining tubes that lack proper mural cell coverage until further maturation takes place
(Limbourg et al., 2009). By generating new vessel sprouts, RBCs and O2 can be delivered
to non-vascularized areas.
For sprouting to occur, the activation of ECs from a basal quiescent state is
required. This entails the breakdown of EC junctions, increase of vessel permeability, and
the release of proteins contained in unique EC intracellular organelles called WeibelPalad bodies (WPBs) (Rondaij et al., 2006). Proteins contained in WPBs play proangiogenic roles in ECs and are required for the rapid angiogenic response of ECs.
Proteins are released from WPBs within seconds of exposure to secretagogues including
VEGF, sphinogsine-1 phosphate (S1P), and thrombin (Matsushita et al., 2005, Matsushita
et al., 2004). The specific proteins released from EC WPBs include vWF, P-selectin,
fibrinolysis molecules, and Angiopoietin-2 (ANGPT2).
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Figure 1.2 Vasculogenesis and sprouting angiogenesis
A. Vasculogenesis occurs in the embryo to generate de novo blood vessels.
Hemangioblasts form blood islands that harbor endothelial and hematopoietic
progenitors. Endothelial progenitors form primitive blood tubes that expand into an
extensive primitive vascular plexus. B. Sprouting angiogenesis entails the migration of
EC tip cells towards a gradient of angiogenic factors that are produced in hypoxic tissues.
VEGF binds to and phosphorylates VEGFR2 on tip cell filopodia, stimulating the
migration of the tip cell towards a chemical growth factor gradient. Tip cells signal to
their neighbouring stalk cells through the Dll4-Notch pathway instructing them to
proliferate and extend the length of the sprout, while also suppressing migratory
behaviour.
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Sprouting angiogenesis entails a multistep branching morphogenesis program that
generates new vessel channels (Caussinus et al., 2008). Sprouts extend out of existing
vessels while maintaining contact with the parent vessel. The formation of a vessel sprout
entails the specification of endothelial cells into three distinct and specialized
phenotypes: tip cells, stalk cells, and phalanx cells (Gerhardt et al., 2003) (Figure 1.2).
Tip cells guide the angiogenic sprout by migrating and becoming polarized in response to
environmental cues and angiogenic growth factor gradients (Ribatti et al., 2012). The
sprout tip contains numerous filopodial extensions that guide the direction of migration
and are 100 nm – 100 µm in length. In contrast, stalk cells trail behind the tip and
proliferate in order to extend the length of the vessel sprout. They also establish junctions
with neighbouring ECs and generate basement membrane components. Phalanx cells
represent the most quiescent ECs, and line vessels once new sprouts have reconnected to
the vasculature. They generate tight junctions and align in a phalanx formation,
reminiscent of the organization employed by ancient Greek soldiers (Mazzone et al.,
2009).
Once sprouts have formed, they connect with other sprouts or existing vessels via
vessel anastomosis. Several mechanisms have been suggested for the formation of a
lumen in sprouting ECs. These mechanisms include intracellular vacuolization in a
process termed cord hollowing, and the attainment of EC basal-apical polarity (Xu et al.,
2011). However, the precise mechanisms dictating how a lumen forms in angiogenic
sprouts remains debated.
1.4.3

Intussusceptive Angiogenesis
Although current understanding of new vessel formation stems primarily from

powerful studies of sprouting angiogenesis, an alternate but underappreciated method for
generating new blood vessels exists. This process is known as intussusceptive, or
“splitting”, angiogenesis (IA).
IA was first described within the developing rat lung microvasculature in 1986
(Caduff et al., 1986). Caduff et al. observed no vessel sprouts in the developing
microvasculature from postnatal day 1 up to day 270 when lung maturation is complete.
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Instead, Caduff et al. observed small holes within the corrosion-casted alveolar
microvasculature that were 1-2.5 µm in diameter. These small holes were first detected
on day 4 during the formation and expansion of lung alveoli and remained frequently
observed up to day 13, with many larger holes evident on day 270. Between birth and day
270, the developing rat lung capillary density increases by 35-fold (Caduff et al., 1986).
It was later discovered in the chick chorioallantoic membrane (CAM)
angiogenesis model that these holes evident in casting were in fact tissue “pillars”
spanning the lumen of microvessels (Patan et al., 1993). Translumenal tissue “pillars” are
thus vascular structures <5 µm in diameter that are generated by a localized intraluminal
protrusion of ECs which create a zone of contact with the opposite wall (Patan et al.,
1993) (Figure 1.3).
For vessel growth to occur by IA, a single vessel is divided or “split” into two
distinct and smaller vessels following the generation of translumenal EC pillars (Djonov
et al., 2000) (Figure 1.3). This entails ECs making contact between opposite walls of a
microvessel, perforation of the EC pillar core, and invasion of the core by perivascular
cells and extracellular matrix, as demonstrated in both CAM and mouse tumor models
(Patan et al., 1993, Djonov et al., 2000, Paku et al., 2011) (Figure 1.3). Pillars have also
recently been identified in the abnormal vessels that form in skeletal muscle following
local delivery of VEGF. In this case, there is enlargement of pre-existing microvessels
and emergence of pillars that increase in size by extending along the long-axis of a
vessel, and also fusing with neighbouring pillars (Gianni-Barrera et al., 2013). This
divides and increases the number of vessels. The precise mechanism of pillar extension is
unknown (Mentzer et al., 2014). Notably, EC pillars do not exhibit typical sprouting tip
cell characteristics such as filopodia or migration towards a chemical gradient (Mentzer
et al., 2014). Moreover, in contrast to sprouting, pillar formation does not disrupt the
vessel basement membrane and is believed to be a non-proliferative process.
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Figure 1.3 Intussusceptive angiogenesis
Intussusceptive angiogenesis entails the formation of translumenal EC pillars in
response to the increased blood flow. Specifically, this pillar generation entails one or
more ECs making a physical connection between opposite walls of a microvessel. Pillars
then divide a single vessel and flow path into two or more daughter vessels of smaller
caliber.
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The roles of pillar formation appear to be: 1) to induce microvascular growth by
dividing an existing vessel, 2) to modify the architecture and arborization of
microvascular networks by shifting the branching angle at bifurcations, and 3)
microvascular pruning by eliminating redundant vessels or those with poor perfusion
(Mentzer et al., 2014). Thus, although not well studied, IA appears to be an important
method intrinsic to the microvasculature for optimizing blood flow.
In contrast to sprouting angiogenesis, the cellular and molecular mechanisms
regulating IA are poorly understood. There are a limited number of studies investigating
this type of angiogenesis. Currently, reported signals involved in generating EC pillars
include activation of the endothelium by increased blood flow and shear stress, and
vascular endothelial growth factor A (VEGF-A) (Djonov et al., 2002, Gianni-Barrera et
al., 2013) (Figure 1.3). Importantly, pillars develop within a flowing blood stream and
increased blood flow has been demonstrated to stimulate longitudinal capillary splitting
(Egginton et al., 2001). However, using computational simulations based on the blood
flow in CAM vasculature, pillars have also been predicted to develop primarily in microregions of vessels with low shear. In this case, pillar development is limited in
surrounding regions of higher shear stress (Lee et al., 2010). This suggests that while
increased shear stress can lead to the initiation of the IA process, there is an interplay
between high and low shear stress as well as a permissive role of focalized low wall shear
stress in pillar development (Lee et al., 2011).
To date, IA has been observed in the development of mammalian bone, retina,
myocardium, kidney, ovary, and the CAM (Hirschberg et al., 2005, Burri et al., 2002, van
Groningen et al., 1991, Makanya et al., 2005, Macchiarelli et al., 2006, Djonov et al.,
2001, Djonov et al., 2000). In addition, it has been identified during physiologic
neovascularization in response to increased shear stress during exercise within adult
healthy skeletal muscle (Egginton et al., 2001). As well, IA has been identified during
compensatory microvascular growth following injury to the rat lung and mouse retina
(Konerding et al., 2010, Taylor et al., 2010), and during pathological neovascularization
within tumors (Styp-Rekowska et al., 2011, Paku et al., 2011).
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1.4.4

Arteriogenesis and Collateralization
Angiogenesis is necessary for delivering blood and O2 to ischemic and

regenerating tissues. However, this process alone has a limited capacity to increase blood
flow and blood volume to the surrounding tissues (Limbourg et al., 2009). For this to
occur, the process of arteriogenesis is required. Arteriogenesis entails the enlargement
and remodeling of pre-existing collateral arteries into larger diameter conductance vessels
for increasing blood flow, in addition to the arterialization of capillaries following
ischemic injury (Schaper, 2009, Mac Gabhann et al., 2010) (Figure 1.4)
In contrast to angiogenesis, the remodeling response is not driven by hypoxia but
by increased fluid shear stress caused by the occlusion of major arteries and diversion of
flow into collateral vessels (Heil et al., 2004, Eitenmuller et al., 2006). It is characterized
by the proliferation of ECs and SMCs, upregulation of genes for adhesive molecules and
cytokines, and a complex process of lumenal expansion and vessel wall thickening to
support an increase of blood flow and shear stress (Arras et al., 1998, Kondoh et al.,
2004, Deindl et al., 2001, Pasyk et al., 1982). Both angiogenesis and arteriogenesis are
important for adaptation and regeneration following ischemic injury.
1.4.5

Molecular Regulation of Angiogenesis

1.4.5.1 Initiation of Angiogenesis by Hypoxia
The most potent initiator of angiogenesis and neovascularization is tissue hypoxia
(Carmeliet, 2000). Hypoxia’s actions are mediated through the gene transcription factor
Hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimeric basic helix-loop-helix
protein that induces the expression of pro-angiogenic molecules in hypoxic cells
(Forsythe et al., 1996, Carmeliet et al., 1998). Its function is crucial for inducing tumour
angiogenesis (Folkman, 2002). Furthermore, HIF-1 has been shown to play a role in
ischemic skeletal muscle angiogenesis, mainly by modulating VEGF expression
(Carmeliet, 2000, Pugh et al., 2003, Gustafsson et al., 1999, Milkiewicz et al., 2004,
Ameln et al., 2005, Manalo et al., 2005, Nakano et al., 2007, Gavin et al., 2000).
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Figure 1.4 Arteriogenesis and collateralization
Arteriogenesis entails the enlargement and remodeling of collateral arteries that
receive little to no flow under normal conditions. Following occlusion of a major artery,
such as the femoral artery that is indicated in the figure, blood flow is diverted into
collateral arteries. In response to heightened flow, the collateral arteries expand their
lumens and remodel to compensate for this. Shown are a normal mouse hindlimb
(above), and a mouse hindlimb following femoral artery excision (below) that has been
perfused with blue latex. The tissue was cleared in order to visualize the hindlimb arterial
network filled with blue latex. These images demonstrate the enlargement of collateral
vessels (arrowheads) following an increase in blood flow induced by excision of the
femoral artery, denoted by x. Arrows indicate the direction of blood flow.
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The activity of HIF-1 is delicately controlled by local oxygen content (BrahimiHorn et al., 2009). The active form of HIF-1 is a heterodimer composed of HIF-1α and
HIF-1β subunits. Under normoxic conditions, HIF-1α is subjected to hydroxylation by
prolylhydroxylase family members, which target the unit for ubiquitination and
degradation (Maxwell et al., 1999). Under hypoxic conditions, HIF-1α is stabilized and
dimerizes with HIF-1β, upon which it translocates to the nucleus and activates the
transcription of over 60 genes, many of which are involved in the activation sprouting
angiogenesis including VEGF-A (Forsythe et al., 1996).
1.4.5.2 VEGFR2 Signaling
1.4.5.2.1 VEGF-A - VEGFR2 Signaling
The vascular endothelial growth factor (VEGF) family consists of VEGF-A, -B,
-C, -D and placental growth factor (PlGF) (Koch et al., 2011). VEGF-A was first
described as a potent vessel permeability factor (Clauss et al., 1990). Later it was
discovered that the binding of VEGF-A to vascular endothelial growth factor receptor 2
(VEGFR2) is the most powerful inducer of angiogenesis and is required for proper
vascular morphogenesis (Carmeliet et al., 1996). Deletion of a single allele of VEGF-A
leads to flawed vasculogenesis and angiogenesis, and is embryonic lethal (Carmeliet et
al., 1996).
VEGFR2 is a membrane-bound tyrosine kinase receptor consisting of an
extracellular ligand-binding domain, a transmembrane domain, and an intracellular
kinase domain (Koch et al., 2011). Activation of VEGFR2 is critical for regulating EC
survival, proliferation, migration, and vessel formation (Olsson et al., 2006). Activation
of VEGFR2 via the binding of its ligand VEGF-A induces receptor homodimerization
and leads to autophosphorylation of the critical tyrosine residues 1054 and 1059 in the
intracellular kinase activation domain (Simons, 2012).
Autophosphorylation at these key residues is required for allowing maximal
VEGFR2 kinase activity (Kendall et al., 1999, Dougher et al., 1999). Moreover,
phosphorylated 1054 is a general marker of VEGFR2 kinase activation (Lanahan et al.,
2010, Kendall et al., 1999). Phosphorylation of the residues 1054 and 1059 engages
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various adaptor molecules required for the phosphorylation of other key residues in
VEGFR2, such as tyrosines 1175 and 1214. This leads to the changes in EC phenotype
and behaviour through the activation of downstream p38 MAPK, PI3K, and Rac
signaling pathways (Koch et al., 2011).
The VEGF-VEGFR2 signaling axis is the master controller of sprouting
angiogenesis, including the synchronization of EC sprouting activity (Kawamura et al.,
2008). For vessel sprouts to form, ECs must increase vessel permeability, increase
proliferation, and increase migratory behaviour. Importantly, the VEGF-A-VEGFR2
signaling axis regulates all of these processes (Olsson et al., 2006). Downstream of
VEGFR2 activation the Src kinase and eNOS pathways modulate cell-cell contact and
increase permeability (Olsson et al., 2006). EC proliferation is induced by the activation
of Shc, PLCγ, PKC, and ERK pathways (Olsson et al., 2006, Pedram et al., 1998). EC
migration is induced by p38 MAPK, HSP27, FAK, Paxillin, Rac, and IQGAP1 pathways
(Koch et al., 2011, Yamaoka-Tojo et al., 2004, Olsson et al., 2006). The PI3K/Akt
signaling pathways also upregulate anti-apoptotic genes that promote EC survival
(Gerber et al., 1998).
EC tip cell selection within a pre-existing vessel is regulated by VEGF-A –
VEGFR2 signaling (Gerhardt et al., 2003). The EC that locally expresses the highest
level of VEGFR2 in the most sensitive to VEGF-A and is driven to become a tip cell
(Gerhardt et al., 2003). Moreover, activation of Cdc42 GTPase by VEGF-A triggers the
formation of filopodia in tip cells (De Smet et al., 2009). Filopodia help guide the
elongation and directionality of the tip cell towards a chemical gradient of matrix-bound
VEGF-A. In contrast, endothelial stalk cells only proliferate in response to VEGF-A
activation for the purpose of elongating the sprout, but they do not migrate (Gerhardt et
al., 2003). Interestingly, EC phenotypes during sprouting are amazingly plastic. ECs
dynamically compete for the tip cell position during sprouting, where the differential
expression of VEGFR2 and downstream Notch signaling over time induces a dynamic
position shuffling of tip and stalk cells. This results in the regular exchange of the leading
tip EC (Jakobsson et al., 2010).
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VEGF-A - VEGFR2 signaling is also important for the induction of arterialvenous specification (Lawson et al., 2002). The VEGF pathway participates in AV
specification by differentially regulating the activation of downstream targets in arterial
and venous ECs, due to their differential expression of VEGFR2 and VEGFR3 and
binding affinity for VEGF ligands (Lawson et al., 2002).
1.4.5.2.2 Ligand-Independent VEGFR2 Signaling
VEGFR2 can also be phosphorylated in a ligand-independent fashion. VEGFR2
exhibits rapid VEGF-independent phosphorylation in response to blood flow shear stress
(Chen et al., 1999, Jin et al., 2003). For this to occur, the formation of an EC-specific
mechanosensory complex is required (Tzima et al., 2005, Coon et al., 2015, Warren et al.,
2014, Simons, 2012, Shay-Salit et al., 2002).
The EC mechanosensory complex is comprised of CD31/PECAM-1, VECadherin, and VEGFR2. This mechanosensory complex is necessary for conferring
proper flow shear stress responsiveness to ECs, the EC alignment to flow, and for EC
survival (Tzima et al., 2005, Coon et al., 2015). These responses are necessary for the
remodeling of the primitive vascular plexus in the embryo and for regulating vasomotor
tone (Coon et al., 2015, Langille et al., 1986). CD31, which is enriched at EC-EC
junctions, directly transmits mechanical blood flow force and is phosphorylated by Srckinase in response to shear stress (Conway et al., 2012, Tzima et al., 2005). Once CD31
is phosphorylated, VE-Cadherin functions as an adaptor molecule and recruits VEGR2 to
the complex by binding directly to its transmembrane domain. Once recruited, VEGFR2
is phosphorylated by Src-kinase. VEGFR2 is phosphorylated at tyrosine 1054 within 15
seconds upon flow initiation in EC culture (Tzima et al., 2005). However, the specific
details regarding how the mechanosensory complex is fully assembled are currently
unknown.
In

contrast

to
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VEGFR2

activation,
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phosphorylation of VEGFR2 increases vessel stability, decreases EC proliferation, and
decreases EC migration. Following shear-induced VEGFR2 phosphorylation, the adaptor
molecules Shc, Grb2 and Sos are recruited to the complex. This in turn activates
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downstream PI3K, Akt, and p38 MAPK signaling pathways that increase cell-cell contact
and decrease vessel permeability (Chen et al., 1999). Moreover, this converts integrins to
a high-affinity state to mediate EC alignment and increases gene expression of KLF2 (Jin
et al., 2003, Tzima et al., 2005). In addition, activation of Rac1 by shear stress in ECs
mediates both cytoskeletal reorganization and affects gene expression (Tzima et al.,
2002). Furthermore, knockdown of VEGFR2 expression induces a decrease of EC
alignment to flow in-vitro, even in the presence of VEGF, demonstrating the requirement
for ligand-independent VEGFR2 phosphorylation for conferring flow responsiveness
(Coon et al., 2015, van der Meer et al., 2010).
Whether ligand-independent VEGFR2 activation stimulates EC tip cell formation
in sprouting angiogenesis is currently unknown. However, increased blood flow and
shear stress are known stimulate IA in healthy skeletal muscle capillaries (Egginton et al.,
2001). The role of ligand-independent VEGFR2 has not been fully elucidated in this
process. However the activation of p38 MAPK, which is phosphorylated downstream of
shear-induced VEGFR2 activation, has been suggested to be required for shear stressinduced IA in healthy mouse skeletal muscle in response systemic prazosin delivery (Gee
et al., 2010).
1.4.5.3 Dll4 - Notch Signaling
Notch signaling is an evolutionarily conserved pathway that is involved in a wide
range of biological processes including cell fate determination, proliferation, and
cardiovascular development (Roca et al., 2007). Signaling through the Notch pathway
occurs through direct cell-cell contact and communication. In mammals, there are four
Notch receptors: Notch1-4. The Notch receptors have five ligands, three being a part of
the Delta protein family (Dll1, Dll3, and Dll4) and two a part of the Jagged protein family
(Jag1 and Jag2).
The Notch pathway regulates sprouting angiogenesis by controlling tip cell
selection at the angiogenic front (Hellstrom et al., 2007, Suchting et al., 2007).
Phosphorylation of VEGFR2 in tip cells induces the overexpression of Dll4. Dll4 is a
transmembrane protein and Notch ligand. Dll4 binds to Notch1 on the surface of
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neighbouring stalk cells. Notch1 signaling suppresses tip cell behaviour by reducing the
expression of VEGFR2 and Dll4, thereby reducing the EC’s sensitivity to VEGF
(Hellstrom et al., 2007, Holderfield et al., 2008, Jakobsson et al., 2010). In addition,
VEGFR1 expression is also induced by Notch signaling, which reduces VEGF ligand
bioavailability in stalk cells and limits tip cell formation and migration.
Jagged1 (Jag1) ligand antagonizes Dll4-Notch1 signaling and controls the number
of endothelial sprouts and tip cells (Benedito et al., 2009). Jag1 is found in stalk cells at
the sprout base, and is an proangiogenic regulator that antagonizes Dll4-Notch signaling
and positively regulates sprouting by reducing endothelial tip cell Notch activation.
1.4.5.4 FGF - FGFR Signaling
Besides VEGF, the fibroblast growth factor (FGF) family is a potent promoter of
embryonic and sprouting angiogenesis. FGF activation of FGFR signaling is critical for
embryonic vascular development and precedes the appearance of VEGF signaling
(Murakami et al., 2011). FGF2-induced endothelial tube formation is mediated by
ERK1/2 (Kuzuya et al., 1999). Furthermore, FGF signaling is required for the
maintenance of blood vessels in the adult (Murakami et al., 2008).
FGF signaling controls expression of VEGFR2 expression in endothelial cells by
activating the VEGFR2 enhancer (Murakami et al., 2011). Basal stimulation of the
endothelium by FGF is required for maintenance of VEGFR2 expression and the ability
to respond to VEGF stimulation and accounts for the hierarchic control of vascular
formation by FGFs and VEGF (Murakami et al., 2011).
In adult tissues, FGFs play important roles in angiogenesis and cancer. FGF2
promotes an angiogenic phenotype in endothelial cells that includes increased
proliferation and migration (Presta et al., 2005). FGF2 has been shown to stimulate a
powerful angiogenesis response within subcutaneous Matrigel implants (Frontini et al.,
2011). As well, FGF2 stimulates mural cells to migrate and acts as a mitogen for ECs,
SMCs, and fibroblasts (Gospodarowicz, 1974). Compared to VEGF-A, FGF2 induces
blood vessels that are less leaky and more normalized.
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1.4.6 Vessel Stabilization and Maturation
1.4.6.1 Mural Cells
Mural cells are essential for the stabilization and maturation of the thin neovessel
wall formed during angiogenesis (Jain, 2003). Stabilization and maturation of the vessel
wall involves the recruitment of pericytes and SMCs following the development of an
endothelial tube. Mural cells deposit surrounding extracellular matrix and basement
membrane to fortify structural stability, as well as elastic laminae in arterial vessels (Yin
et al., 2015). Moreover, mural cell recruitment inhibits excessive angiogenesis and
terminates the dependence of VEGF-stimulation for EC survival in newly formed blood
vessels (Benjamin et al., 1998). As well, pericytes can abolish an angiogenic EC
phenotype by inducing EC quiescence and inhibiting EC migration by paracrine and cellcell contact-dependent control mechanisms (Orlidge et al., 1987).
In addition, mural cells are required and for increasing the complexity and
hierarchical organization of vessels (Jain, 2003). Faulty or incomplete mural cell
recruitment during embryonic development leads to inconsistent vessel diameters, EC
hyperplasia, and diminished EC AV differentiation (Hellstrom et al., 2001). Overall, the
recruitment of mural cells to newly formed microvessels is fundamental for proper
vascular development and function.
1.4.6.2 PDGF – PDGFR Signaling
Platelet-derived growth factor (PDGF) is a fundamental mediator for the
stabilization of nascent vessels. Pericytes and SMCs can be recruited to neovessels
through several signaling pathways, and one of the best characterized is the PDGFPDGFRβ signaling pathway. PDGFs are produced in active ECs and act as a mitogen and
chemoattractant for cells of mesenchymal origin including pericytes, SMCs, and their
progenitors (Shinbrot et al., 1994). PDGF-BB ligand binds to and activates the receptor
PDGFRβ, which is highly expressed by pericytes and SMCs (Bjarnegard et al., 2004).
Signaling through the PDGF-BB – PDGFRβ axis has been demonstrated to be
necessary for recruiting pericytes and SMCs to the developing vasculature in the embryo
(Lutolf et al., 2005, Hellstrom et al., 1999). Moreover it is required for the wrapping of
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angiogenic neovessels in tissue implants and the ischemic mouse hindlimb (Frontini et
al., 2011). Inhibition of PDGFRβ signaling leads to embryonic lethality, as the lack of
vessel stabilization results in dilated and thin-walled vessels that are leaky. Furthermore,
a loss of this signaling in adult PDGF-BB and PDGFRβ knockout models impairs blood
flow and increases tissue markers of hypoxia including VEGF (Hellstrom et al., 2001).
An absence of pericytes leads to defects in endothelial tube maintenance and
homeostasis, whereas a lack of wrapping SMCs renders vessels non-vasoresponsive.
1.4.6.3 Angiopoietin – Tie Receptor Signaling
The Angiopoietin family is critical for regulating vessel stabilization and
maturation. Angiopoietins are a family of four secreted proteins that signal to Tie
receptors (Sato et al., 1993). Tie receptors are expressed on the EC plasma membrane,
whereas pericytes, SMCs, and fibroblasts express Angiopoietin-1 (ANGPT1) (Davis et
al., 1996). ANGPT1 binds to and phosphorylates the Tie2 receptor. Loss of Ang1 or Tie2
is embryonic lethal and renders a poorly structured and destabilized vasculature (Sato et
al., 1995). When ECs are in contact, Tie2 is located at the cell-cell interface and inhibits
vessel permeability by preventing monolayer destabilization. Stimulation of EC Tie2
with ANGPT1 also induces the recruitment of SMCs to nascent channels in a PDGFRβindependent signaling pathway (Uemura et al., 2002).
In addition to their role in vascular stabilization, angiopoietins also have proangiogenic roles by destabilizing the vasculature. Angiopoietin-2 (ANGPT2) destabilizes
vessels by reducing pericyte coverage, and can lead to vessel regression (Huang et al.,
2009). During active angiogenesis, ANGPT2 binding to the Tie2 receptor facilitates
endothelial sprouting in the presence of VEGF. ANGPT2 is upregulated by local hypoxia
and by proangiogenic growth factors including VEGF and FGF (Mandriota et al., 1998).
Importantly, PDGF-BB can simultaneously increase the expression of ANGPT1
and reduce the expression of ANGPT2 in mural cells through post-transcriptional
destabilization, preventing ongoing or excessive vessel destabilization induced by
ANGPT2 (Phelps et al., 2006). Clearly, the balance between ANGPT1-Tie2 and
ANGPT2-Tie2 signaling is critical for determining the fate of a newly formed vessel.
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1.4.6.4 Fibroblast Growth Factor 9
Fibroblast growth factor 9 (FGF9) is a mesenchyme-targeting growth factor that
is necessary for embryonic development of the lung, heart, and cerebellum (Lavine et al.,
2006). It was first identified in gliomas, and embryonic tissues have been found to exhibit
a widespread expression of FGF9 (Miyamoto et al., 1993). In the embryo, the role of
FGF9 has been investigated during coronary vessel development, where it signals to
cardiomyoblasts to initiate a wave of signaling via the upregulation of sonic hedgehog
(Shh) signaling, as well as the expression of VEGF and Angiopoietins. Together, these
are required for proper coronary vessel growth (Lavine et al., 2006).
FGF9 is noteworthy in the context of vascular stabilization and maturation
because unlike other FGF family members, it has no direct effect on endothelial tube
formation. Instead, it promotes the stabilization of nascent vessel channels (Frontini et al.,
2011). FGF9 promotes the ordered layering of pericytes and smooth muscles around new
blood vessels in ischemic muscle through the activation of Shh signaling and the
selective amplification of PDGFRβ-expressing mesenchymal cells (Frontini et al., 2011).
This was associated with vasomotor competency and vessel longevity.

1.5
1.5.1

Model Systems for Studying Angiogenesis In Vivo
Zebrafish
The zebrafish is a classic model for studying vasculogenesis and sprouting

angiogenesis during development. The zebrafish is also a powerful genetic tool for
dissecting and understanding the molecular mechanisms regulating pathological
angiogenesis (Ellertsdottir et al., 2010). It is also important for studying the processes of
AV specification, lumen formation, and vascular regeneration. This because the
vasculature rapidly develops within the zebrafish and in a highly reproducible manner.
The dorsal aorta and vein form by vasculogenesis, and new sprouts called intersegmental
vessels later develop from the dorsal and migrate towards the cardinal vein (Isogai et al.,
2001).
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The zebrafish tissue is optically transparent which enables easy visualization of
blood vessels. Moreover, there is an abundance of transgenic lines that report the
vasculature by fluorescent protein expression. This enables noninvasive visualization of
the vasculature and allows for time-lapse imaging of growing vessels by brightfield or
confocal microscopy. Moreover, the small size and abundance of zebrafish enables high
throughput screening. The zebrafish can also be sectioned and immunostained to study
the vasculature at cellular and molecular levels of resolution.
1.5.2

Chick Chorioallantoic Membrane
The avian embryo is another classical model for studying developmental

vasculogenesis and angiogenesis in-vivo. The most widely used avian angiogenesis
model is the chick chorioallantoic membrane (CAM). The CAM is a highly vascularized
structure situated right below the eggshell (Baum et al., 2010). Careful opening of the
eggshell creates a window to view the CAM. From days 3-10 after fertilization, ECs
rapidly develop a vascularized network by sprouting, and then an angiogenic switch leads
to growth and remodeling by intussusceptive angiogenesis (Ribatti et al., 2001). The ease
of access, reproducible vascular pattern, and the ability to take repeated measurements
over time makes the CAM suitable for the study of pro- and anti-angiogenic drugs.
Inspection of the CAM vasculature is classically performed by vascular corrosion
casting for evaluating network architecture, in addition to intravital microscopy following
intravascular perfusion with fluorescent dyes or particles for studying the formation of
neovessels and blood flow dynamics over time (Lee et al., 2010). This makes the CAM
model suitable for evaluating flow-dependent remodeling of the vasculature.
1.5.3

Retina
The ex-vivo model of angiogenesis in the developing mouse retina is one of the

most widely used models for evaluating the molecular control of sprouting angiogenesis.
Most of what is known about the cellular processes and molecular regulation of sprouting
angiogenesis has been derived from studying the developing vasculature in the retina.
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Angiogenesis in the mouse retina begins only after birth and in the central region
of the retina at the optic nerve head. The microvascular architecture of the retina is
unique in the sense that it is organized in a two-dimensional planar arrangement
(Pitulescu et al., 2010, Hellstrom et al., 2007). The vasculature expands from the center
of the retina towards the periphery by sprouting angiogenesis and tip cell formation.
While sprouting continues at the angiogenic front, the vessels near the center remodel and
form arteries and veins. Arteries and veins extend radially from the central optic nerve
towards the retinal periphery at regular intervals. Arteries bifurcate laterally along their
length into capillary plexuses that are highly branched and form a web-like meshwork
(Eilken et al., 2010). The capillary plexuses are aligned precisely with horizontal neural
and astrocytic laminae. Although sprouting is the predominant form of angiogenesis in
the retina, IA can also occur as a vascular adaptation response to hypoxia in the adult
(Taylor et al., 2010).
Key advantages of the ex-vivo retina model for studying angiogenesis are threefold. First, all components of the vascular tree are organized within a flat twodimensional network, allowing the simultaneous visualization of the all types of vessels
within the network. Second, the direction of the angiogenic wave is highly reproducible
and enables the easy identification of sprouting tip cells at the forefront of the vascular
wave, and the simultaneous assessment of vessel remodeling near the center. The thin
and optically transparent retina is an ideal tissue for visualizing vessels by threedimensional confocal laser scanning microscopy after whole-mount immunostaining ECs
and mural cells. Finally, it is a powerful system for studying vessel growth and
remodeling in disease models, and following genetic knock-out or knock-in intervention.
1.5.4

Tumor
Tumors aggressively recruit a vascular network to sustain their growth (Kamoun

et al., 2010). At first, growing tumors obtain their O2 and nutrients from blood vessels
that are within diffusion limits in the surrounding tissue. Over time, the tumor grows to a
point where diffusion is insufficient for O2 to the reach the core. At this point, the tumor
becomes hypoxic and activates an angiogenic switch. This response to hypoxia results in
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the massive infiltration of new vessels into the central regions of the tumor. However, the
blood vessels formed in tumors are irregular and unorganized and are unable to
effectively deliver O2 (Yin et al., 2015). Perfusion in tumours is spatially and temporally
heterogeneous, with slow RBC velocities and chaotic flow paths (Kamoun et al.,
2010,Yin, 2015 #151).
Classically, studying tumor blood vessels is performed by histology and
immunostaining strategies. Fluorescent antibodies targeted to EC markers, or
intravascular perfusion with fluorescently conjugated lectins and subsequent microscopic
imaging, are commonly used techniques for assessing tumor vessel density, organization,
and diameter. For evaluating tumor perfusion, cranial or mammary fat pad widow
chambers overlying subcutaneously implanted tumors allows for direct examination of in
vivo tumor angiogenesis over time (Huang et al., 1999). With the incorporation of
fluorescently labeled blood cells or microspheres, the tumor vasculature can be observed
at high resolution using real-time epifluorescence, laser scanning, or multiphoton
fluorescence microscopy (Kamoun et al., 2010). Moreover, these techniques can be used
in combination with the delivery of pro- or anti-angiogenic compounds to test their
efficacy on stimulating or abolishing tumor angiogenesis, respectively.
1.5.5

Bone
The bone microvasculature is formed exclusively by angiogenesis (Sivaraj et al.,

2016). In the mouse, blood vessels invade the developing bone by sprouting angiogenesis
on E13.5-E14.5, and vascular growth is completed in adolescence (Maes et al., 2010).
The release of pro-angiogenic factors from chondrocytes located at both ends of a
developing long bone guide growing vessels along the bone’s longitudinal axis. These
vessels remodel into two distinct capillary beds with differential morphology and
function (Sivaraj et al., 2016). Blood vessel formation and bone ossification are
completed in tandem.
Bone, like skeletal muscle, is a highly vascularized tissue that contains a
hierarchical microvascular network. Afferent arteries enter bone and branch into an
extensive capillary network within the bone core, which then drain into a large vein in the
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center of the bone marrow (Kusumbe et al., 2014). Interestingly, however, long bone
contains two subtypes of capillaries that are regionally dispersed, albeit interconnected
into a single meshwork with peculiar organization. In the bone metaphysis, capillaries
exhibit a columnar and densely-packed parallel organization, and are hierarchically
upstream from the bone marrow capillaries which form a highly branched and sinusoidal
network (Sivaraj et al., 2016). Interestingly, arterioles directly connect only to the
capillaries within the bone metaphysis and venules drain blood from capillaries within the
bone marrow. This particular architecture renders two distinct metabolic environments
within the bone, with well-oxygenated and hypoxic environments within the bone
metaphysis and marrow, respectively.
The angiogenesis and vessel remodeling process during bone repair in the adult is
not well understood but involves ingrowth of blood vessels from surrounding compact
bone (Sivaraj et al., 2016). The hierarchically upstream metaphysis capillaries consist of
a CD31-high endomucin-high EC population that becomes activated upon injury or
hypoxia. These cells give rise to neovessels in bone (Kusumbe et al., 2014). Intravital
imaging has revealed that neovascularization in murine bone involves the extension and
anastomotic fusion of EC buds, which are functionally equivalent to endothelial sprouting
tip cells seen in other organs, but exist in the form of rounded “buds” instead of tips with
filopodia (Ramasamy et al., 2016).
1.5.6

Skeletal Muscle
Compared to angiogenesis during development, and the angiogenesis that occurs

in the aforementioned organs and model systems, the angiogenesis process in adult
skeletal muscle is not well understood. This is the case even though skeletal muscle is
known to exhibit a robust neovascularization response in both physiologic and pathologic
conditions (Hudlicka et al., 1992, Wagner, 2001). This is partly because tools for
studying angiogenesis in-vivo in other organs are less suited for studying angiogenesis in
skeletal muscle, and skeletal muscle tissue is not optically transparent.
The physiologic angiogenesis response in skeletal occur can occur in response to
exercise and skeletal muscle contraction. Exercise induces perturbations in local oxygen
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content and hemodynamics within the muscle. Intraluminal vessel stimulation by
increases in blood flow shear stress following intraluminal administration of prazosin,
and extraluminal stimulation by myocyte stretch and contraction, lead to an increase in
skeletal muscle capillary density (Egginton et al., 2001, Zhou et al., 1998, Williams et al.,
2006, Brown et al., 2003, Haas et al., 2000, Prior et al., 2004). Increased intraluminal
shear in response to prazosin delivery induces capillary division by IA, whereas external
mechanical stimulation of the endothelium leads to the breakdown of basement
membrane and sprouting angiogenesis (Egginton et al., 2001). In these scenarios, pillars
and tip cells have been identified by high-resolution electron microscopy. Skeletal muscle
contraction also produces VEGF within myocytes and VEGF-A is required for exerciseinduced angiogenesis (Olfert et al., 2010).
A common system for studying angiogenesis in ischemic skeletal muscle is in the
mouse hindlimb following femoral artery ligation or excision (Limbourg et al., 2009).
Moreover, the model mimics aspects of human PAD and thus is ideal for studying
ischemia-driven neovascularization in muscle. The femoral artery is the major feeder
artery for the mouse hindlimb. The femoral artery branches into the profunda femoris
artery, which divides into collateral arterial vessels within muscles of the proximal
hindlimb (Limbourg et al., 2009). The model uses this distinct anatomy to investigate
arteriogenesis within the aforementioned collateral vessels as blood flow is diverted here
following permanent blockage of the femoral artery. Furthermore, the model induces
ischemia and angiogenesis in distal hindlimb muscles following the permanent blockage
of blood flow, and is the site used for studying ischemia-induced neovascularization. The
C57Bl/6 strain has the most robust arteriogenesis and angiogenesis response to femoral
artery excision (Couffinhal et al., 1998, Scholz et al., 2002, Helisch et al., 2006, Duvall et
al., 2004).
To assess the response to femoral artery excision laser Doppler imaging, whole
mount pigment particle perfusion, histological strategies, and Doppler ultrasound are
employed. Laser Doppler imaging of the paw has indicated that within 28 days following
femoral artery excision bulk blood flow returns to near-normal levels via the vigorous
opening and remodelling of collateral vessels (Helisch et al., 2006). In addition,
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histological techniques have indicated that angiogenesis concomitantly occurs in
infarcted hindlimb muscles distal to the surgical site, and the ischemic muscle has an endstage microvascular density higher than that of healthy muscle (Limbourg et al., 2009).
Importantly however, very little is known about how new blood vessels form in
skeletal muscle following ischemic injury. Studies using the hindlimb ischemia model
have detected an increase in skeletal muscle capillary density by histology and
immunostaining, but precisely how these new capillaries formed is not known. To date,
only one study has shown direct evidence of sprouting tip cells within a partially
infarcted ischemic muscle by whole-mount immunostaining (Al Haj Zen et al., 2010).
Whether de novo vasculogenesis occurs in adult skeletal muscle remains controversial, as
pro-angiogenic progenitor cells have been identified in skeletal muscle after ischemic
injury but their precise role in promoting neovascularization is unclear (Aicher et al.,
2007, Leroyer et al., 2009, Asahara et al., 1999, Ziegelhoeffer et al., 2004).
Furthermore, the literature is unclear as to whether angiogenesis occurs in mouse
models of minor ischemia, in the absence of myocyte necrosis and subsequent
myogenesis. Prolonged, moderate flow reduction to skeletal muscle does not necessarily
lead to inflammation or extensive capillary growth, and the existing microcirculation
remains intact (Brown et al., 2003).
Importantly, the currently widespread tools and strategies used to study
angiogenesis and evaluate microvascular blood flow in ischemic muscle, such as laser
Doppler imaging and histology, lack the spatial and temporal resolution necessary to
directly visualize and measure neo-microcirculatory architecture, hierarchy, connectivity,
RBC transit and distribution, vasoreactivity, and flow control. Therefore, the networklevel architecture and physiology of newly formed microvessels in ischemic or necrotic
and regenerating skeletal muscle is unknown. Thus it has not yet been explicitly
determined whether the network architecture and function of a newly formed
microvasculature is properly equipped to optimize blood flow at the site of oxygen
delivery.
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1.6

Therapeutic Angiogenesis
Treatments for patients with PAD and CLI include managing systemic

atherosclerosis

and

surgical

and

catheter-based

revascularization.

Therapeutic

angiogenesis is another approach that has been tested in clinical trials (Annex, 2013). The
inherently strong capacity of skeletal muscle to regenerate (Carlson, 1973, Tedesco et al.,
2010) with an associated angiogenesis response to ischemia (Couffinhal et al., 1998,
Limbourg et al., 2009) has formed the rationale for therapeutic angiogenesis in patients
with PAD. Therapeutic angiogenesis encompasses strategies that promote or augment the
development of new microvessels as means to treat patients with ischemic vascular
disease. The overarching goal of this therapy is to increase oxygen delivery to ischemic
tissues that have been rendered hypoxic by compromised perfusion, and promote the
restoration of normal tissue function. Another goal of therapeutic angiogenesis is to
promote the regeneration of injured tissues (Madeddu, 2005). Regenerative angiogenesis
is critical for restoring perfusion to damaged tissues that are attempting to regenerate
following ischemic injury and necrosis.
Research in these areas has focused on returning bulk blood flow to affected
organs via surgical intervention and angiogenic growth factor delivery methods. Growth
factor delivery has demonstrated promising results in animal models by potently
stimulating neovessel growth, leading to their testing in clinical trials. For critical limb
ischemia these growth factors include plasmid or adenoviral injection of VEGF-A, FGF1,
FGF2, FGF4, and HGF (Annex, 2013, Tongers et al., 2008).
Despite their promise, there has been little success in translating these preclinical
results into benefit for patients with peripheral or coronary vascular disease to date
(Simons et al., 2002, Henry et al., 2003, Norgren et al., 2007). These trials have shown
indications of short-term benefit in limb function, however the benefits do not last.
Patient selection and dosing concentration may entail some of the reasons for the lack of
therapeutic success.
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1.7

Anti-Angiogenic and Vascular Normalization Therapy
Tumors recruit a vascular network to sustain their growth. This response underlies

the rationale for the use of anti-angiogenic agents for cancer therapy (Chung et al., 2010).
In 1971, Judah Folkman coined the term anti-angiogenic therapy, which entails
promoting the regression or destruction of tumor vessels so that they cannot sustain their
growth (Folkman, 1971). However, despite an appealing premise and some clinical
success, anti-angiogenic therapy has not transformed cancer management. As
monotherapy, and combined therapy using multiple tyrosine kinase inhibitors, these antiangiogenic drugs have only been beneficial for few types of tumors and have not
improved patient survival (Ebos et al., 2011).
The less than anticipated advances with anti-angiogenesis approaches suggest that
the relationship between tumor vessels and tumor behavior is more complex than
originally considered (Jain, 2005). Important in this regard is that as described in Section
1.2.3.2., tumor vessels do not resemble normal vessels. This limits the delivery of
chemotherapeutic drugs to the tumour cells and blunts the response to radiation therapy
(Jain, 2005). With these limitations in mind, an alternative approach to targeting the
tumor vasculature has been proposed, based not on obliterating tumor vessels but on
normalizing them. Several studies have demonstrated that tumor vessels have the
capacity to improve their integrity following anti-VEGF therapy (Tong et al., 2004).
Furthermore, normalization therapy induces the improvement of mural cell wrapping and
reduction of vessel density (Goel et al., 2011). These findings suggest that normalizing
instead of obliterating the tumor vasculature may improve cancer therapy by preventing
metastasis and increasing the delivery of chemotherapy drugs.

1.8

Tools for Studying Microvascular Perfusion
Numerous tools are currently available for evaluating microvascular perfusion,

and each has it’s own advantages and limitations. Measurements include qualitative and
quantitative indices of bulk flow, flow velocity, and flow distribution. The focus of this
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section will be on tools typically employed for evaluating microvascular perfusion in the
mouse hindlimb, with a brief overview of existing tools used in the clinic.
Laser Doppler imaging is an optical approach for investigating perfusion in
mouse models of hindlimb ischemia. The approach directs laser light into the tissue. The
light is scattered by moving RBCs and produces a frequency shift produced by the
Doppler effect, and is detected by the scanner to measure velocity (Briers, 2001). Laser
Doppler imaging is capable of evaluating changes in superficial perfusion over time
following femoral artery excision, as it is sensitive only to perfusion in the upper 200-300
µm of the skin (Jakobsson et al., 1993). Therefore it is unable to evaluate perfusion
within deeper tissues, and is limited by low spatial and temporal resolution. Because of
this, it is not capable of measuring blood flow in individual microvessels, or perfusion at
the capillary level. Instead, it provides only an average indication of the magnitude and
distribution of flow within the hindlimb. It also cannot discriminate the local return of
flow to an arteriogenesis or angiogenesis response. An advantage of this technique
however is that it is non-invasive and can take repeated measurements of the same animal
over time.
Doppler ultrasound is a non-invasive method used for studying angiogenesis and
measuring tissue perfusion. Doppler ultrasound entails the acoustic detection of moving
particles within the blood stream (Leong-Poi et al., 2003). Intravascular microbubble
delivery used in conjunction with Doppler ultrasound imaging allows quantitative
measurement of microcirculatory blood flow and pulsatility (Leong-Poi et al., 2003).
Moreover, they can be targeted to surface EC markers to localize signals to active areas
of vessel growth. This tool has been used to evaluate the magnitude of perfusion in
hindlimb ischemia mouse models. However, like laser Doppler imaging, it suffers from
low spatial resolution at cannot directly measure flow at the site of oxygen delivery.
MR imaging has been used to study changes in tissue perfusion and permeability
over time that are associated with angiogenesis. Regional tissue perfusion can be assessed
with MR imaging after administration of gadolinium-based contrast agents or arterial
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spin labeling (Luo et al., 2002). However, this approach lacks sensitivity for targeted
molecular imaging and has a limited ability to directly measure microcirculatory flow.
Optical coherence tomography (OCT) is a high-resolution and three-dimensional
technique for detecting blood flow in tissues. OCT entails illuminating tissue with light of
low coherence and detecting back-scattered light based on coherence matching between
the incident and reflected beams (Ntziachristos, 2010). This strategy has been used to
map regional perfusion and vascular architecture up to 3 mm deep in hindlimb ischemia
models (Jia et al., 2011, Poole et al., 2013). However, this technique lacks sensitivity for
targeted molecular imaging and is unable to image microvessels that are less than ~20 µm
in diameter (Mariampillai et al., 2012).
Importantly, these described techniques cannot evaluate perfusion directly at the
capillary level. In contrast, intravital microscopy does have the power to study capillary
architecture and perfusion in living tissues. Intravital microscopy is an invasive technique
that can provide powerful cellular, anatomic, and functional insight into vascular
physiology and disease (Jain et al., 2002, Fukumura et al., 2008, McDonald et al., 2003,
Taqueti et al., 2013, Vajkoczy et al., 2000, Lehr et al., 1993, Menger et al., 1993). There
are many approaches to intravital microscopy including brightfield transillumination,
fluorescence epi-illumination, multiphoton microscopy, and spinning disk confocal
imaging. Each has its own application to different tissues and disease processes.
An overarching tenet of my thesis is that intravital video microscopy has the
potential to study angiogenesis at the resolution necessary for advancing the
understanding of skeletal muscle angiogenesis. Furthermore, it has the potential to
discover the processes and targets required for successful postnatal angiogenesis, and
serve as a platform for testing strategies for augmenting microvascular function. This is
because intravital microscopy can image individual microvessels at high spatial and
temporal resolution. Therefore, intravital microscopy has the potential to afford an
unprecedented window into capillary-level architecture and hemodynamics.
Intravital microscopy has been developed for studying human blood flow and
malignant disease, but only recently. This entailed developing a novel intra-operative
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microscopy platform with a robotic arm to inspect the tumor microcirculation at the
capillary level, including the use of fluorescent dyes to generate contrast for visualizing
RBCs (Fisher et al., 2016). As well, intravital fluorescence lifetime imaging has been
used in humans since 1999 for studying penetration of nanoparticles and skin cell
metabolism (Leite-Silva et al., 2013), and endoscopic autofluorescence strategies for
distinguishing normal and cancerous tissues. Other tools that are used in the clinic for
evaluating perfusion, but are typically uncommon, include nail-fold sidestream darkfield
imaging and capillaroscopy (Goedhart et al., 2007), sublingual orthogonal polarization
spectral imaging (OPS) (Martin et al., 2009), laser Doppler flowmetry (Debbabi et al.,
2010), and Doppler optical microangiography (Baran et al., 2015). Development of
minimally invasive intravital microscopy could hold exciting potential.

1.9

Aims of the Thesis
The foregoing review highlights the considerable body of research in the field of

vascular regeneration. The underlying premise of my thesis is that, despite the current
state of the art, an understanding of the architecture and function of the microneovasculature at both the network level and functional level remains poor.
To address this research gap, the broad goals of my thesis were to: 1) develop
approaches and strategies to interrogate the newly formed microvasculature in adult mice,
at high spatial and temporal resolution, including real-time; and 2) to uncover the
architectural and functional attributes of these networks, attributes that define the extent
to which they can appropriately delivery RBCs to the tissues.
I present my data in three Chapters:
Chapter 2 Overview: My objective was to determine the microvascular network
architecture, hierarchy, and RBC transit dynamics in a model of orthotopic mouse renal
cell carcinoma. Using intravital microscopy and a novel real-time strategy to elucidate
the vasoreactivity, I uniquely ascertained the microcirculatory dynamics in this tissue and
the extent to which it could be improved by the growth factor, FGF9.
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Chapter 3 Overview: My next objective was to determine the physiological
attributes of the regenerated microcirculation in the ischemic mouse hindlimb. For this, I
undertook femoral artery excision in the mouse and delineated the temporal profile of
microvascular network architecture, hierarchy, and RBC transit in the regenerated
extensor digitorum longus (EDL) muscle. In addition, I determined whether the
regenerated microcirculation could regulate blood flow in response to local hypoxia and
the SMC wrapping profile of the regenerated terminal arterioles.
Chapter 4 Overview: My objective in this chapter was to determine the microarchitectural events by which the earliest flowing neovessels in ischemic skeletal muscle
convert into an arborized network. I undertook this by scrutinizing a critical early-stage
neovascularization process with real-time RBC analysis, processed RBC transit mapping,
high-resolution tissue histology, 3-dimensional reconstructions, and VEGFR blocking
studies in vivo.
Collectively, my findings provide entirely new data and perspectives on the
formation, vulnerabilities, and cellular dynamics of the newly forming microvasculature
in tumors and ischemic and regenerating skeletal muscle.
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CHAPTER 2
Assessment of Microvascular Architecture and Function in
Mouse Renal Cell Carcinoma Via Novel Real-Time
Microscopy Strategy
Portions of this chapter are reproduced with permission from: Yin, H., Frontini, M. J.,
Arpino, J. M., Nong, Z., O'Neil, C., Xu, Y., Balint, B., Ward, A. D., Chakrabarti, S., Ellis,
C. G., Gros, R. & Pickering, J. G. 2015. Fibroblast Growth Factor 9 Imparts Hierarchy
and Vasoreactivity to the Microcirculation of Renal Tumors and Suppresses Metastases.
J Biol Chem, 290, 22127-42.

2.1 Introduction
A highly organized and functional microvascular network architecture is
fundamental for maintaining organ function and homeostasis. This includes a hierarchical
arteriole-capillary-venule (ACV) network, single file transit of RBCs in capillaries, and
local regulation of RBC transit into the network (Pries et al., 1995, Pries et al., 1996,
Koller et al., 1987, Ellis et al., 1994, Segal, 2005).
Tools and approaches for assessing the microvasculature in tissues are limited.
Currently used strategies such as laser Doppler imaging or tissue histology provide little
information on microvascular network-level architecture or hierarchy, and not at high
spatial resolution. Furthermore, these tools provide little to no information on
microvascular perfusion, RBC transit dynamics, and vasoreactivity. Understanding of the
architecture and function of microvascular networks under pathological conditions is
particularly limited.
A primary goal of my thesis was to develop approaches to understand the
microcirculation in pathological tissues. Tumors represent a pathological tissue with
profoundly abnormal microvessels. As well, the tumor vasculature has gained major
attention because local blood flow can determine tumor behaviour and malignancy
(Rummelt et al., 1994, Goel et al., 2011). Because of this, tumor vessels are a target for
therapy with the goal of killing tumor cells by obliterating tumor vessels (Folkman, 1971,
Chung et al., 2010).
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The fact that tumor vessels are also very abnormal provides an additional
consideration into understanding tumor biology. The tumor microvasculature is typically
characterized by dilated vessels and haphazard vessel branching which impairs O2
delivery (Jain, 1988, Less et al., 1991, Nagy et al., 2009, Fukumura et al., 2010, Tong et
al., 2004). In light of this, an alternative approach to targeting the tumor vasculature has
been proposed. This approach is not based on the classical tactic of obliterating tumor
vessels but, instead, on potentially normalizing the vessels and improving their capacity
for enhancing perfusion (Tong et al., 2004, Mazzone et al., 2009). The goal of this
normalization would be to kill tumor cells by improving the delivery of chemotherapeutic
drugs and the tumor’s response to radiation treatment (Jain, 2005, De Bock et al., 2011).
In this chapter, I describe the development of a strategy for evaluating
microvascular network architecture and blood flow, at high spatial and temporal
resolution, in renal tumors in mice. This strategy entailed real-time imaging of RBCs in
transit, using intravital video microscopy and following intravascular injection with high
molecular weight fluorescently-labeled dextran. I also developed an in vivo approach to
interrogate the vasomotor competence of tumor microvessels. Finally, I capitalized on a
recent discovery that delivery of fibroblast growth factor 9 (FGF9) can productively
modify skeletal muscle microvasculature (Frontini et al., 2011). I tested whether FGF9
could normalize tumor microvascular architecture, hierarchy, or vasoreactivity.

2.2 Materials and Methods
2.2.1 Cell Culture
Renca Cells (ATCC, CRL-2947), a transformed kidney cell line from BALB/cCR
(Charles River) mice, were maintained in RPMI 1640 (Invitrogen) containing 10% fetal
bovine serum. Cultures of Renca cells expressing either GFP or human FGF9 were
generated by infection with adenovirus expressing the respective cDNA for 16 h at 37°C.
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2.2.2 Orthotopic Renal Carcinoma Model
Female BALB/c mice (Charles River) at 2 months of age were used and all
experiments were conducted in accordance with the University of Western Ontario
Animal Use Subcommittee. Implantation of Renca cells into the subcapsular space of
female BALB/c mice yields an orthotopic tumor model that mimics the behavior of adult
human renal cell carcinoma, including spontaneous metastases to the lung (Salup et al.,
1985). Orthotopic primary tumors were generated from 2.5x105 Renca cells resuspended
in phosphate-buffered-saline (PBS) and mixed 1:1 (v/v) with growth factor-reduced
Matrigel (BD Biosciences). Cell-Matrigel suspensions were injected as 30-µL aliquots
into the subcapsular space of the left kidney of BALB/c mice. On designated days,
animals were euthanized with isofluorane inhalation and both kidneys harvested for
histologic analyses. Renca cells were transduced with adenovirus encoding either GFP or
human FGF9.
2.2.3 Intravital Microscopy
Tumor-bearing BALB/c mice were anesthetized with inhaled isoflurane, the
kidney tumor was exteriorized and placed within the central recess of a custom-built
transparent plexiglass chamber positioned on the stage of an inverted microscope (IX81,
Olympus) and kept moist by filling the chamber with 0.5 mL of 37°C Krebs
physiological salt solution, pH 7.4. The tumor was epi-illuminated with a 120 W Mercury
X-Cite high-pressure bulb light source with 10x and 20x objectives (Olympus
UPlanSApo). Blood flow in the tumor was visualized by either ultraviolet epiillumination (DAPI U-MWU2: 330-385 nm excitation filter, 420 nm emission filter) or
blue light epi-illumination (U-MWIBA2: 460-490 nm excitation filter, 510-550 nm
emission filter) following intravenous tail vein administration of FITC-labeled dextran
(2x106 MW; 20 mg/mL, 50 µL, Sigma). Images were acquired using a cooled chargecoupled device camera (Rolera-XR, QImaging) at a rate of 21 images/s. Live image
sequences were digitized and stored as uncompressed AVI movie files using custom
frame capture software (Neo-Vision) and in-house software written in the MATLAB
(Mathworks) programming environment. Offline analysis of movie files was conducted
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using ImageJ (NIH) software to quantify the vascular network morphometry of at least 10
random fields of view, in both control and FGF9-exposed tumors. Vascular length
density was determined by manual tracing of all vessel centerlines and total network
length was expressed relative to tumor area. Branch point density was determined by
manual point counting of all vascular bifurcations and expressed as total bifurcations
relative to total network length. Lumen diameter was determined by manually
quantifying widths of individual vessels, perpendicular to the vessel centerline.
Capillaries were defined as vessels with single-file red blood cell flow. Microcirculatory
units were defined as flow routes in which RBCs flowed from an arteriole-like vessel into
one or more capillaries that drained into a venous structure characterized by slower flow
than the feeding arteriole. Simple microcirculatory units were defined as those with a
single capillary between an arteriole-venule pair and complex circulatory units were
those with two or more capillaries between the pair. Vasoreactivity was assessed in
arteries 20-60 µm in diameter, assessing the entire exposed tumor surface, at baseline and
following administration of phenylephrine (Sigma, 1x10-6 M), after flushing with Krebs
solution and administering potassium chloride (KCl, 1x10-2 M), and after flushing with
Krebs solution and administering sodium nitroprusside (SNP) (1x10-7 M).
2.2.4 Local Delivery of Anti-PDGFRβ Antibody to Renal Tumors
Seven days after Renca cell implantation, mice were anesthetized with isoflurane
and the left kidney and associated tumor were re-exposed. Rat monoclonal PDGFRβ
blocking antibody (16-1402-82, eBioscience) or rat IgG isotype-matched control (164231-82, eBioscience) were diluted to 50 µg/mL in 30% Pluronic F-127 gel (Sigma) and
the gel was then applied to the tumor surface with two sequential applications, 30 s apart,
using a fine brush. After 3 days the tumors were subjected to intravital microscopy, as
above.
2.2.5 Statistics
Statistical analyses were performed using Prism 5 (GraphPad software). Values
are presented as mean ± standard error of the mean (sem). Groups were compared by
two-tailed t-test. Comparison of vessel diameters, which were not normally distributed,

77
was undertaken using Mann-Whitney testing. Frequencies of capillaries positioned
between arterioles and venules, and arteries displaying vasoreactivity were compared
using Fisher’s exact test.

2.3 Results
2.3.1 Generation of a Vascularized Tumor For Real-Time Microscopy Assessment
Colleagues in Dr. Pickering’s laboratory had previously demonstrated that
implantation of the renal adenocarcinoma cell line, Renca, into the kidney subcapsular
space of female BALB/c mice generates an orthotopic kidney tumor (Frontini, 2010)
(Figure 2.1). Renca-derived tumors after 14 days were 3-fold heavier (514.9±114.6 mg)
than contralateral control kidneys (146.8±10.2 mg). Microvessels were readily detectable
in 14-day-old tumors, based on hematoxylin and eosin staining, and immunostaining
revealed that over 90% of these microvessels were lined by CD31-positive endothelial
cells (Frontini, 2010).
2.3.2 The Microvascular Architecture in Renal Tumors is Profoundly
Disorganized
To evaluate and characterize the microvascular network architecture of Rencaderived tumors, I developed a real-time microvessel visualization approach. This entailed
exteriorizing the kidney and surrounding tumor and imaging RBCs in transit by
epifluorescence intravital microscopy (Figure 2.2 a). This revealed highly disorganized
and chaotic RBC flow within the Renca tumor (Figure 2.2 b). RBC transit was strikingly
slow, with RBCs tumbling through enlarged and tortuous vascular channels (Figure 2.2
b). In addition, the movement of RBCs throughout the microvascular network was
seemingly random, characterized by frequent directional changes at vessel bifurcations
and by opposing flow directions within two parallel vessels.
To make a broad comparison of the tumor microcirculation to that of a normal
tissue, I also used a similar approach to study the microvascular network architecture in
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Figure 2.1 Generation of a mouse orthotopic renal carcinoma
Photograph of a kidney tumor harvested 14 days after renal subcapsular injection of
Renca cells in growth factor-reduced Matrigel. The corresponding, non-injected
contralateral kidney is shown on the right. From: (Frontini, 2010).
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Figure 2.2 Network architecture of normal and abnormal microcirculations
A. Schematic of kidney tumor exteriorization and epifluorescence intravital video
microscopy setup.
B. Still frame from an ultraviolet light epifluorescence microscopy video
sequence showing the abnormal microvascular network architecture of the
Renca-derived tumor.
C. Still frame from an ultraviolet light epifluorescence microscopy video
sequence showing the structured hierarchy of arterioles (A), capillaries (C),
and venules (V) in healthy mouse extensor digitorum longus (EDL) muscle.
D. Table of comparisons between network length density (µm vessel / µm2
surface area), network branching density (number of bifurcations / mm vessel
length), and vessel segment lumen diameter (µm) in Renca tumor and mouse
EDL skeletal muscle. For length and branching density, 10 fields of view were
averaged from three tumors and five hindlimb skeletal muscles. For lumen
diameter, 346 microvessels from three tumors and 164 microvessels from five
skeletal muscles were measured.
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the mouse extensor digitorum longus (EDL) muscle. This revealed that within the EDL
muscle, RBCs flowed rapidly through highly organized, narrow-caliber vascular channels
(Figure 2.2 c). Moreover, the movement of RBCs in neighbouring vessels occurred in a
generally unified flow direction and was characterized by the flow of RBCs from
arterioles to capillaries to venules (Figure 2.2 c). Therefore, the microvascular network of
Renca-derived tumors contrasted strikingly with that of a healthy microcirculation in a
normal tissue.
Quantitative assessment of microvascular network architecture revealed that the
renal tumor and EDL muscle were both highly vascularized tissues (vascular length
density: 0.032±0.01 vs 0.029±0.01 µm/µm2, P=0.212) (Figure 2.2 b-d). However, the
tumor network exhibited a high level of vessel branching (11.5±1.1 vs 4.3±1.1
bifurcations/ mm vessel, P<0.0001) (Figure 2.2 b-d). As well, the individual vessel
segments were markedly dilated (31.8±1.9 vs 5.6±0.1 µm, P<0.0001) (Figure 2.2 b-d).
Thus, both qualitatively and quantitatively, the microvascular network in Renca-derived
tumors was profoundly abnormal.
2.3.3 Detection of FGF9-Mediated Changes to the Renal Tumor Microvascular
Architecture
Delivery of FGF9 has previously been shown to productively modify the skeletal
muscle microvasculature (Frontini et al., 2011). Therefore, I next questioned whether my
imaging strategy could provide insights as to whether delivery of FGF9 could improve
the tumor microvascular network architecture, recognizing the profoundly disorganized
network I identified. To do this, Renca cells expressing either GFP or human FGF9 were
implanted into the kidney subcapsular space of female BALB/c mice. Both GFP- and
FGF9-expressing Renca cells yielded rapidly expanding local tumors. Colleagues in Dr.
Pickering’s laboratory previously found that FGF9 had little to no direct effect on the
growth of tumor cells (Frontini, 2010). Also, immunoblotting revealed that FGF9
expression was detectable in Renca-FGF9 tumors for at least 14 days, but FGF9 was not
detected in control (GFP) tumor (Frontini, 2010). Furthermore, both tumor types were of
equal weight (Frontini, 2010).
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Imaging RBC transit in the tumors by intravital microscopy revealed striking
changes to the microvascular network architecture imparted by local delivery of FGF9.
Whereas vessels in control tumors were densely packed and highly branched, those in
FGF9-expressing tumors were more spaced and evenly distributed with an overall less
chaotic appearance (Figure 2.3 a,b). Quantitative analysis revealed a 33% reduction in
microvessel length density (P=0.034), a 67% reduction in mean lumen diameter
(P<0.0001), and 57% few branch points (P=0.019) (Figure 2.3 c).
As well, in contrast to the rough appearance of control tumor microvessels and the
associated sluggish flow, there was a “smooth” appearance to some vessels in FGF9expressing tumors with faster RBC transit. The latter suggested the emergence of an
arterialized vessel (Figure 2.3 b). Consistent with this, there was heterogeneity in vessel
architecture throughout the network, with both fast and slow flowing vessels. In the latter
case, there were RBC-free spaces in the lumen, consistent with a venous structure (Figure
2.3 b). Therefore, delivery of FGF9 led to reduced vascularity, less branching, narrower
channels, and the suggestion of more differentiated vessel types.
2.3.4 FGF9 Normalizes Microvascular Network Hierarchy and RBC Distribution
I next sought to determine the microvascular network hierarchy and physiologic
vessel specification in the renal tumor microcirculation. To do this, I assessed blood flow
routes throughout the tumor microvasculature by tracking the motion of RBCs using realtime microscopy at double magnification, which allowed for a more detailed assessment
of individual RBC movement. In control GFP-expressing tumors, RBC transit was
characterized by serpentine flow routes (Figure 2.4 a). As well, RBC movement from
channel to channel was seemingly random (Figure 2.4 a). Moreover, transitions in vessel
caliber in the direction of blood flow were non-progressive (Figure 2.4 a,b). That is, the
transitions did not follow a large-smaller-larger network hierarchy pattern typical of a
normal

microcirculation

with

an

ordered

arteriole-capillary-venule

hierarchy.

Furthermore, there were substantial step changes in lumen diameter from parent to
daughter vessel (Figure 2.4 b).
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Figure 2.3 Productive modification of the tumor microvascular architecture by
delivery of FGF9
A-B. Ultraviolet fluorescence intravital microscopy images of RBCs flowing within
the vasculature of GFP-expressing (A) and FGF9-expressing (B) renal tumors
14 days after injection of Renca cells. GFP-expressing tumors (A) show a
densely packed network of highly branched vessels. The network in FGF9expressing tumors (B) is less dense and less branched, with the appearance of
arterialized (A) and venous (V) structures.
C. Graphs depicting vascular length density (*p=0.034), lumen diameter (**
p<0.0001), and branch point density († p=0.019). At least 10 fields of view
were averaged for each mouse, with 3 GFP-expressing tumors and 4 FGF9expressing tumors.
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Figure 2.4 FGF9 imparts hierarchy to the tumor vasculature
A. High magnification intravital image illustrating serpentine and chaotic flow
routes (yellow arrows) in GFP-expressing tumors.
B. High magnification intravital image illustrating orphaned capillaries (white
arrows) and lumen diameter step changes (dotted yellow lines) in GFPexpressing tumors. Yellow arrow depicts flow route.
C. High magnification intravital images of two distinct FGF9-expressing tumors
with ordered flow through hierarchical arterial (A)- capillary (C)- venous (V)
microcirculatory units. Arrows depict flow routes, and dotted arrows shows
flow routes through arteriole located deeper within tissue.
D. Graphs depicting the density of simple and complex microcirculatory units of
arterial to capillary to venous flow (*p<0.0001; † p=0.007), capillary density
defined as vessels with single file RBC flow (p=0.233), and percentage of
capillaries positioned within a microcirculatory unit (*p=0.028). At least 10
fields of view were averaged for each mouse, with 3 GFP-expressing tumors
and 4 FGF9-expressing tumors.
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In contrast to control tumors, I identified discrete hierarchical ACV
microcirculatory units in FGF9-expressing tumors. In these units, RBCs flowed through
gradually and progressively smaller caliber vessels, entered one or more capillaries, and
then drained into a collecting venule (Figure 2.4 c). I termed the microcirculatory units
that entered a single capillary as simple microcirculatory units and those entering more
than one capillary as complex microcirculatory units.
Notably, within capillaries, RBCs transited in single file, with plasma gaps
between each cell (Figure 2.4 b,c). By this definition, capillaries were rare in control
tumors (Figure 2.4 d). Moreover, those that were identified were effectively orphaned,
with no evidence for a feeder arteriole or a draining venule. Instead, they were bizarrely
situated between two large caliber venous-like channels (Figure 2.4 b). In contrast, 30%
of capillaries in FGF9-expressing tumors were appropriately positioned within a bona
fide microcirculatory unit (P=0.028, Figure 2.4 d). Thus, delivery of FGF9 imparted
hierarchy to the tumor microvasculature.
2.3.5 FGF9 Generates a Vasoreactive Tumor Vasculature
I next sought to determine whether the FGF9-modified microvascular tree was
capable of regulating blood flow. In a normal microvascular network, this is
accomplished through the vasoreactivity of arteriolar vessels. However, this has never
been assessed before in a tumor microvascular network. To do this, I established a system
for the local delivery of vasoconstrictive and vasodilatory agents to the exposed tumor
surface (Figure 2.2 a). Ten days after implantation of GFP- or FGF9-expressing tumor
cells, mice received a systemic injection of FITC-conjugated high molecular weight
dextran, vessels were imaged by intravital microscopy, and phenylephrine (1x10-5 M),
potassium chloride (KCl, 1x10-2 M), and sodium nitroprusside (1x10-7 M) were
sequentially administered. By recording video frames of the entire exposed tumor
surface, I ascertained that although vasoresponsiveness was not evident in the control
tumors, it was present at sites in FGF9-expressing tumors. In some vessels, discrete sites
of vasoconstriction developed in response to phenylephrine (Figure 2.5 a). Constriction
further increased upon KCl delivery, with more diffuse lumen narrowing (Figure 2.5 a).
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Figure 2.5 FGF9 imparts tumor vessels with vasoreactivity
A. Intravital microscopy images of vessels within orthotopic renal tumors 10 days
after injection of Renca cells, imaged live by intravital microscopy following
injection of FITC-labeled dextran. Images depict the vascular lumen before and
after subfusion of phenylephrine (10-5 M), KCl (10-2 M), and SNP (10-7 M), for a
minimum of 3 min as indicated. Arrows within the lumen depict the direction of
flow. Top panel, vessel within an FGF9-expressing tumor showing focal
vasoconstriction (arrows) in response to phenylephrine subfusion, and both focal
and diffuse constriction following KCl subfusion. The lumen diameter widens
after subfusion with SNP. Middle panel, vessels within an FGF9-expressing
tumor showing flow down a network with progressively smaller branches.
Following phenylephrine subfusion, diffuse vessel constriction can be seen as
well as complete cessation of flow in some of the distal vessel branches (short
arrows). This is accompanied by a loss of fluorescence signal throughout the
tumor, indicating widespread reduction in tumor perfusion. Diffuse vessel
constriction, cessation of flow in distal vessels (short arrow), and generalized
hypoperfusion are even more pronounced following KCl administration. These
changes are partially reversed following delivery of SNP. Bottom panel, vessels
within a GFP-expressing tumor showing no change in luminal diameter or flow
indicators following delivery of vasomotor agents.
B. Plot of all vessel segments imaged, 20-60 µm in diameter and with continuous
flow into progressively smaller branches, which displayed vasoreactivity. n=34
and 28 vessels in GFP- and FGF9-expressing tumors, respectively (p=0.0085).
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After SNP, these changes were almost completely reversed and the vessels relaxed
(Figure 2.5 a). In regions where an arborized and tapered arterial tree was present,
vasoconstriction was sometimes associated with complete cessation of flow in one or
more of the arterial branches. This was coupled to a corresponding diffuse loss of FITC
signal in the surrounding tumor environment, suggesting reduced perfusion to the region
(Figure 2.5 a, middle).
Quantitative analysis of all vessels between 20 and 60 µm in diameter that flowed
into narrower caliber vessels confirmed a statistically significant acquisition of
vasoreactivity in FGF9-expressing tumors (Figure 2.5 b). The ability to regulate flow
through vasomotion, with functional α-adrenergic and nitric oxide signaling, represents a
level of physiologic maturity not previously identified in tumor microvessels.
2.3.6 FGF9-Mediated Network Differentiation is Abrogated by Local Inhibition of
PDGFRβ
I next applied the real-time microscopy strategy to help dissect the mechanism
behind FGF9-driven microvascular network differentiation. Dr. Pickering’s laboratory
had previously shown that delivery of FGF9 increases the expression of PDGFRβ
(Frontini, 2010). Furthermore, using the Renca-derived tumor model, it was found that
FGF9 selectively amplified a PDGFRβ-positive stromal mesenchymal cell population in
the tumor, which were found to wrap endothelial cell-lined channels (Yin et al., 2015).
Given the existence of an FGF9-sensitive, PDGFRβ-expressing stromal population, I
asked if the PDGFRβ receptor mediated the FGF9-induced reshaping of the
microvasculature. To test this, I developed a strategy to apply Pluronic-F127 gel
containing anti- PDGFRβ antibody, or isotype-matched IgG, to the surface of 7-day-old
tumor. I then assessed the impact of PDGFRβ blockade on network architecture using the
intravital microscopy-based assessment of the vascular network three days later.
Exposure of FGF9-exposed tumors to PDGFRβ blocking antibody yielded vessels
that were significantly more dilated (2.0-fold, P<0.0001) (Figure 2.6 a,b). Moreover, the
tumor microvessels were more branched (1.7-fold, P=0.003) (Figure 2.6 a,b).
Furthermore, the number of capillaries in FGF9-exposed tumors was reduced by 57%
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Figure 2.6 PDGFRβ blockade abrogates the effects of FGF9 on tumor network
architecture and vasoreactivity
A. Intravital microscopy image of FGF9-exposed tumors locally treated with control
IgG or anti-PDGFRβ antibody, showing that PDGFRβ blockade (right) renders a
disordered microvasculature that resembles a GFP-expressing tumor and contrasts
the ordered arrangement of vessels in FGF9-exposed tumors (left). Specifically, a
hyper-dilation of vessels (lumens constrained by yellow dotted lines), increased
branching, and a lack of ordered network hierarchy are shown.
B. Graphs showing data from FGF9-incubated tumors exposed to anti-PDGFRβ
antibody or control IgG, depicting vascular lumen diameter (*p<0.001), branch
point density (*p=0.003), length density (p=0.094) or capillary density
(*p=0.046). Data are averaged from at least 10 fields of view for each antibody
treatment condition.
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(P=0.046) (Figure 2.6 a). In addition, by dynamically imaging vessel lumen caliber I
found no evidence for constriction of microvessels in response to phenylephrine or KCl
in FGF9-exposed tumors subjected to PDGFRβ blockade. Thus, the structural and
functional actions of FGF9 on the tumor vasculature depended on PDGFRβ-positive
stromal cells.

2.4 Discussion
In this study, I have demonstrated a powerful new approach for evaluating the
renal tumor microvasculature in mice. Using epifluorescence intravital microscopy, and
by tracking the movement of RBCs, this real-time strategy revealed profound
abnormalities in RBC transit and network architecture, including an absence of
microcirculatory hierarchy. Thus, the construction of an organized microcirculation for
properly delivering RBCs into capillaries was not replicated during generation of the
tumor microvasculature.
This microvascular imaging strategy for assessing tumor vasculature has several
strengths. First, the approach enables rapid visualization of microvascular networks over
a large area of tumor. Each field of view can be rapidly imaged (~15 seconds), followed
by simply moving to the next field of view. Second, the strategy enables high spatial (0.61.3 µm2 pixel size) and high temporal resolution (21 images/second) imaging. This
provides a flow-based assessment of microvascular network architecture. Third,
individual RBCs in transit can be delineated in real-time to assess network hierarchy,
RBC transit dynamics, and vessel specification. Fourth, this strategy can be used in
conjunction with the local delivery of vasoactive agents to assess microvessel
vasoreactivity and changes in network perfusion, in real-time and in space. A limitation
of this imaging strategy is that the microvasculature cannot be visualized within tissue
that is deeper than ~50 µm from the tumor surface.
Real-time micro imaging of blood flow not only gave detailed insight into the
deranged tumor vasculature, it also powerfully revealed the consequences of delivering
FGF9 to the tumor. The paradigm of tumor vessel normalization has emerged in recent
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years and it is proposed that anti-angiogenesis therapies may confer their benefit, at least
in part, through vessel normalization (Goel et al., 2011). To date, indicators of vessel
normalization have included reduced vessel density, smaller caliber channels, enhanced
endothelial cell integrity, and increased coverage by mural cells (Goel et al., 2011, Kim et
al., 1993, Yuan et al., 1996, Greenberg et al., 2008, Carmeliet et al., 2011). However, if
the goal is to approximate the perfusion attributes of healthy tissue, there remains a
substantial “gap” between the architectural and flow status of a post-anti-angiogenesis
targeted vasculature and that of healthy tissues. The findings herein with FGF9 delivery
indicate that this differentiation gap can be narrowed and that a physiologically advanced
microcirculation in tumors is achievable.
The emergence of a hierarchical network following delivery of FGF9 where fast
flowing arterioles fed capillaries that drain into slow flowing venules was particularly
striking. A degree of vascular network hierarchy has been suggested in glioblastomas
treated with cedranib, as indicated by a mixture of high- and low-flow vessels (Emblem
et al., 2013). Hierarchy after anti-angiogenesis therapy in mice has also been suggested
by improvements in tumor metabolism and drug delivery (Maes et al., 2014, Chauhan et
al., 2012). However, these changes in blood flow and drug delivery could also be due to
alterations in hydrostatic pressure (Goel et al., 2011). The current intravital, micron-level
assessment of the vasculature provides direct evidence that microcirculatory hierarchy
can be obtained in tumors. FGF9 yielded a network with reduced vessel density, reduced
vessel diameter, reduced vessel branching, and hierarchical arteriole-capillary-venule
microcirculatory units. This hierarchical architecture provides a functional route for
flowing RBCs, avoiding recycling of deoxygenated blood.
Real-time visualization of all flowing RBCs enabled us to define capillaries as
vessels in which RBC transit proceeded exclusively in single file. The emergence of bona
fide capillaries has not been identified in tumors before. A seminal report by Tong and
co-workers (Tong et al., 2004) described a reduction in vessel caliber in response to
VEGFR2 blockade, with the emergence of more vessels below 20 µm in diameter.
However, vessels in this size range can still accommodate simultaneous transit of
multiple cells, unlike capillaries in normal tissues where diameters average 4-6 µm

96
(Baum et al., 2013, Wang et al., 2011). We determined that capillaries with single file red
blood cell flow were rare in control tumors and most of those that were found were
orphaned from arterioles. By contrast, FGF9 generated bona fide capillaries appropriately
situated within microcirculatory units to optimize oxygen delivery.
My finding of vasomotor competence in the microcirculation of FGF9-exposed
tumors is also relevant to generating functional perfusion in tumors. Several integrated
control systems regulate microvascular flow, including centrally initiated neural
impulses, circulating hormonal factors, local myogenic responses, and retrograde
conducted vascular signaling from local hypoxic cues (Segal, 2005, Clifford, 2011). The
fact that arterial-caliber vessels in FGF9-exposed tumors contracted to α-adrenergic
stimulus and dilated in response to nitroprusside, with concomitant shifts in distal
perfusion, reveals a previously unobserved competency in regulating tumor
microcirculatory flow. Although we cannot exclude the possibility that some of the
vasoactive arteries were pre-existing vessels that became engulfed by the growing tumor,
the widespread emergence of vasoreactivity exclusively in FGF9-exposed tumors argues
for maturation of de novo generated tumor blood vessels.
The real-time intravital microscopy approach also established that the PDGFRβ
was central to the productive vascular remodeling conferred by FGF9. Blockade of
PDGFRβ in the tumors prevented the productive vascular remodeling by FGF9, and led
to hyperdilation of the channels and reduction of bona-fide capillaries. As well, it
abolished the vasoreactivity imparted to feeder vessels in FGF9-exposed tumors.
In summary, using a novel real-time microvascular imaging strategy, I have
undertaken a flow-based characterization of tumor microvascular architecture, hierarchy,
capillary flow, and vasoreactivity. This has revealed both profound abnormalities, but
also the capacity to regain microvascular differentiation through the delivery of FGF9.
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CHAPTER 3
Four-Dimensional Microvascular Analysis Reveals That
Regenerative Angiogenesis in Ischemic Muscle Produces a
Flawed Microcirculation
Reproduced (adapted) with permission from: Arpino, J. M., Nong, Z., Li, F., Yin, H.,
Ghonaim, N. W., Milkovich, S., Balint, B., O'Neil, C., Fraser, G. M., Goldman, D., Ellis,
C. G. & Pickering, J. G. 2017. Four-Dimensional Microvascular Analysis Reveals that
Regenerative Angiogenesis in Ischemic Muscle Produces a Flawed Microcirculation.
Circ Res. 120, 1453-65

3.1 Introduction
It is well established that a robust angiogenesis response can occur following
ischemic injury to skeletal muscle. This neovascularization response, together with
opening of collateral vessels, can restore blood flow to the otherwise compromised
muscle (Couffinhal et al., 1998, Limbourg et al., 2009). The innate capacity to regenerate
a vasculature in muscle has also provided an important rationale for efforts to augment
angiogenesis for individuals with peripheral vascular disease. However, to date such
strategies have met with little to no success (Annex, 2013, Simons et al., 2003). There
may be several reasons for this lack of success, but a fundamental and unanswered
question is the extent to which a regenerated microvasculature in adult muscle can meet
the metabolic needs of the tissue.
The microcirculation in normal skeletal muscle consists of a highly-organized
network of arterioles, capillaries, and venules, structurally arranged to optimize oxygen
transport. This microcirculatory network provides the necessary conduits for red blood
cells (RBCs) to deliver their oxygen. In addition, the network dynamically controls the
passage of RBCs throughout the tissue. This local control system ensures that RBC
delivery is tightly coupled to the metabolic needs of the tissue. An important driver of
this control loop is the local oxygen content, which can inform the feeder arterioles to
dilate or constrict as appropriate (Segal, 2005). Thus, integration of precise structural and
functional attributes of the microcirculation are critical to oxygenating muscle tissues.
However, the attributes of a regenerated microcirculation in skeletal muscle are largely
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uncharacterized. The network microarchitecture is poorly understood and whether the
network can dynamically regulate RBC transit is entirely unknown.
One of the best-studied models of regenerative angiogenesis following ischemia is
ligation or excision of the femoral artery in mice (Limbourg et al., 2009). Use of laser
Doppler imaging has established near complete return of bulk blood flow to the ischemic
mouse hindlimb, particularly in the C57Bl/6 strain (Scholz et al., 2002, Helisch et al.,
2006). This return of flow has been shown to be due to both collateral vessel opening
(Couffinhal et al., 1998, Scholz et al., 2002, Helisch et al., 2006, Duvall et al., 2004) and
generation of new microvessels (Limbourg et al., 2009, Scholz et al., 2002), as
established from angiographic and histologic studies. However, standard histology
techniques do not address network-level architecture of the microvasculature. As well, in
vivo imaging tools typically lack the spatial resolution to resolve distinct microvessels or
to measure blood flow within them. Accordingly, answering whether the regenerated
microcirculation is optimized for oxygen delivery requires different methodologies that
can provide higher spatial and temporal resolution and are suitable for evaluating skeletal
muscle angiogenesis.
Herein, I describe an integrated, high-resolution 4-dimensional imaging approach
for studying the regenerated microvasculature in skeletal muscle. I utilized this approach
to determine if the reconstructed microcirculation recapitulates the anatomy and
physiology of a normal microvasculature. I report that despite extensive angiogenesis and
remodeling, the regenerated microcirculation is a profoundly flawed network that cannot
adequately control the delivery of RBCs.

3.2 Materials and Methods
3.2.1 Mouse Hindlimb Ischemia
Experiments were conducted in accordance with the University of Western
Ontario’s Animal Care and Use Subcommittee. Male C57BL/6J mice (Jackson
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Laboratories, Bar Harbor, ME) 12 weeks of age were anesthetized with ketamine
(80mg/kg) and xylazine (10mg/kg) administered intraperitoneally. Hindlimb ischemia
was induced by ligating the right femoral artery above and below the profunda femoris
branch using 6-0 silk sutures and excising the intervening 5-6 mm portion of artery
(Limbourg et al., 2009, Frontini et al., 2011).
3.2.2 Histology and Immunostaining
Extensor digitorum longus (EDL) muscles were dissected, fixed in either Trisbuffered zinc or 4% paraformaldehyde (PFA) overnight and embedded in paraffin. Fiveµm thick cross-sections of EDL muscle were stained with hematoxylin and eosin. Near
adjacent sections were subjected to heat-mediated antigen retrieval with citrate buffer and
immunostained for endothelial cells using biotinylated rat monoclonal anti-mouse CD31
antibody (1:100, BD Biosciences 553371) and DAB Substrate (Vector). Nuclei were
visualized by counterstaining with hematoxylin. For immunofluorescence detection of
endothelial cells, five-µm thick sections of EDL muscle were subjected to antigen
retrieval and immunostained using rat monoclonal anti-mouse CD31 antibody (1:20,
Dianova, Clone SZ31) or rat monoclonal anti-mouse endomucin antibody (1:100, Santa
Cruz, Clone V.7C7, sc-65495) and detected using Alexa Fluor-488 conjugated goat antirat IgG (1:100 for CD31, 1:200 for endomucin, Life Technologies). Endothelial cells
were also stained using biotinylated isolectin-b4 (1:100, Sigma, BSI-B4, L2140),
detected using Dylight 488-conjugated streptavidin (1:200, Vector) and immunostained
for Von Willebrand factor (vWF). In the latter instance, EDL muscles were fixed in 4%
PFA at room temperature for two hours, subjected to cryoprotection by immersion in
15% sucrose at room temperature for two hours then 30% sucrose at 4°C overnight,
frozen in OCT compound (Tissue-Tek), and stored at -80°C. Ten-µm thick frozen
sections were post-fixed with 4% PFA for ten minutes and immunostained using rabbit
polyclonal anti-vWF antibody (1:50 in 0.1% Triton-x 100, Millipore AB7356) and
biotinylated goat anti-rabbit IgG (1:100 in 0.1% Triton-X 100, Vector) and Dylight 488conjugated streptavidin (1:200 in 0.1% Triton-X 100, Vector). Nuclei were visualized
with DAPI Fluoromount-G (SouthernBiotech, 0100-020). Sections were imaged by
widefield microscopy (Olympus BX-51) and photomicrographs captured with Northern
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Eclipse (EMPIX Imaging Inc.) software.
Capillary density and capillary-to-muscle fiber ratio were quantified in 10 equally
spaced high-powered (60x objective) fields from a 50-µm thick zone at the muscle
periphery using ImageJ (NIH). Muscle fiber density and cross-sectional area were
quantified in the mid-zone of the native and regenerated EDL muscle under highpowered view (40x objective) using ImageJ (NIH). For infarct analysis of all muscles in
entire the hindlimb, the PFA-fixed hindlimb was decalcified by immersing in 6.5%
EDTA solution (pH 7.0) for 10 days and then divided into five blocks that were
embedded in paraffin, sectioned, and stained for hematoxylin and eosin.
3.2.3 Detection of Muscle Hypoxia
Muscle hypoxia was assessed by immunohistochemical detection of pimonidazole
adducts, following intraperitoneal injection of pimonidazole hydrochloride (60 mg/kg,
HypoxyprobeTM-1Kit, Hypoxyprobe, Inc.) into mice 28 days following femoral artery
excision. Forty minutes after injection, mice were sacrificed by isofluorane overdose,
perfused sequentially with PBS and 4% PFA via left ventricle cannulation at
physiological pressure, and both injured and contralateral EDL muscles were dissected.
Five-µm thick paraffin-embedded cross-sections were immunostained with a monoclonal
mouse anti-pimonidazole antibody (Hypoxyprobe-1 mAb, 1:50) and the signal detected
according to the manufacturer’s protocol with DAB substrate (Vector). Injured EDL
muscles dissected from mice 28 days following femoral artery excision that were not
injected with pimonidazole hydrochloride served as a technical control. Sections were
counterstained with hematoxylin and hypoxia signal was quantified from entire EDL
muscle mid-zone cross-sections using ImageJ, by isolating DAB via the colour
deconvolution plugin (Ruifrok et al., 2001) and measuring the raw integrated signal
density following thresholding, using an identical grey scale (61-255) for all samples.
3.2.4 Transcript Analysis by RT-PCR
Total RNA from uninjured and regenerated EDL muscles 28 days following
femoral artery excision was extracted with Trizol (Life Technologies) and RNEasy
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(QIAGEN) and subjected to reverse transcription as described previously (Frontini et al.,
2011). The mRNA abundance of adrenomedullin, lysyl oxidase (LOXL2), procollagen
lysyl hydroxylase 2 (PLOD2), and VEGF-A was quantified using quantitative RT-PCR
and SYBR Green chemistry and a ViiA 7 Real Time PCR System (Life Technologies).
Gene expression was normalized to the mouse 18S signal using the ΔΔCt method.
Primers

pairs

(OriGene)

employed

were:

Adrenomedullin,

5’-

GCCAGATACTCCTTCGCAGTTC-3’ and 5’-GCGACTACTCTGCTGTCAAGGA-3’;
LOXL2,

5’-TTCTGCCTGGAGGACACTGAGT-3’

CGGTCACCTATCTGTAGTGGCT-3’;

and

5’-

PLOD2,

5’-

CATCCGAGAGTTCATTGCTCCAG-3’ and 5’-CATGAGTGG ACTTTCTGTCGCG3’;

VEGF-A

5’-CTGCTGTAACGATGAAGCCCTG-3’

CCTCTCTACTCGAAGGATGTCG-3’;

and

ANGPT1

5’5’-

AACCGAGCCTACTCACAGTACG-3’ and 5’-GCATCCTTCGTGCTGAATCGG-3’;
and

ANGPT2

5’-

AACTCGCTCCTTCAGAAGCAGC-3’

and

5’-

TTCCGCACAGTCTCTGAAGGTG-3’.
3.2.5 Intravital Video Microscopy
RBC transit in individual microvessels within a 50 µm-deep zone across the entire
mouse EDL surface was assessed by epifluorescent intravital video microscopy (IVVM).
Briefly, mice were anesthetized with ketamine and xylazine intraperitoneally and a
longitudinal incision was made over the anterior hindlimb. Tibialis anterior and peroneus
longus muscles were separated from surrounding fascia and spread apart to reveal the
underlying EDL (Tyml et al., 1991). The EDL was covered with an 8x8 mm glass
coverslip, and positioned face-down on the stage of an inverted microscope (Olympus
IX81), maintaining body temperature at 37°C. After a 20-minute stabilization period, the
EDL was epi-illuminated with a 120 W Mercury X-Cite high-pressure bulb light source,
via a 10x objective (Olympus UPlanSApo). RBC transit was visualized by either
ultraviolet light epi-illumination (DAPI U-MWU2: 330-385 nm excitation filter, 420 nm
emission filter) or blue light epi-illumination (U-MWIBA2: 460-490 nm excitation filter,
510-550 nm emission filter) (Frontini et al., 2011, Yin et al., 2015) following intrapenile
injection of FITC-labeled dextran (2x106 MW; 20 mg/mL, 30 µL, Sigma). Video
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recordings (696x520 pixels, 21 images/s) were captured using a cooled charge-coupled
device camera (Rolera-XR, QImaging) and displayed in real-time on a computer monitor
for at least 315 images (15 seconds). For all studies, the entire EDL surface was recorded
and analyzed (7-10 fields of view). Video sequences were digitized and stored as
uncompressed AVI files for post-processing using custom acquisition software
(NeoVision) and in-house software written in the MATLAB (Mathworks) programming
environment.
RBC hemoglobin O2 saturation in capillaries near the EDL surface was assessed
by white light transillumination IVVM, as described previously (Ellis et al., 2010, Fraser
et al., 2012). For this, a silk suture was attached to the distal EDL tendon. The tendon was
severed distal to the ligature, and the EDL was reflected onto the microscope stage
(Olympus IX81) and secured at approximately its in situ resting length and orientation.
The EDL was kept moist with Plasma-lyte 148 (Baxter International) at 37°C, and
covered with polyvinylidene chloride film (Saran Wrap, Dow Chemical) and a glass
coverslip to isolate it from room air. The EDL was transilluminated with a 100-W xenon
lamp, and transmitted light was captured with 10x and 20x objectives (Olympus
UPlanSApo) and a parfocal beam splitter (DualCam) fitted with 442-nm (an O2 sensitive
wavelength for oxy- and deoxyhemoglobin) (Faber et al., 2003) and 454-nm (an
isosbestic or O2 insensitive wavelength) band pass filters for dual video cameras. The
beam splitter passed 442-nm light to one cooled charge-coupled device camera (RoleraXR, QImaging) and 454-nm light to a second camera, and dual video recordings
(696x520 pixels, 21 images/s) were simultaneously obtained using custom capture
software (Neovision). Images from both cameras were registered using the beam splitter
and the capture software ensured synchronized frame-by-frame acquisition from both
cameras. A minimum of 20 fields of view (10 at the arteriolar end, and 10 and the venular
end of a capillary network) were randomly selected and recorded for 60 seconds in each
EDL muscle. Video sequences were stored as uncompressed PNG files for postprocessing using in-house software written in the MATLAB (Mathworks) programming
environment. O2 saturation in capillaries was obtained by analysis of PNG files using
custom image analysis software written in Matlab, as described by Ellis et al (Ellis et al.,

106
1990, Ellis et al., 1992) and Japee et al (Japee et al., 2004, Japee et al., 2005). Briefly, infocus capillary segments were selected, and the location of the vessel centerline was used
to extract light intensity values from every video frame and generate space-time images
for both the 442- and 454-nm wavelengths. The light intensity values were analyzed
frame-by-frame to identify the location of each RBC and plasma gap within the capillary.
The mean optical density (OD) of each RBC at both wavelengths, was computed as
OD=log(Io/Im) were Io is the measured light intensity of the plasma gaps (intensity of
incident light) and Im is the measured light intensity values for RBCs. The mean RBC
hemoglobin O2 saturation was determined from the ratio of OD(442)/OD(454), which is
linearly related to O2 saturation, i.e. SO2 = a + b * ODratio. The slope and intercept were
determined from an in vivo calibration.
3.2.6 Analysis of Microvascular Network Architecture
Length density and bifurcation density of EDL muscle microvascular networks
were quantified from RBC transit maps, which effectively displayed a micro-angiogram
of all flowing microvessels, using ImageJ. RBC transit maps were generated from IVVM
video sequences using custom MATLAB software as described (Japee et al., 2004,
Varghese et al., 2005). From the videos generated by ultraviolet light epi-illumination,
RBC transit maps were generated from “minimum” (MIN) images, which displayed the
minimum light intensity value and therefore RBC transit at a given pixel during the
duration of the video sequence. From the videos generated by blue light epi-illumination,
RBC transit maps were generated from “sum of all differences” (SAD) images, which
displayed the cumulative sum of the square of differences in light intensity values at each
pixel between consecutive video frames, thus generating a single map of all microvessels
perfused with RBCs and plasma. Length density (microvasculature length [µm] / EDL
area [µm2]) was quantified at each time-point via manual tracing of all vessel centerlines
and normalizing total network length to EDL area. Bifurcation density was determined by
manual point counting of all vessel bifurcations and normalizing to total network length.
Arteriole-capillary-venule microcirculatory units and AV malformations were identified
from blue light epi-illumination videos and corresponding SAD images.
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3.2.7 Analysis of Capillary Network Hemodynamic Resistance
To assess possible changes in capillary network resistance, three control and three
regenerated networks (all at day 28) were reconstructed using 10x IVVM data from fields
of view acquired to determine RBC flow and network architecture, as described above.
Each network was reconstructed into a collection of nodes and connecting cylindrical
vessel segments using our previously developed software (Fraser et al., 2012). Two-phase
(RBCs and plasma) steady-state blood flow simulations were performed using an
established computational model (Pries et al., 1990, Pries et al., 1994, Goldman et al.,
2000, Al-Khazraji et al., 2015) with a fixed pressure difference (DP) between all inflow
and outflow nodes. The resistance for each network was calculated as DP divided by the
total flow (Qtot) through (i.e., into or out of) the network, R=DP/Qtot. Flow was mainly
unidirectional (e.g., in at bottom and out at top of network), but for two networks flow
was bidirectional indicating a major source (arteriole) or sink (venule) within the
network. For these networks, resistances were calculated for upward and downward
flowing portions separately and added to approximate the resistance of a single network
with unidirectional flow. For all networks resistance was normalized by dividing by
length (L) in the main flow directional and multiplying by width (W) in the perpendicular
direction, so that Rnorm=W×R/L. This was done to account for variability in network
lengths and widths produced by the capture and reconstruction procedure, since
resistance is proportional to vessel length and total flow should be proportional to width
of a network.
3.2.8 Analysis of Capillary Red Blood Cell Velocity and Distribution
Red blood cell velocities (VRBC [µm/sec]) in individual capillaries exhibiting
characteristic single-file RBC transit were quantified from video files using space-time
images (Ellis et al., 1992, Japee et al., 2005). Briefly, 1-second (21 frames) interval mean
red blood cell velocities were calculated using custom MATLAB software, generating a
2D gray scale plot of RBC location change with time. This enabled an unbiased
quantification of RBC transit velocities within capillaries throughout the entire muscle.
RBC velocity was determined from a total of 1658 one-second intervals in 115 uninjured
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capillaries, and from 2269 one- second intervals in 138 neocapillaries, 28 days following
femoral artery excision. Histograms of mean VRBC determinations from each uninjured
capillary and neocapillary were generated to define the spatial heterogeneity of red blood
cell velocity within the microvasculature. The number of non-flowing capillaries and
neocapillaries was determined from blue light epi-illumination videos, cross-referencing
with corresponding SAD images, evident as either empty channels of plasma or
capillaries with stationary RBCs for at least 15 seconds duration.
3.2.9 Assessment of Network Responsivity to Hypoxia
To evaluate the network responsivity to an acute hypoxic challenge, I constructed
a localized O2 delivery system. The hindlimb and exposed EDL muscle was positioned in
a custom-built frame (Sugru®, FormFormForm Ltd.) fashioned to stabilize the EDL
muscle for an extended period (≥8 minutes) of imaging, with a 2cm x 2mm opening. A
custom-built gas flow chamber controlled by computer-modulated flow meters was
integrated within the microscope stage (Ghonaim et al., 2011, Ellis et al., 2012). The
hindlimb was positioned above the chamber with the EDL muscle contacting either an
optically transparent O2-permeable 100-µm thick polydimethylsiloxane (PDMS) polymer
membrane or a 50-µm thick fluorosilicone acrylate disk (Ellis et al., 2012). Chamber O2
levels were measured using a fiber-optic pO2 sensor (Ocean Optics) in the gas outlet. Gas
consisting of 12% O2, 5% CO2, and 83% N2 at 37°C was passed through the chamber for
5 minutes to generate a hyperoxic surface O2 environment across the entire EDL, and
standardize the baseline O2 content for both normal and regenerated muscle. This %O2
was selected based on a previously established capillary normoxia tension in the rat EDL
of 6.3% O2 (Goldman, 2008). IVVM blood flow recording was initiated and 30 seconds
later the EDL muscle was subjected to the hypoxia challenge by changing the gas content
to 2% O2, 5% CO2, and 93% N2, effectively removing O2 from the EDL muscle. RBC
transit was continuously recorded before and after the hypoxia challenge for a minimum
of three minutes, and VRBC and RBC supply rate (#RBCs/sec) were quantified.
Mean VRBC and mean RBC supply rates were determined in a total of 255
capillaries from control and regenerated EDL muscles. Hyperoxia RBC measurements
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were based on 30 seconds of recording prior to induction of hypoxia. Hypoxia RBC
measurements were acquired from 120-180 seconds of recording following a 20 second
transition phase. A stable hyperemic response to hypoxia was considered sustained if the
plateau VRBC persisted for at least 120 seconds.
3.2.10 Laser Scanning Confocal Microscopy and 3-Dimensional Reconstruction of
Precapillary Arterioles
For thick-section immunostaining, mice were sacrificed by isofluorane overdose
and perfused sequentially with PBS and 4% PFA via left ventricle cannulation at
physiologic pressure. EDL muscles were dissected, immersed in 4% PFA for 2 hours,
cryoprotected with 15% sucrose for 2 hours and 30% sucrose overnight at 4°C. Tissues
were then embedded in OCT embedding medium (Tissue-Tek) and stored at -80°C. 100µm thick longitudinal cryosections were permeabilized with 0.5% Triton-X in PBS and
double-immunostained using biotinylated rat anti-mouse CD31 antibody (1:50) and
mouse anti-smooth muscle (SM) α-actin alkaline phosphatase-conjugated antibody (1:50,
Clone 1A4, Sigma A5691). Bound antibodies were visualized using Streptavidin-488
(1:100, Sigma) and Alexa Fluor 546-conjugated goat anti-mouse IgG (1:200, Life
Technologies).

Nuclei

were

visualized

with

TO-PRO-3

iodide

(1:500,

Life

Technologies). Thick-sections were transferred to positively charged glass slides,
mounted with PermaFluor (Thermo Scientific), and flanked with 100-µm thick plastic
coverslip spacers (Thermo Scientific) prior to coverslipping and sealing.
Arterioles 7-20 µm in diameter were imaged with an LSM 510 Meta Confocal
Microscope (Zeiss) using a 40x water-immersion objective and Argon2 (488 nm
excitation) and HeNe1 (543 nm excitation) lasers, generating up to 50, 0.5 µm-thick zslices at 2048x2048 image resolution. Z-slices were reconstructed into 3-dimensional
projections with Image Viewer (Leica) software. To quantify the spacing between
adjacent SMC processes, the SM α-actin (red) signal was isolated from 3-dimensional
projections with Photoshop (Adobe) and the maximum distance from one SM-α-actin
containing process to the next along the arteriolar center-axis was ascertained using
ImageJ. Vessel coverage by SMCs was determined after measuring the total inter-process
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gap area and total arteriole segment area ImageJ.
3.2.11 Statistics
All values passing D’Agostino and Pearson omnibus normality testing were
presented as mean ± SEM. Those not passing the normality test were presented as median
and IQR. Comparisons among normally distributed variables were made by t-test or
analysis of variance with Bonferonni’s post hoc test. Comparisons among hypoxia RBC
measurements, width of inter-process gaps, and VRBC were made by Mann-Whitney test
or Kruskall-Wallis test with Dunn’s post hoc test. Comparisons among percent of
arterioles with AV malformations, percent of capillaries depicting a greater than 5-fold
hyperemic hypoxia response, and percent of capillaries sustaining a hyperemic hypoxia
response were made by Fisher’s exact contingency test. Mean VRBC histograms were
compared using a two-way Kolmogorov-Smirnov test in MATLAB custom software.

3.3. Results
3.3.1 Femoral Artery Excision Induces Widespread Infarction and Capillary
Obliteration in the EDL Muscle Followed by Extensive Regeneration
To study the regeneration of microvessels following ischemic injury, C57BL/6
mice were subjected to right femoral artery excision. I screened all muscles in the
hindlimb for the extent of infarction and identified that the anterior muscle bundle distal
to the knee was the most extensively damaged (data not shown). Within this bundle is the
extensor digitorum longus (EDL) muscle, which I found to be 2 cm long, 2 mm wide, and
with well-defined borders making it well suited to a comprehensive assessment.
Furthermore, the EDL was accessibly located for live imaging. Histological assessment
revealed that one day following femoral artery excision, the entire EDL muscle was
infarcted and necrotic. Myofibers were shrunken, had lost their nuclei, and stained palely
with eosin (Figure 3.1 a,b). However ten days after surgery the muscle had repopulated
with intensely staining myocytes with large central nuclei, indicative of regenerated
skeletal myocytes (Figure 3.1 c) (Paoni et al., 2002). By 28 days the regenerated
myocytes had matured, with larger diameters and more condensed nuclei (Figure 3.1 d).
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Figure 3.1 Histology of the EDL muscle before and after femoral artery excision
A-D. Hematoxylin and eosin-stained sections of EDL muscle before surgery (A),
one day following surgery showing pale, shrunken myocytes without nuclei (B),
after 10 days showing repopulated myocytes with central nuclei (arrows) (C), and
after 28 days (D).
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To evaluate the microvasculature, sections were immunostained using a panel of
distinct endothelial markers. Immunostaining uninjured EDL muscles for CD31,
endomucin, vWF, and isolectin-b4 revealed capillaries at the interface between the
skeletal myofibers (Figure 3.2 a). One day after femoral artery excision,
immunoreactivity relative to control muscle fell to 14%, 11%, 23%, and 44% for each
marker, respectively (Figure 3.2 b). Remarkably, three days after surgery,
immunoreactivity for CD31, endomucin, and vWF was entirely absent, with some
residual isolectin-b4 staining (34%) (Figure 3.2 a,b). Notably, the latter stains basement
membranes in addition to endothelial cells (Peters et al., 1979). Furthermore, H&E
staining revealed a complete absence of capillaries, with only the occasional fibrous
ghost structure without nuclei (Figure 3.3 a,b). Capillary obliteration was evident down to
~150 µm below the muscle surface with only scattered capillaries in the muscle core.
Interestingly, neocapillaries emerged thereafter throughout the EDL muscle, in concert
with the skeletal myogenesis (Figure 3.4 a). By 28 days their density exceeded that of
control EDL muscle by 1.65-fold (P=0.006, Figure 3.4 a,b) although with a capillary-tomuscle fiber ratio that was similar to control muscle (1.09±0.06 vs. 1.07±0.06, P=0.841,
Figure 3.4 b). Collectively, these findings reveal extensive capillary destruction in EDL
muscle following ischemic injury, followed by a vigorous microvascular regeneration
program that was associated with skeletal muscle regeneration.
3.3.2 The Regenerated EDL Muscle Displays Chronic Hypoxia Despite Robust
Angiogenesis
I next asked whether the regenerated EDL muscle returned to a well-oxygenated
state. To assess for hypoxia, tissues were immunostained for pimonidazole adducts
following in vivo perfusion with Hypoxyprobe-1. Control EDL muscle showed no
hypoxia signal (Figure 3.5 a). However, regenerated EDL muscle (28 days) displayed
widespread hypoxia signals in the muscle fiber cytoplasm and nuclei, with myofiber-tomyofiber variability (Figure 3.5 b,c). I also identified increased expression of the
hypoxia-dependent, HIF-1α-regulated genes adrenomedullin (P=0.004), lysyl oxidase
(LOXL2) (P=0.043) and procollagen lysyl hydroxylase (PLOD2) (P=0.008, Figure 3.5
d). Interestingly, expression of VEGF-A, which can stabilize sooner than that of
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Figure 3.2 Absence of EC markers in the EDL muscle following femoral artery
excision
A. Fluorescence micrographs of EDL muscle before and 3 days after surgery
immunostained for CD31, endomucin, vWF, and isolectin-b4 showing capillaries
(arrow) surrounding myofibers (asterisk) in control EDL and loss of capillaries
following ischemic insult. Nuclei are visualized with DAPI.
B. Quantitative data for capillary density as identified by each marker. (n=5
native; n=3 each for days 1 and 3, *p<0.0001, †p=0.001, ‡p=0.0002, §p=0.0013,
||p=0.0004 vs native).
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Figure 3.3 Loss of capillaries following ischemic injury to the EDL muscle
A-B. Hematoxylin and eosin-stained sections of EDL muscle before (A) and three
days following femoral artery excision (B). The native muscle fibers are
surrounded by capillaries and discrete endothelial cell nuclei can be seen (A,
arrows). Following ischemic injury, the skeletal myocytes have lost their nuclei.
Capillaries are no longer evident, with only the occasional fibrous ghost structure
without nuclei (B, arrowheads).
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Online Figure I Loss of Capillaries Following Ischemic Injury to the EDL Muscle
A-B. Hematoxylin and eosin-stained sections of EDL muscle before (A) and three days following femoral
artery excision (B). The native muscle fibers are surrounded by capillaries and discrete endothelial cell nuclei can
be seen (A, arrows). Following ischemic injury, the skeletal myocytes have lost their nuclei. Capillaries are no
longer evident, with only the occasional fibrous ghost structure without nuclei (B, arrowheads).
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Figure 3.4 Regeneration of capillaries in the EDL muscle following femoral artery
excision
A. Photomicrographs of EDL muscle immunostained for CD31 showing
capillaries in uninjured EDL muscle (left, arrows), their disappearance one day
following surgery (middle), and regenerated capillaries 28 days following surgery
(right, arrows).
B. Graphs showing density of capillaries and capillary-to- muscle fiber ratios in
native (n=3) and regenerated (28 days, n=3) EDL muscle (*p=0.006).
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Figure 3.5 Evidence for hypoxia in the regenerated EDL muscle
A-B. Photomicrographs of sections of native (A) and regenerated (day 28, B)
EDL muscle harvested after infusion of Hypoxyprobe-1 and immunostained for
pimonidazole.
C. Graph depicting quantified pimonidazole signal in regenerated EDL muscle
not infused with Hypoxyprobe-1 (technical control, n=3), in native (contralateral)
muscle (n=4), and regenerated muscle (n=4, *p=0.007).
D. Graph depicting relative mRNA abundance of hypoxia- dependent genes in
uninjured (n=4) and regenerated (n=4) EDL muscles (*p=0.004, 0.043, 0.008,
0.029, 0.003 vs respective control).
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Adrenomedullin (Fujita et al., 2002), was not greater than that in the control muscle
(P=0.272) and neither was that of angiopoietin-1 (P=0.370). However, angiopoietin-2
was substantially upregulated (P=0.029) as was the ratio of angiopoietin-2/angiopoietin-1
(P=0.003). These findings suggest that, despite having a capillary-myofiber ratio similar
to baseline, the regenerated EDL muscle was subjected to a chronic, non-angiogenic level
of hypoxia.
3.3.3 In Vivo Microvascular Imaging Reveals Robust Network Regeneration But
With An Aberrant Branching Architecture
To establish the network architecture of the regenerated microvasculature, I
performed real-time microscopy following intravenous injection of FITC-labeled high
molecular size Dextran. This enabled visualization of flowing microvessels, with RBCs
in relief against the fluorescent plasma, within a 50 µm-thick zone along the entire EDL
muscle. As well, I generated RBC transit maps, from 15-second video sequences, which
revealed the location and geometry of all flowing microvessels, contrasted against
stationary and thus non-visible muscle. Transit maps and live video sequences revealed a
highly organized microvasculature in uninjured EDL muscle with hierarchical units of
feeder arterioles, capillaries, and post-capillary venules (Figure 3.6 a, Online Video 3.1).
Feeder arterioles penetrated orthogonally through the muscle to the surface zone, where
they bifurcated into capillaries. Capillaries could also be seen to bifurcate, as they
coursed parallel to the EDL surface, ultimately converging and draining into venules.
One day following femoral artery excision, blood flow in the EDL
microvasculature had ceased and there was no RBC transit signal (Fig. 3.6 a, Online
Video 3.2). However, 10 days after injury, an extensive but relatively chaotic network of
flowing neovessels had regenerated (Figure 3.6 a). Quantitative analysis confirmed a
hyper-vascular network, with a 21% greater length density than in normal EDL muscle
(P=0.037, Figure 3.6 b) and a 3-fold increase in the number of branches, normalized to
total network length (P<0.0001, Figure 3.6 c). Although microvessels of different lumen
caliber were present, there was no evidence for arteriole-capillary-venular hierarchy at
this time point (Online Video 3.3). However, the network subsequently underwent rapid
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Figure 3.6 Microvascular network architecture before and after ischemic injury
A. RBC transit maps within native EDL muscle microvasculature and one, ten, 28,
56, and 120 days following femoral artery excision, showing no RBC transit one
day after ischemic insult and subsequent regeneration of a flowing EDL
microvasculature. Hatched lines denote EDL muscle borders. Corresponding realtime videos for each panel are available in the Online Supplement.
B-C. Graphs showing EDL muscle microvascular network length density (B) and
branch density (C) (n=3-5 for each time point) B: *p=0.037, 0.041, 0.019,
<0.0001, <0.0001, respectively vs control; C: *p<0.0001 vs control, † p<0.0001
vs. Day10.

o

ul
di at
st io
rib n
ut Re
e. se
D ar
es ch
tr P
oy e
af er R
te e
r u vi
se ew
. .D

irc

rC

irc
ul
di at
st io
rib n
ut Re
e. se
D ar
es ch
tr P
oy e

rC

Fo

Fo

no
t
FIGURE 3

124

A

125
structural maturation. Transit maps indicated that by day 14 there had been substantial
branch pruning (Figure 3.6 c) and both network length and branch density stabilized by
day 14-21. Real-time tracking of RBCs also revealed that the network had acquired
arteriole-capillary-venule hierarchy by day 14.
Twenty-eight days after ischemic injury, the network resembled that of the
uninjured EDL muscle (Figure 3.6 a, Online Video 3.4). Notably however, there was still
a 21% greater vessel length density compared to the normal network (P=0.019) and a
residual 1.6-fold increase in bifurcations (P<0.0001). Remarkably, elevated length and
branch densities were still present 56 and 120 days after ischemic injury (Figure 3.6 a-c,
Online Videos 3.5 and 3.6).
I also identified several abnormalities in architecture of the feeder arterioles. First,
arterioles were seen to course parallel to the muscle fibers, rather than orthogonal to
them, running up to 1 mm before bifurcating (Figure 3.7). Second, abnormalities in
arterial branch caliber were found. In uninjured muscle, arterioles bifurcated into equalcaliber daughter branches whereas neo-arterioles branched into daughter vessels with
strikingly unequal lumen diameters (Figure 3.7, Online Video 3.7). Third, neo-arterioles
were seen not only to bifurcate, but also to trifurcate and quadrificate (Figure 3.7), a
distinctly abnormal feature of the microcirculation (Fukumura et al., 2010, Less et al.,
1991). Whereas only bifurcations were found in control muscle, supernumerary
branching was identified in 6.5, 6.7, and 7.7% of arterioles within the neovasculature on
days 28, 56, and 120, respectively.
I next asked how the altered architecture of the regenerated network might impact
overall resistance to flow. To assess this, I undertook computational modeling of flow in
the network, based on information derived from the videos and the processed RBC transit
maps, for control and regenerated (28-day) networks. This predicted a 66% decline in
network resistance, indicating a hemodynamic consequence of the altered network
architecture (P=0.032, Figure 3.8). Thus, despite a rapid microvascular regeneration
cascade, these findings reveal multiple architectural abnormalities, even in the late-stage
network, that are predicted to impact hemodynamics within the network.
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Figure 3.7 Aberrant architecture of regenerated feeder arterioles
Transit maps of branching arterioles of native and regenerated EDL muscle
showing symmetrical bifurcation, asymmetrical bifurcation, trifurcation, and
quadrification. Arrows depict the direction of parent vessel flow. The curved
arrow denotes orthogonal inflow from below the plane.
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e and after ischemic injury. A, Red blood cell (RBC) transit maps within native
ture and 1, 10, 28, 56, and 120 days after femoral artery excision, showing no RBC
eneration of a flowing EDL microvasculature. Hatched lines denote EDL muscle
nel are available in the Online Data Supplement. B and C, Graphs showing EDL
branch density (C; n=3–5 for each time point). B: *P=0.037, 0.041, 0.019, <0.0001,
control, †P<0.0001 vs day 10. D, Transit maps of branching arterioles of native and
tion, asymmetrical bifurcation, trifurcation, and quadrification. Arrows depict the
otes orthogonal inflow from below the plane.
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hrough the
DL muscle.

2.0±1.6 capillaries/mm2 in the entire control EDL microvasculature displayed stopped flow for a duration of at least 15
seconds, and this increased by over 9-, 19-, and 19-fold in
the regenerated EDL on days 28, 56, and 120, respectively
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Figure 3.8 Capillary network hemodynamic resistance
A-B. Three-dimensional microvascular network reconstructions of IVVM data
collected from native (A) and regenerated (B, 28 days) EDL muscle. Each
reconstruction is a collection of nodes and cylindrical vessel segments. Color
coding denotes depth separation of the capillary segments.
C. Graph showing capillary network hemodynamic resistance ascertained by
simulating two-phase (RBCs and plasma) steady-state blood flow through threedimensional network reconstructions (n=3 native and regenerated network
reconstructions, *p=0.032).
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Online Figure II Capillary Network Hemodynamic Resistance
A-B. Three-dimensional microvascular network reconstructions of IVVM data collected from native (A)
and regenerated (B, 28 days) EDL muscle. Each reconstruction is a collection of nodes and cylindrical vessel
segments. Color coding denotes depth separation of the capillary segments. C. Graph showing capillary network
hemodynamic resistance ascertained by simulating two-phase (RBCs and plasma) steady-state blood flow through
three-dimensional network reconstructions (n=3 native and regenerated network reconstructions, *p=0.032).
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3.3.4 Red Blood Cells Transit Slowly Through The Regenerated Microvasculature
I next sought to determine if RBC transit through regenerated network differed
from that of normal EDL muscle. Within the uninjured EDL, RBCs traversed through
capillaries in single-file with a velocity (VRBC) of 526.8 (337.0-727.0) µm/s (median
(IQR), Figure 3.9 a). In contrast, within the early regenerated vasculature (10 days),
median VRBC was only 36% of that of native capillaries (P<0.0001). RBC transit was
chaotic, with frequent direction changes as they passed through the hyper-branched, nonhierarchical network. Furthermore, the smallest caliber neovessels had 2-3 RBCs
tumbling side-by-side, rather than transiting in single-file (Online Video 3.3). At 28 days,
single-file RBC transit in neocapillaries was evident and arteriolar and venular flow was
discernable (Online Video 3.4). However, median VRBC remained low, at 52% of that of
normal capillaries (P<0.0001). Notably, VRBC was even lower on days 56 and 120 (23%
that of normal capillaries, P<0.0001, Figure 3.9 a).
I also identified an abundance of neocapillaries in which blood flow was halted
altogether. This was evident either as a static column of plasma devoid of RBCs or as
channels with stationary RBCs (Figure 3.9 b, Online Video 3.8). On average, 2.0±1.6
capillaries/mm2 in the entire control EDL microvasculature displayed stopped-flow for a
duration of at least 15 seconds and this increased by over 9-, 19-, and 19-fold in the
regenerated EDL on days 28, 56, and 120, respectively (Figure 3.9 c).
3.3.5

The

Regenerated

Microvasculature

Contains

Arteriolar-Venular

Malformations
The movement of oxygenated RBCs from arterioles to capillaries is fundamental
to efficient oxygen delivery. However, I found that despite the return of single-file
capillary transit, not all arterioles diverged into a capillary network. Instead, I observed
neo-arterioles from which one branch diverged into a capillary mesh while the other
branch flowed directly into a venule (Figure 3.10 a,b, Online Videos 3.9-3.11). RBC
transit within the direct AV connection was not single-file and flux was demonstrably
greater than in the adjacent capillary system, revealing conditions for diverting
oxygenated RBCs directly into the venule. Quantitative analysis revealed that 37, 32, and
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Figure 3.9 RBC transit in capillaries within the EDL microvasculature
A. Box and whisker (10-90 percentile) plot of red blood cell velocities (VRBC) in
individual capillaries within native and injured/regenerating EDL muscle evaluated
at the designated times. Values were obtained from a total of 860 capillaries. Each
value is derived from RBC velocities, averaged over a 15-second imaging timeframe, within each capillary.
B. Sequential video still-frames depicting dynamic RBC transit in control muscle
(boxes, top row) and stalled perfusion in 28-day regenerated muscle (boxes, middle
and bottom row). RBCs appear in relief against the fluorescent plasma. Arrows
depict stagnant RBCs. Corresponding real-time videos are found in the Online
Supplement (Online Video 3.8).
C. Graph depicting density of capillaries with flow halted for at least 15 seconds.
n=4 native and n=3 for each of day 28, 56, and 120 EDL muscles.
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Figure 3.10 RBC transit maps of arteriole-capillary-venule units
A. Native EDL muscle microvasculature with a parent arteriole that bifurcates into
daughter vessels, both of which diverge into capillary meshes that drain into a
venule system. A simplified, not-to-scale, schematic of the unit is shown on the
right.
B. Regenerated EDL muscle (day 28) with a parent arteriole that trifurcates into
daughter vessels of unequal caliber. Daughter vessel one diverges into a capillary
mesh that drains into a venule whereas daughter vessel two drains directly into a
venule, also depicted in the adjacent schematic. Corresponding real-time videos are
found in the Online Supplement (Online Videos 3.9 and 3.10) and reveal high RBC
flux in the AV connection.
C. Graph depicting the percentage of arterioles that branch into an AV connection.
The entire network from 5 native EDL muscles and from 3, 4, and 4, regenerated
muscles on days 28, 56, and 120, respectively was evaluated as indicated below the
graph (*p<0.0001 vs native).
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33% of all neo-arterioles on days 28, 56, and 120, respectively, branched into an AV
connection, whereas AV shunts were rarely observed (2%) in control muscle (P<0.0001)
(Figure 3.10 c).
3.3.6 RBC Velocity Dispersion is Severely Blunted in the Regenerated
Microvasculature With An Abnormal Oxygen Delivery Profile
I next assessed for heterogeneity in RBC transit among capillaries within a
network (Duling et al., 1987, Ellis et al., 1994). This heterogeneity is fundamental to the
skeletal muscle circulation and critical for precisely matching the metabolic demands of
each myofiber in the muscle with RBC delivery (Ellis et al., 2012, Ellis et al., 1994). To
assess network heterogeneity, I compared the frequency distributions of mean VRBC
amongst capillaries over the entire EDL zone. The inter-capillary VRBC histogram derived
from the 28-day regenerated network was significantly different than that of the native
network, with both a leftward shift and narrower range (K-S stat=0.54, P=1.12x10-13)
(Figure 3.11). In addition, the normal microcirculation was found to contain a hyperemic
subpopulation of capillaries with a particularly high VRBC (>1000 µm/s). In contrast, there
was no hyperemic subpopulation of capillaries in the regenerated network day 28. These
abnormalities did not normalize over time and in fact were worse on days 56 and 120.
Thus, the regenerated microcirculation displayed profoundly reduced dispersion in VRBC,
suggesting an inability of the network to tune the delivery of O2 to meet the needs of
individual myofibers.
To determine if the homogeneity in VRBC was associated with abnormal O2
delivery, I directly measured hemoglobin O2 saturation in RBCs transiting through the
capillaries. Using dual wavelength absorption microscopy to distinguish oxy- and
deoxyhemoglobin, I found that median RBC O2 saturation in regenerated capillaries (120
days) was 75% of that in normal capillaries (P=0.0003). This reduction was evident not
only for RBCs at the downstream end of the capillary (69%, P=0.002) but also at the
upstream end (77%, P=0.005) (Figure 3.12). Furthermore, there was a strikingly wide
spread in RBC O2 saturation in the regenerated capillaries, with O2 saturations as low as
2% and as high as 87%. These findings indicate the variable presence of regions with
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Figure 3.11 RBC velocity dispersion within the microvasculature
Frequency histograms of the average capillary VRBC within native and
regenerated EDL muscles 28, 56, and 120 days after injury. The distribution is
significantly narrowed on day 28 (K-S stat=0.54, p=1.12x10-13) and remains
narrow and left-shifted.
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Figure 3.12 Capillary RBC hemoglobin O2 saturation
A. Box and whisker (min-max) plot of capillary RBC hemoglobin O2 saturation in
native capillaries in control EDL muscle and regenerated capillaries in EDL
muscle 120 days after ischemic injury. Data are from 24 capillaries from 3 native
EDL muscles and 56 neocapillaries from 3 regenerated muscles. *p=0.0003.
B-C. Plots depict RBC hemoglobin O2 saturation selectively in post-arteriolar
capillary segments (*p=0.005) and in pre-venular capillary segments (*p=0.002).
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Online Figure III Capillary RBC Hemoglobin O2 Saturation
A. Box and whisker (min-max) plot of capillary RBC hemoglobin O2 saturation in native capillaries in
control EDL muscle and regenerated capillaries in EDL muscle 120 days after ischemic injury. Data are from 24
capillaries from 3 native EDL muscles and 56 neocapillaries from 3 regenerated muscles. *p=0.0003. Plots in B and

140
profoundly unmet O2 demands, further supporting a failure of local tuning of RBC
delivery.
3.3.7 The Regenerated Microvasculature Has Impaired Flow Responsiveness to
Hypoxia
To directly determine if the regenerated microcirculation could regulate blood
flow, I generated a methodology to locally control the O2 content in the mouse EDL
muscle. A defined O2-containing gas mixture was delivered to the EDL muscle through a
gas-permeable membrane. After generating a stable PO2 of 12% at the muscle site, I
abruptly decreased the ambient oxygen content to 2%, establishing conditions for microremoval of muscle O2. The ability of the microvasculature to respond to this hypoxic
challenge was then evaluated by tracking both RBC velocity and RBC supply rate
through individual capillaries.
Figure 3.13a depicts RBC velocity response profiles to local hypoxia, illustrating
a brisk and sustained VRBC increase in a native capillary but a blunted and transient
response in a regenerated capillary. Although there was a range of responses among
capillaries (Figure 3.13 b,c), overall there was a significant reduction in both VRBC and
RBC supply rate responsivity within the regenerated microvascular network. Among 163
capillaries in normal EDL muscle, hypoxia induced a 1.53-fold increase in median VRBC
and a 1.7-fold increase in median RBC supply rate (Figure 3.13 b,c, Online Video 3.12).
Relative to these responses, the VRBC and RBC supply rates were significantly lower on
each of days 28, 56, and 120 after ischemic injury (Figure 3.13 b,c). These findings
identify that the regenerated microvasculature is impaired in its ability to effectively
augment RBC delivery when faced with local hypoxia.
3.3.8 Smooth Muscle Cell Wrapping Around Regenerated Arterioles is Aberrant
The combination of impaired responsivity to hypoxia and the homogeneity of
RBC velocities throughout the network implicated failure of a vasomotor tuning
mechanism. I considered that a unifying basis for this failure might reside in the cellular
architecture of the feeder arterioles. To elucidate the microstructure of normal and
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Figure 3.13 Network responsivity to hypoxia
A. RBC velocity response profiles to local hypoxia. VRBC were acquired every
second within a single capillary for each condition before and after hypoxia
challenge.
B-C. Graphs depicting the VRBC and RBC supply rate responses to local hypoxia.
On the left, the fold-change response in individual capillaries is shown for day 28.
The line depicts the median. On the right, the relative median responses (and 4555 percentile) at the time points indicated are shown. Data are from 164, 65, 27,
and 60 capillaries from control (n=6), day 28 (n=3), day 56 (n=3), and day 120
(n=3) EDL muscles, respectively. For VRBC: *p=0.004 †p=0.001, ‡p=0.021 vs
control. For RBC supply rate: *p=0.004 †p=0.0004 ‡p=0.005 vs control.
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regenerated arterioles, I generated 3-dimensional confocal reconstructions from 100 µmthick sections of EDL muscle double-immunolabeled for CD31 and SM-α-actin. In
normal EDL, arterioles were found to be intimately invested by SMCs. The precise
architecture varied with arteriolar caliber and location within the tree. SMCs on arterioles
of diameter 12-20 µm enveloped the artery with circumferential processes containing
SM-α-actin, which I could resolve as individual microfilament bundles (Figure 3.14 a,b).
SMCs on arterioles 7-12 µm diameter also circumferentially wrapped the vessel with
SM-α-actin cytoplasmic protrusions, but these processes were somewhat thinner and
more variably oriented (Figure 3.14 a,c). SMC investment and protrusion-based wrapping
terminated once the vessel diameter fell to 5-8 µm, consistent with transition to a
capillary (Figure 3.14 a).
SMCs were also found to layer around arterioles of the regenerated network and
send out processes. However in contrast to native arterioles, the coverage was
discontinuous and disordered (Figure 3.14 a-c). In some neo-arterioles, there were zones
up to 13 µm in length that were largely devoid of SM-α-actin bundles. Moreover even in
regions where SMC processes wrapped the vessel, the spacing between adjacent
processes was increased compared to that of normal arterioles of similar caliber (Figure
3.14 b,c arrows). Quantitative analysis revealed that the median space from one SM-αactin containing process to the next in normal terminal arterioles was 0.74 µm (Figure
3.14 d). These gaps constituted 7% of the arteriolar surface area (Figure 3.14 e). In
contrast, 28 days after injury the median inter-process space was 1.40 µm (P<0.0001),
which corresponded to 22% of the neo-arteriolar surface area (P<0.0001, Figure 3.14
d,e). Increased process spacing was also observed at days 56 and 120, although this
improved somewhat. However, prominent gaps in SMC process coverage were still
evident, with widely variable process orientations, rendering a haphazard and disordered
coverage profile (Figure 3.14 c, arrows). These findings strongly implicate arteriolar wall
micro-disorder as a basis for impaired control over RBC delivery through the regenerated
skeletal muscle.
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Figure 3.14 Aberrant wrapping of SMCs around arterioles in the regenerated
microvasculature
A. Confocal micrographs of distal arteriolar trees from normal and regenerated
EDL muscle, immunostained for CD31 (green) and SM-α-actin (red). Images are
projections of 30 optical sections. Arrows indicate sites of discontinuous SMC
coverage.
B. Confocal micrographs of projected optical sections of arteriolar segments ~1415 µm in diameter of control and regenerated (day 28) muscle, immunolabeled for
SM α-actin (red).
C. Projected optical sections of arteriolar segments ~9 µm in diameter of control
and regenerated (day 56 and 120) muscle, immunolabeled for SM-α-actin (red)
and TO-PRO-3 (blue). Arrows indicate sites of discontinuous SMC coverage, and
arrowhead indicates site of aberrant process orientation.
D. Graph depicting the SMC inter-process gap widths. Data are from 25 arterioles
from native EDL muscles, and 23, 19, 22 neoarterioles from EDL muscles 28, 56,
and 120 days after ischemic injury. *p<0.0001 vs native).
E. Graph depicting surface area coverage of feeder arterioles by SM-α-actincontaining processes. *p<0.0001 vs native.
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3.4 Discussion
Through high-resolution mapping of RBC transit, dynamic tracking of RBC
velocities, and optical reconstruction of terminal arterioles, I have discovered that the
reconstructed microvasculature in EDL muscle is a highly-flawed network. The array of
abnormalities I uncovered in this regenerated tissue included: 1) aberrant arteriolar
branching; 2) arteriolar-venular shunting; 3) slow RBC transit through capillaries; 4) a
monotony of RBC transit velocities throughout the capillary system; and 5) an impaired
vasomotor control system. These abnormalities were still evident 4 months following
injury, indicating a failure to normalize. The functional importance of these abnormalities
was supported by the presence of hypoxia signals and profoundly abnormal capillary O2
saturations in the EDL muscle, despite a capillary-to-skeletal myocyte ratio that was
similar to that of normal EDL muscle. Thus, notwithstanding an extensive regenerative
response, the microvascular neo-network was ill suited for effective oxygen delivery.
This is the first study to evaluate regenerative angiogenesis in skeletal muscle at a
network level and at the site where gas and nutrient exchange occurs. The mouse EDL
subjected to femoral artery excision proved to be a valuable model for this because the
entire EDL muscle was infarcted and the native microcirculation was destroyed, as
evidenced by staining with H&E and a panel of endothelial markers. All subsequently
identified microvessels could thus reliably be attributed to a regeneration program. This
contrasts with other sites in the mouse hindlimb where infarction is patchy and a mix of
pre-existing and new microvessels would co-exist (Couffinhal et al., 1998, Helisch et al.,
2006). High-resolution mapping of RBC transit in the regenerating EDL revealed that the
vascularization response was in many respects impressive. It entailed an early hypervascular phase that covered the entire EDL muscle surface zone. Branching was
extensive at this early stage and the network was not yet hierarchical. However, rapid
branch pruning and re- alignment of microvessels quickly ensued, yielding a network that
coursed primarily parallel to long axis of the maturing skeletal myofibers. Moreover,
within 14 days of the ischemic insult, these vessels had differentiated into arteriolecapillary-venular circulation units, further indicating the rapid angiogenesis and network
remodeling program.
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Nevertheless, discordance between the microvascular restoration process and
functionality of the RBC delivery system was remarkable. Whether the identified array of
microcirculatory defects exists in all models of ischemia, as well as different mouse
strains and forms of injury, is unknown. However femoral artery excision in C57BL/6
mice constitutes a substantial insult and is also a setting where the return of bulk flow is
robust, reaching 85-100% that of the contralateral limb (Couffinhal et al., 1998, Scholz et
al., 2002, Helisch et al., 2006). The current findings therefore highlight the “hidden”
pathophysiology that can exist in the microcirculation. Some differences in capillary
network architecture might be expected, given the different size and arrangement of
regenerated myofibers. However, the abnormal RBC transit, impaired vasoreactive
control, and violations of arteriole-capillary-venule geometry and hierarchy constitute
previously unrecognized pathologies in this regenerative setting. Moreover, these defects
would not be detectable with currently employed techniques for assessing blood flow,
such as laser-Doppler, Doppler-ultrasound, and MR imaging strategies.
Our

findings

of

asymmetric

arteriolar

bifurcations,

trifurcations,

and

quadrifications in the regenerated microvasculature identify a distinctly abnormal
arteriolar morphogenesis program. Bifurcation of arterioles into symmetrical caliber
branches is fundamental to the microcirculation and ensures ordered dispersion of red
cells though the capillary network (Koller et al., 1987, Al-Khazraji et al., 2015, Pries et
al., 1989, Frame et al., 1993). Although the molecular underpinnings of this arteriolar
dysgenesis response are unknown, it is noteworthy that both asymmetric arteriolar
branching and super-numerary branching are features of the highly disordered
microvasculature of tumors (Fukumura et al., 2010, Less et al., 1991). The similarities
between the tumor and regenerated muscle milieu would only be partial but it is
noteworthy that aberrant arteriole branching in tumors is considered to be one of the
causes of tumor hypoxia (Fukumura et al., 2010, Less et al., 1991, Baish et al., 2000).
The potential for arteriolar asymmetry to similarly contribute to hypoxia in skeletal
muscle is also supported by mathematical modeling, which has indicated skimming of
plasma, disparate local hematocrits, and regional heterogeneity in oxygen tensions
unrelated to tissue needs (Less et al., 1991, Pries et al., 1989, Pries et al., 1996).
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Our discovery of arteriole-venule shunts in the regenerated microcirculation was
striking and reveals another basis for impaired oxygen delivery to the muscle. These
aberrant conduits were not found in any of the uninjured muscles yet constituted the
output pattern of 37% terminal arterioles. Their presence in muscle can be expected to
compromise gas exchange by diverting red cells away from nearby single-file transit
capillaries into the high flow micro-shunts. Interestingly, these micro-shunts were
scattered throughout the vascular tree, which differs from the focal arterio-venous
malformations seen in conditions such as hereditary hemorrhagic telangiectasia (Park et
al., 2009, Braverman et al., 1990). The shunts emerged at the same time as capillaries
were forming elsewhere in the network, suggesting a primary, albeit localized, failure in
capillary differentiation. This differs from recent studies in the brain where arterialvenous malformations arise via pathological transformation of pre-existing capillaries
(Murphy et al., 2014).
The velocity of RBCs within capillaries provides important clues about oxygen
delivery in tissues. The sluggish transit of RBCs through regenerated capillaries was
particularly noteworthy given that the metabolic demands of regenerating skeletal
myofibers would be expected to increase, not decline (Koopman et al., 2014). Our transit
maps and video analyses point to several causes of the slow capillary flow, including a
greater total path length of the regenerated microvascular network and the steal
phenomenon from the abundant arteriole-venule shunts (Ellis et al., 2002, Lam et al.,
1994). The persistent increase in the prevalence of capillaries with entirely halted RBC
transit also suggests luminal plugging of microvessels and/or competing pressure heads
within the network. The absence of capillaries in which RBC velocities rose above 1000
µm/s is also noteworthy because RBCs transiting through hyperdynamic capillaries have
the potential to deliver oxygen not only to the adjacent tissue but to RBCs in nearby
capillaries, effectively re-loading them as they approach the distal capillary segment
(Ellis et al., 2012, Koning et al., 2014). Collectively, these abnormalities in RBC transit
velocities strongly suggest that slow RBC transit is a pathological entity of the
regenerated microvascular network.
The normal microvasculature does not act as an inert set of micro-tubes but,
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instead, as an exquisitely controlled vasomotor system that distributes RBCs in an
orchestrated manner to meet the needs of the tissue (Segal, 2005). Hypoxia is a powerful
stimulus for enhancing delivery of RBCs in skeletal muscle (Jia et al., 2011, Parthasarathi
et al., 1999). The oxygen-exchange strategy I employed, coupled with direct tracking of
RBC transit in individual capillaries, provided a uniquely rapid means of generating a
hypoxic muscle milieu and directly linking this to network responsivity. Whereas RBC
velocity and supply rates in control EDL muscle rapidly increased in response to hypoxic
challenge, the responses in the regenerated vasculature were blunted. Thus, the
regenerated microvasculature was defective in a fundamental control process for
modulating RBC delivery. This muted responsivity could also explain the striking
monotony in RBC velocities I observed throughout the network. Although it is possible
that the demands of the regenerated EDL were more uniform than in the normal EDL,
this seems unlikely given the striking variations in capillary RBC O2 saturation that I
identified. Together, the findings indicate that the regenerated network does not have the
ability to tune the delivery RBCs to match the regional needs.
What might be the mechanism for this relative inertness in the regenerated
microcirculation? Distal arterioles constitute the critical effector limb for RBC delivery
and the site where hormonal, metabolic, or neural regulatory factors impinge. Threedimensional reconstruction of confocal optical images afforded an unprecedented
assessment of how SMCs and their contractile elements are organized around these
arterioles. Our finding of circumferential wrapping of SMC processes is consistent with
studies using scanning electron microscopy (Holley et al., 1983) and has recently been
delineated in brain arterioles using genetically encoded mural cells (Hill et al., 2015).
Remarkably, in addition to the banded pattern of the SMC processes, I was also able to
resolve individual actin microfilament bundles, which revealed there to be 3 to 5 discrete
actin microfilament bundles per process, in 10-20 µm diameter arterioles. The finding
that SMC processes also wrapped arterioles in the regenerated network is consistent with
our intravital microscopy findings of arteriole-capillary-venule units. However, the
increased spacing between the SM-α-actin containing processes identifies an architectural
defect in the contractile machinery. In fact, in the regenerated vessels I found that there
was more gap between the SM-α-actin containing processes than area covered by the
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processes. This defect was even more striking in arteriolar segments immediately
upstream of the capillary, where the actin processes were neither circumferential nor
spiral, but oriented haphazardly. Given that arterioles of the caliber studied (7-20 µm)
were invested by only a single layer of SMC processes, the architectural details of these
processes stand to be vital determinants of the extent to which RBC entry into the
capillaries is controlled. I do not currently know if additional defects in the vasomotor
control loop exist, such as in oxygen sensing by the endothelium, gap-junction mediated
signal conduction, or communication between the endothelium and SMCs. Nonetheless,
the findings implicate an entirely new reason for microvascular dysfunction, based on
disorder of the otherwise exquisitely patterned actin-containing protrusions.
In summary, using 4D microvascular imaging and an obliteration-restoration
model of angiogenesis, I have uncovered profound and persistent network-level
dysfunction in the regenerated microcirculation in mouse skeletal muscle. These findings
suggest that, in the setting of vascular regeneration following skeletal muscle infarction,
impaired network functionality rather than limited angiogenesis may be a key
determinant of ongoing ischemia. Strategies to impart advanced physiology to the postinfarction microcirculation, including recapitulating normal arteriolar morphogenesis, are
warranted.
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CHAPTER 4
Vascular Regeneration Following Skeletal Muscle Ischemia
Occurs By Intussusceptive Angiogenesis and Differential
VEGFR2 Responsiveness

4.1 Introduction
Skeletal muscle is the largest organ in humans representing 40% of body weight
and receiving 20-90% of total cardiac output (Pederson et al., 2012, Delp et al., 2004).
The high and variable metabolic requirements of skeletal muscle demand an immense
and finely tuned microcirculation, capable of regulating blood flow over a tremendous
range (Segal, 2005). The microcirculatory architecture is that of a hierarchical network.
Within this network, capillaries are strategically positioned at the interface of individual
muscle fibers to allow RBCs to effectively deliver their oxygen (Krogh, 1919, Arpino et
al., 2017).
Skeletal muscle has a strong innate neovascularization response to ischemic injury
(Couffinhal et al., 1998, Limbourg et al., 2009). One model that has served as an
important platform for understanding neovascularization in skeletal muscle is excision or
ligation of the femoral artery in mice (Limbourg et al., 2009). This model has
demonstrated that, following ischemic injury, blood flow is naturally restored to skeletal
muscle over time. Flow restoration occurs via the opening of collateral vessels and the
regeneration of new microvessels (Couffinhal et al., 1998, Limbourg et al., 2009).
Furthermore, several studies have demonstrated that this neovascularization response can
be enhanced via exogenous growth factor and cellular delivery (Takeshita et al., 1994,
Isner et al., 1996, Isner et al., 1999, Kalka et al., 1999). This regenerative response has
formed the rationale for promoting “therapeutic angiogenesis” in the limbs of patients
with peripheral arterial disease (PAD).
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However, PAD remains a widespread clinical problem. Innate neovascularization
appears to be limited or ineffective within the ischemic muscles of patients (Annex,
2013). In addition, therapeutically enhancing this process using strategies effective in
mouse models has not been found to improve perfusion in the limbs of patients with PAD
(Annex, 2013, Simons et al., 2003). Together, these limitations suggest that the current
understanding of the cellular mechanisms and processes underlying neovascularization in
ischemic skeletal muscle is incomplete.
Currently, the main tenets of adult neovascularization revolve around the process
of sprouting angiogenesis (Eilken et al., 2010). Sprouting angiogenesis has been
extensively studied in the developing mouse retina and the zebrafish embryo. The
sprouting process is characterized by the protrusion and migration of endothelial tip cells
from pre-existing vessels into surrounding tissue. Sprouting angiogenesis is substantially
controlled by the VEGF signaling system. Tip cell selection requires VEGFA-VEGFR2
signaling, with subsequent downstream Dll4-Notch1 signaling (Ruhrberg et al., 2002,
Gerhardt et al., 2003, Hellstrom et al., 2007). Sprouting angiogenesis has been identified
in healthy adult skeletal muscle in response to mechanical stretch or chronic muscle
contraction, on the basis of electron microscopic evidence for capillary endothelial cell
(EC) abluminal protrusion (Egginton et al., 2001, Hansen-Smith et al., 1996, Zhou et al.,
1998b).
Studies of hindlimb ischemia have consistently identified a robust increase in
capillary density within ischemic skeletal muscle. This response has generally been
attributed to sprouting angiogenesis and postnatal vasculogenesis (Hershey et al., 2001,
Madeddu, 2005, Limbourg et al., 2009). The latter process has been reported to be driven
by progenitor cells, either from bone marrow or within the ischemic skeletal muscle
(Asahara et al., 1999, Asahara et al., 1997, Aicher et al., 2007, Leroyer et al., 2009,
Ziegelhoeffer et al., 2004). However, for sprouting angiogenesis, there is remarkably
little evidence to directly implicate its involvement in skeletal muscle angiogenesis
following ischemic injury. To the best of our knowledge, only one study has directly
identified an endothelial tip cell within the ischemic mouse skeletal muscle, in this case
by immunostaining the injured adductor muscle (Al Haj Zen et al., 2010).
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An additional mode of neovascularization and capillary generation has been
identified and termed intussusceptive angiogenesis (IA). Intussusceptive, or splitting,
angiogenesis entails the internal division of a single vessel into two distinct channels
(Styp-Rekowska et al., 2011). IA has been identified in healthy skeletal muscle in
response to elevated blood flow and high shear stress (Egginton et al., 2001, Zhou et al.,
1998a, Hansen-Smith et al., 1996, Williams et al., 2006a, Williams et al., 2006b, Haas et
al., 2000, Prior et al., 2004, Brown et al., 2003). One study has also reported IA in
response to substantial overexpression of VEGF (Gianni-Barrera et al., 2013). However,
IA in muscle is not known to be extensive and, relative to sprouting angiogenesis, the
cellular and molecular processes regulating IA are poorly understood. Furthermore, IA
has not been identified in ischemic skeletal muscle.
Herein, I describe the early events of de-novo microvascular network regeneration
in skeletal muscle following ischemic injury. Using a real-time strategy for dynamically
imaging RBCs within ischemic skeletal muscle (Arpino et al., 2017), I discovered that
following ischemia-induced muscle infarction an unusual, dilated, and non-differentiated
microvasculature with low blood flow and shear stress developed. This primordial
microvasculature then rapidly transformed into an arborized network via EC “inward”
protrusion and IA. Inward protrusion and primordial vessel splitting were associated with
heterogeneity in EC phenotype and depended on suppressed VEGFR2 activation. These
events prompt the reconsideration of angiogenesis paradigms in injured muscle and
associated therapeutic strategies for ischemic disease.

4.2 Methods
4.2.1 Hindlimb Ischemia
Experiments were conducted in accordance with the University of Western
Ontario’s Animal Care and Use Subcommittee. Male C57BL/6J mice (Jackson
Laboratories, Bar Harbor, ME) 12 weeks of age were anesthetized with ketamine (80
mg/kg) and xylazine (10 mg/kg) administered intraperitoneally. Hindlimb ischemia was
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induced by ligating the right femoral artery above and below the profunda femoris branch
using 6-0 silk sutures and excising the intervening 5-6 mm portion of artery (Limbourg et
al., 2009, Frontini et al., 2011).
4.2.2 Histology and Immunostaining
The hindlimb anterior muscle bundle that includes the extensor digitorum longus
(EDL), tibialis anterior, and peroneus longus muscles were dissected, fixed in either Trisbuffered zinc or 4% paraformaldehyde (PFA) overnight, and embedded in paraffin. Fiveµm thick cross-sections of muscle through the proximal, middle, and distal regions were
stained with hematoxylin and eosin. For immunofluorescence detection of ECs, near
adjacent five-µm thick sections of muscle were subjected to heat-mediated antigen
retrieval with citrate buffer and immunostained using rabbit polyclonal anti-mouse CD31
antibody (1:100, Thermo Scientific, RB-10333-P1) and detected using biotinylated
donkey anti-rabbit IgG (1:200, Jackson ImmunoResearch) and Dylight 549-conjugated
streptavidin (1:200, Vector) or rat monoclonal anti-mouse CD31 antibody (1:20,
Dianova, Clone SZ31) and detected using Alexa Fluor-488 conjugated goat anti-rat IgG
(1:100, Life Technologies). ECs were also immunostained using rat monoclonal antimouse endomucin antibody (1:100, Santa Cruz, Clone V.7C7, sc-65495) and detected
using Alexa Fluor-488 conjugated goat anti-rat IgG (1:200, Life Technologies) or goat
polyclonal anti-mouse VE-Cadherin antibody (1:100, R&D Systems, AF1002) and
detected using Alexa Fluor-488 conjugated donkey anti-goat IgG (1:200, Life
Technologies). For immunofluorescence detection of VEGFR2 activation in ECs, fiveµm thick sections of muscle were subjected to antigen retrieval and doubleimmunostained using rat monoclonal anti-mouse endomucin antibody (1:100, Santa
Cruz, Clone V.7C7, sc-65495) and rabbit polyclonal anti-VEGF receptor 2 phospho
y1054 + y1059 antibody (1:50, Abcam, ab5473). Bound antibodies were detected using
Alexa Fluor-488 conjugated goat anti-rat IgG (1:200, Life Technologies) and Alexa
Fluor-594 conjugated goat anti-rabbit IgG (1:100, Life Technologies). Nuclei were
visualized with DAPI Fluoromount-G (SouthernBiotech, 0100-020). Sections were
imaged by widefield microscopy (Olympus BX-51) and photomicrographs captured with
Northern Eclipse (EMPIX Imaging Inc.) software.
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4.2.3 Intravital Video Microscopy
RBC transit in individual microvessels within a 50 µm-deep zone across the entire
mouse EDL surface was assessed by epifluorescent intravital video microscopy (IVVM)
as described previously (Arpino et al., 2017). Briefly, mice were anesthetized with
ketamine and xylazine intraperitoneally and a longitudinal incision was made over the
anterior hindlimb. Tibialis anterior and peroneus longus muscles were separated from
surrounding fascia and spread apart to reveal the underlying EDL (Tyml et al., 1991).
The EDL was covered with an 8x8 mm glass coverslip, and positioned face-down on the
stage of an inverted microscope (Olympus IX81), maintaining body temperature at 37°C.
After a 20-minute stabilization period, the EDL was epi-illuminated with a 120 W
Mercury X-Cite high-pressure bulb light source, via 10x and 20x objectives (Olympus
UPlanSApo). RBC transit was visualized by either ultraviolet light epi-illumination
(DAPI U-MWU2: 330-385 nm excitation filter, 420 nm emission filter) or blue light epiillumination (U-MWIBA2: 460-490 nm excitation filter, 510-550 nm emission filter)
(Frontini et al., 2011, Yin et al., 2015) following intrapenile injection of FITC-labeled
dextran (2x106 MW; 20 mg/mL, 30 µL, Sigma). Video recordings (696 x 520 pixels, 21
images/sec) were captured using a cooled charge-coupled device camera (Rolera-XR,
QImaging) and displayed in real-time on a computer monitor for at least 315 images (15
seconds). For all studies, the entire EDL surface was recorded and analyzed (7-10 fields
of view). Video sequences were digitized and stored as uncompressed AVI files for postprocessing using custom acquisition software (NeoVision) and in-house software written
in the MATLAB (Mathworks) programming environment.
4.2.4 Analysis of Microvascular Network Architecture and Identification of
Intraluminal Micro-Obstructions
Vessel lumen diameter, vascular density, bifurcation density, pillar density, and
vessel split density of EDL muscle microvascular networks were quantified from RBC
transit maps using ImageJ (NIH). RBC transit maps effectively displayed a microangiogram of all flowing microvessels, and were generated from IVVM video sequences
using custom MATLAB software as described (Japee et al., 2004, Varghese et al., 2005).
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From the videos generated by blue-light epi-illumination, RBC transit maps were
generated from “sum of all differences” (SAD) images, which displayed the cumulative
sum of the square of differences in light intensity values at each pixel between
consecutive video frames, thus generating a single map of all microvessels perfused with
RBCs and plasma.
Vessel lumen diameter was quantified manually perpendicular to the vessel
centerline. Vascular density (microvasculature length [µm] / vascularized EDL area
[µm2]) was quantified at each time-point via manual tracing of all vessel centerlines and
normalizing total microvasculature length to vascularized EDL area. Bifurcation density
was determined by manual point counting of all vessel bifurcations and normalizing to
total microvasculature length. Intraluminal pillars were identified in RBC transit maps as
circular (2-8 µm diameter) signal voids within flowing microvessels. Vessel splits were
identified as RBC transit loops, wherein RBCs in transit diverged from a single vessel
into two distinct smaller vessels and then reconverged into a single conduit at least 50 µm
downstream. Pillar or split density was expressed as the total number of intraluminal
pillars or vessel splits normalized to total microvasculature length. Arteriole-capillaryvenule (ACV) microcirculatory units were identified from blue light epi-illumination
videos and corresponding SAD images.
4.2.5 Cell Culture
Human umbilical vein endothelial cells (HUVECs, Lonza) were maintained in
Endothelial Growth Medium-2 (EGM-2) BulletKit (Lonza, CC-3162) containing 2% fetal
bovine serum and VEGF-A, with media changes every other day. After 8-10 passages,
HUVEC cultures were generated at 70-75% confluence and were transfected with either
control siRNA (50 nM, Origene, SR30004) or KDR (VEGFR2) siRNA (50 nM, Origene,
SR302557) with Lipofectamine RNAiMAX kit (Thermo Fisher, 13778100) for 24 hours
at 37°C. Six to eight hours following siRNA transfection, HUVECs were transduced with
adenovirus encoding either RFP (5 µL/mL of media) or GFP (50 µL/mL of media) for
16-18 hours at 37°C. Approximately 32 hours following infection with siRNA, HUVECs
were split and plated on glass coverslips at a 1:10 ratio (8000 siVEGFR2 HUVECs :
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72000 siControl HUVECs) per well. Cells were grown for 48 hours to form a co-cultured
monolayer at ~80% confluence. Cells were then fixed with 4% PFA for 20 minutes.
Select monolayers were treated with S1P (1 µM in 0.3 M NaOH, Cayman Chemical,
#62570) or vehicle solution for 3 minutes to stimulate activation of the cytoskeleton
before fixation (Vouret-Craviari et al., 2002). VEGFR2 knockdown was confirmed
following cell harvest and lysing by quantitative RT-PCR and SYBR Green chemistry
and a ViiA 7 Real Time PCR System (Life Technologies). Primer pairs (Origene)
employed

were

5’-

GGAACCTCACTATCCGCAGAGT-3’

and

3’-

CCAAGTTCGTCTTTTCCTGGGC-5’.
4.2.6 Whole-Mount Immunostaining of Mouse Retinas
For whole-mount immunostaining of mouse retinas, retinas were harvested from
five day-old C57BL/6 mice as described (Pitulescu et al., 2010). Briefly, mice were
sacrificed by isoflurane overdose and eyeballs were enucleated. Eyeballs were rinsed in
PBS, then fixed with 4% PFA for four hours at 4°C. After dissection the retina was rinsed
briefly with PBS, and incubated with retina-blocking buffer (RBB) (PBS pH 7.4, 0.5%
Triton-X 100, 1% BSA, 5% Donkey Serum) overnight at 4°C. The retina was then
washed with Pblec buffer (PBS pH 6.8, 1% Triton-X-100, 1 mM MgCl2, 1 mM CaCl2,
0.1 mM MnCl2) and incubated with biotynilated isolectin-b4 (1:50, Sigma, BSI-B4,
L2140) in Pblec buffer overnight at 4°C. Next, the retina was washed with 1:1 RBB:PBS,
and incubated with rabbit polyclonal anti-VEGF receptor 2 phospho y1054 + y1059
antibody (1:50, Abcam ab5473) in RBB and 2.5% donkey serum overnight at 4°C. The
retina was then washed with 1:1 RBB:PBS and bound antibodies were visualized using
Dylight 488-conjugated streptavidin (1:100, Vector Laboratories) and Alexa Fluor-546
conjugated donkey anti-rabbit IgG (1:100, Life Technologies) in RBB + 2.5% donkey
serum for 2 hours. The retina was sliced into four flat quadrants, transferred to positively
charged glass slides, and mounted with Fluoromount-G (SouthernBiotech 0100-01) prior
to coverslipping and sealing.
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4.2.7 Thick-Section Immunostaining of Mouse Skeletal Muscle
For thick-section immunostaining of skeletal muscle, mice were sacrificed by
isoflurane overdose and perfused sequentially with PBS and 4% PFA via left ventricle
cannulation at physiologic pressure. EDL muscles were dissected, immersed in 4% PFA
for 2 hours, cryoprotected with 15% sucrose for 2 hours and 30% sucrose overnight at
4°C. Tissues were then embedded in OCT embedding medium (Tissue-Tek) and stored at
-80°C. 100-µm thick longitudinal cryosections were permeabilized with 0.5% Triton-X
100 in PBS and double immunostained using biotinylated rat anti-mouse CD31 antibody
(1:25, BD Biosciences 553371) and rabbit polyclonal anti-VEGF receptor 2 phospho
y1054 + y1059 antibody (1:50, Abcam ab5473) or rabbit polyclonal anti-NG2 antibody
(1:200, Millipore AB 5320). Bound antibodies were visualized using Dylight 488conjugated streptavidin (1:100, Vector Laboratories) and Alexa Fluor-546 conjugated
donkey anti-rabbit IgG (1:100 or 1:200, Life Technologies). Nuclei were visualized with
TO-PRO-3 iodide (1:500, Life Technologies). Thick-sections were transferred to
positively charged glass slides, mounted with Fluoromount-G (SouthernBiotech 0100-01)
and flanked with 100-µm thick plastic coverslip spacers (Thermo Scientific) prior to
coverslipping and sealing.
4.2.8 Laser Scanning Confocal Microscopy and 3-Dimensional Reconstruction
Mouse retina endothelial tip cells, and uninjured capillaries and mother vessels in
EDL muscle were imaged with an LSM 510 Meta Confocal Microscope (Zeiss) using a
40x water-immersion objective and Argon2 (488 nm excitation), HeNe1 (543 nm
excitation), and HeNe2 (633 nm excitation) lasers, generating up to 50, 1 µm-thick zslices at 2048x2048 image resolution. Z-slices were reconstructed into 3-dimensional
maximum intensity projections with Image Viewer and Zen (Zeiss) software. To
determine the localization of VEGFR2 activation within mother vessels and intraluminal
protrusions or pillars, 3-dimensional reconstructions were scrutinized through each of
their individual optical sections and orthogonal XZ and YZ projections in order to
identify locations of pVEGFR2 signal. pVEGFR2 signal was considered to be lateralized
on intraluminal protrusions and pillars if the signal was localized and enriched on only
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one side of the pillar, with the dividing axis perpendicular to the direction of flow.
pVEGFR2 signal was deemed to be non-lateralized if signal was localized on both sides
of the pillar with similar enrichment.
HUVEC monolayers on glass coverslips were transferred facedown with the
center exposed onto flanking 100-µm thick plastic spacers (Thermo Scientific), then
placed atop positively charged glass slides covered with Prolong Gold Antifade Mountant
(Thermo Scientific). HUVECs were imaged with an LSM 510 Meta Confocal
Microscope (Zeiss) using a 40x water-immersion objective and Argon2 (488 nm
excitation), and HeNe1 (543 nm excitation) lasers, generating up to 40, 0.5 µm-thick zslices at 1024x1024 image resolution. Z-slices were reconstructed into 3-dimensonal
maximum intensity and surface projections with Zen (Zeiss) software. To quantify the
surface area (µm2) of HUVECs, individual cells were manually circumscribed using
ImageJ. To quantify the thickness (µm) of HUVECs orthogonal XZ and YZ projections
were generated with Zen (Zeiss) software, and the maximum thickness of individual cells
was measured manually using ImageJ.
4.2.9 Analysis of Red Blood Cell Velocity and Vessel Wall Shear Rate
Red blood cell velocities (VRBC [µm/sec]) in individual microvessels were
quantified from video files using space-time images as described previously (Ellis et al.,
1992, Japee et al., 2005, Arpino et al., 2017). Briefly, 1-second (21 frames) interval mean
red blood cell velocities were calculated using custom MATLAB software, generating a
2D gray scale plot of RBC location change with time. This enabled an unbiased
quantification of RBC transit velocities within microvessels throughout the entire EDL
muscle. Mean VRBC averaged over a 15-second imaging time-frame within each
microvessel was determined in a total of 115 uninjured capillaries, 82 microvessels 5
days following surgery, and 93 microvessels 7 days following surgery. Experimentally
derived vessel wall shear rate [sec-1] was calculated using the equation shown below as
described by Al-Khazraji et al., with vessel lumen diameter (D) and maximum velocity
(vessel centerline velocity, VExpt Max) used as equation inputs (Al-Khazraji et al., 2016).
Vessel wall shear rate was calculated in 48 microvessels five days following surgery
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ranging from 7.3 – 38.5 µm in diameter.
44x D + 1.99
!x!V!"#$!!"#
166!x! D + 0.39
Vessel!Wall!Shear!Rate = !
0.022!x! D + 0.00074!
4.2.10 Semi-Thin Sectioning
Semi-thin sectioning of hindlimb anterior muscles was performed as described for
the mouse renal corpuscle (Roth et al., 2015). Mice were sacrificed by isofluorane
overdose, and perfused sequentially with PBS and 4% PFA via left ventricle cannulation
at physiologic pressure. Anterior hindlimb muscles were dissected and immersed in
Karnovsky’s fixative (3% Glutaraldehyde, 2% formaldehyde in 0.1 M Sorenson buffer,
Electron Microscopy Sciences, 15731-10) overnight at 4°C. Tissues were then subjected
to a second round of fixation the next day in fresh Karnovsky’s fixative for one hour and
dehydrated in increasing concentrations of electron microscopy-grade ethanol solutions
(Electron Microscopy Sciences) in ddH2O as follows: 50% for 1.5 hours, 70% for 1 hour,
95% for 1 hour, and 100% for 1 hour. Next, the tissue was infiltrated with 100%
propylene oxide for 1 hour (Electron Microscopy Sciences) and then infiltrated with a 1:1
mixture of propylene oxide and embedding medium (5 mL Embed-812, 3mL Araldite, 11
mL DDSA, and 0.3 mL DMP-30, Electron Microscopy Sciences) for 1 hour. Next, the
tissue was infiltrated overnight with 100% embedding medium at room temperature. The
next day, tissue was subjected to fresh 100% embedding medium for 1 hour. All
aforementioned fixation, dehydration, propylene oxide infiltration, and embedding
medium infiltration steps were performed within glass vials continuously spun on an
orbital rotator. Tissues were placed in pre-constructed wells (Electron Microscopy
Sciences) along with 100% embedding medium using a syringe with a blunt-tip 181/2
gauge needle and incubated for 72 hours at 60°C in order to polymerize the medium.
For sectioning, tissue blocks were trimmed with steel razor blades into a truncated
pyramid with a trapezoid cut block face, with the upper and lower edges being parallel.
The adhesive Pattex Compact (Henkel KGaA, Dusseldorf, Germany) was diluted in
xylene (6 drops of xylene for a 5 mm3 volume of adhesive) and applied to the underside
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of the block with a needle tip for generating tissue section ribbons. Glass slides used to
mount sections were treated prior to sectioning to remove their water-retention properties
by immersion in an ethanol (96%) ammonia (25%) solution at a ratio of 9:1 for at least 1
day and then scrubbed with a sponge and dish soap and thoroughly rinsed with distilled
water. Tissue blocks were sectioned into semi-thin (0.5 µm thickness) serial ribbons
using a Histo Jumbo diamond knife (Diatome AG, Biel, Switzerland) and ultramicrotome
(Reichert- Jung Ultracut E). Once ribbons were generated, treated glass slides were
carefully slid into the Histo Jumbo diamond knife water trough and the floating ribbons
were gently guided onto the slide. ddH2O was added to the slide and placed on a hotplate
for 1 hour at 60°C.
For staining of semi-thin sections, polychromatic and methylene blue stains were
prepared according to Sato et al. and D’Amico (Sato et al., 1973, D'Amico, 2005).
Polychromatic stain was prepared by dissolving monobasic sodium phosphate (0.5 g,
Sigma), basic fuchsine (0.25 g, Electron Microscopy Sciences), and methylene blue (0.2
g, Electron Microscopy Sciences) in 15 mL of 0.5% boric acid solution, followed by the
addition of 70 mL of ddH2O and 10 mL of 0.72% NaOH (pH 6.8). Methylene blue stain
was prepared by dissolving methylene blue (0.75 g, Electron Microscopy Sciences),
azure B (0.25 g, Electron Microscopy Sciences), and borax (0.5 g, Electron Microscopy
Sciences) in 100 mL of ddH2O. Approximately 1 mL of polychromatic solution was
added to the slides placed on a hot plate at 55°C for 5 minutes, rinsed with ddH2O, and
then followed by the addition of 1 mL of methylene blue stain for 10 seconds. Serial
sections were mounted with Eukitt mounting medium (Sigma, 03989) and coverslipped.
Up to 1000 serial sections were obtained from a single tissue block, and 3 native EDL
muscles and 3 EDL muscles harvested five days following surgery were sectioned.
Stained serial sections were digitally scanned using a ScanScope CS brightfield digital
slide scanner with a 40x objective (Aperio Technologies, Vista, CA, USA). Digital
micrographs of serial sections were captured using Sedeen Viewer Software and exported
as TIFF image files. Up to 50 serial TIFF image files of individual microvessels were
rotated and aligned semi-automatically in Photoshop (Adobe). Videos were generated
using 3D Slicer (Fedorov et al., 2012).
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4.2.11 In-Vivo Blockade of VEGFR2 Signaling
For acute in-vivo blockade of VEGFR2 signaling, mice were injected
intraperitoneally with individual VEGFR2-selective chemical tyrosine kinase inhibitors
or an anti-VEGFR2 antibody 4.5 days following surgery. Specific details for each
individual inhibition regimen are described in detail below. To determine the effect of
acute VEGFR2 signaling inhibition on microvascular network architecture, blue-light
epifluorescence intravital microscopy of the EDL muscle was performed on day 5
following surgery (16-18 hours after injection), as above.
Apatinib (YN968D1): Apatanib (Selleckchem, S2221) is a selective VEGFR2
tyrosine kinase inhibitor with an IC50 of 1 nM. A working solution was prepared by
dissolving 10mg of Apatinib powder into sterile 560 µL dimethyl sulfoxide (DMSO,
Sigma) and 560 µL modified PBS (140 mM NaCl, 9 mM of Na2HPO4, 1.3 mM of
NaH2PO4, pH 7.4) with continuous agitation. On day 4.5 following surgery, 168 µL of
Apatinib solution (60 mg/kg) was injected intraperitoneally into mice (Tong et al., 2012,
Tian et al., 2011, Mi et al., 2010, Lin et al., 2014). An equivalent volume of sterile
vehicle solution was administered intraperitoneally into littermate controls. IVVM was
performed 16-18 hours following administration.
Cabozantinib and ZM 323881: Cabozantinib (Selleckchem, XL184, BMS907351) and ZM323881 HCl (Selleckchem, S2896) are selective VEGFR2 tyrosine
kinase inhibitors with an IC50 of 0.035 nM and <2 nM, respectively. Working solutions
were prepared by dissolving Cabozantinib or ZM323881 HCl into sterile 2% DMSO
(Sigma), 30% polyethylene glycol 300 (PEG-300, Sigma), 5% Tween-80 (Sigma), and
63% ddH2O, according to the manufacturers instructions. On day 4.5 following surgery,
375 µL of Cabozantinib solution (30 mg/kg) or 400 µL of ZM323881 HCl solution (60
mg/kg) was injected intraperitoneally into mice (Zhao et al., 2016, Sameni et al., 2016,
Phan et al., 2015). Sterile vehicle solution was administered intraperitoneally into
littermate controls. IVVM was performed 16-18 hours following injected.
DC101: DC101 (BioXCell, BE0060) is a monoclonal anti-mouse in-vivo
VEGFR2 blocking antibody. On day 4.5 following surgery, 200 µL of DC101 in sterile

167
PBS pH 7.0 (40 mg/kg) or 200 µL of isotype control (BioXCell, BE0088, 40 mg/kg) was
injected intraperitoneally into mice (Ding et al., 2015, Arulanandam et al., 2015,
Larrayoz et al., 2014). IVVM was performed 16-18 hours following administration.
4.2.12 Statistics
Statistical analyses were performed using Prism 5 (Graphpad Software). All
values passing D’Agostino and Pearson omnibus normality test are presented as mean ±
SEM. Those not passing the normality test are presented as median and IQR.
Comparisons among normally distributed variables were made by t-test or analysis of
variance with Bonferonni’s post hoc test. Comparisons among non-normally distributed
variables were made by Mann-Whitney test or Kruskall-Wallis test with Dunn’s post hoc
test. Linear regression analyses were used to assess relationships between vessel wall
shear rate and diameter. Statistical significance was set at P<0.05.

4.3 Results
4.3.1 Vascular Regeneration in Ischemic Muscle Entails the Emergence of Large
Caliber Primordial Vessels
To study the processes by which a microvascular network regenerates following
ischemic injury to skeletal muscle, C57Bl/6 mice were subjected to right femoral artery
excision. The extensor digitorum longus (EDL) muscle and microvasculature was then
evaluated daily for five days by histology. Hematoxylin and eosin staining revealed that
the entire EDL muscle was infarcted on day one following surgery (Figure 4.1 a,c). This
was evident through palely stained myocytes with absent nuclei (Figure 4.1 c). A similar
appearance was seen on days two and three. On day four an inflammatory response
emerged (Figure 4.1 e). On day five there was extensive inflammation with clearing of
necrotic muscle debris (Figure 4.1 g). Myocyte regeneration initiated on day five, as
evidenced by the appearance of miniature hyper-eosinophilic satellite cells with central
nuclei in the spaces where the muscle was destroyed (Figure 4.1 g).
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Figure 4.1 Histology of the EDL muscle following ischemic injury and necrosis and
the emergence of primordial vessels
Hematoxylin and eosin-stained sections of EDL muscle before surgery (A),
one day following surgery showing palely stained myocytes with absent nuclei (C),
four days following surgery showing the emergence of an inflammatory response
(arrows, E), and five days following surgery showing the appearance of satellite
cells with central nuclei in the spaces where the muscle was destroyed (arrows, G).
Fluorescence micrographs of EDL muscle immunostained for CD31 (green)
showing capillaries (arrows) surrounding myofibers (asterisk) before surgery (B),
near complete loss of capillaries after ischemic insult one day following surgery
(D), the absence of capillaries four days following surgery (F), and the emergence
of a neovasculature comprised of dilated primordial vessels (arrows) with thin
CD31+ walls five days following surgery (H). Nuclei are visualized with DAPI.

169

Hematoxylin and Eosin
A

CD31 Immunofluorescence
B

*

Native

C

D

E

F

G

H

Day 1

Day 4

Day 5

170
Immunostaining for CD31 revealed near-complete loss of CD31-stained
capillaries by day one and complete absence by day 3, consistent with my previous
findings (Arpino et al., 2017) (Figure 4.1 b,d). Microvessels remained absent on day four
(Figure 4.1 f). Remarkably however, on day five, there was a seemingly abrupt
appearance of new vascular structures that stained positively for the EC marker CD31
(Figure 4.1 h). These primordial neovessels were much larger than normal capillaries, up
to 31 µm in diameter, but the walls of the neovessels were thin (Figure 4.1 b,d).
4.3.2 Primordial Vessels in Regenerating Skeletal Muscle Lack Microvascular
Network Hierarchy or Specification
To evaluate primordial vessels at a network level, I performed daily real-time
microscopy of the EDL surface zone following intravenous injection of FITC-labeled
Dextran (Arpino et al., 2017). High-magnification RBC transit maps of native EDL
muscle revealed a highly organized microvascular network containing parallel capillaries
(Figure 4.2 a). RBC transit was completely absent on days one through four following
surgery (Figure 4.2 b,c). On day five, RBC transit maps revealed the large caliber,
primordial vessels as the first flow-receiving channels in the EDL muscle following
femoral artery excision (Figure 4.2 d). Networks of primordial vessels were first detected
in the distal-most region of the EDL surface.
Quantitative analysis highlighted the striking dilatation of primordial vessels
compared to normal capillaries (12.2 (9.6 – 17.0) vs 5.5 (5.1 – 6.0) µm, median (IQR),
P<0.0001) (Figure 4.2 e). Moreover, individual primordial vessels exhibited remarkable
intravessel diameter variability along the vessel segment length, in contrast to normal
capillaries (Figure 4.2 a,d,f). Furthermore, the primordial network architecture had no
evidence for hierarchy or specification, in contrast to the hierarchical arteriole-capillaryvenule (ACV) units of normal microvascular networks (Figure 4.3).
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Figure 4.2 RBC transit maps of primordial vessels
A. RBC transit map of native EDL muscle microvasculature showing a highly
organized network with capillaries (arrow) arranged in parallel between individual
muscle fibers.
B-C. RBC transit maps of EDL muscle on one (B) and four (C) days after femoral
artery excision showing no RBC transit after ischemic injury.
D. RBC transit map of EDL muscle five days after femoral artery excision
showing the emergence of a flowing neo-microvasculature comprised of
primordial vessels (arrows).
E. Graph showing box and whisker (10-90 percentile) plot of microvessel lumen
diameter as evaluated from 164 capillary segments in 3 native EDL muscles and
from 377 neovessels in 5 EDL muscles on day five following surgery. *p<0.0001.
F. Line plot depiction of intravessel diameter heterogeneity along the vessel
segment length in a representative normal capillary (n=1) and a representative
primordial vessel (n=1).
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Figure 4.3 Network architecture of primordial vessels
High-magnification RBC transit maps of the native EDL muscle microvasculature
(left) and the primordial neo-microvasculature that emerges five days following femoral
artery excision (right). Networks of primordial vessels (right, arrows) bear little
resemblance to native capillaries or hierarchical arteriole-capillary-venule units in native
EDL muscle (left, A=arteriole, C=capillary, V=venule).
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4.3.3 Primordial Vessels are Mother Vessels that Rapidly Transform Into an
Extensive Microvascular Network
In Chapter 3, I established that an extensive microvasculature with arteriolecapillary-venule hierarchy regenerates in the infarcted and regenerating EDL muscle
(Arpino et al., 2017). Remarkably, immunostaining for CD31 revealed that by day seven
dilated primordial channels were no longer detectable. Instead, I found a microvascular
network with lumens of smaller caliber. These vessels were widely dispersed throughout
the tissue and at the interface of newly formed muscle fibers (Figure 4.4 a,b). RBC transit
maps confirmed that the primordial channels had rapidly transformed into a widely
distributed and arborized microvascular network within 48 hours, including the
emergence of neocapillaries (Figure 4.4 c-e).
Quantitative analysis of RBC transit maps revealed that the lumen diameter of
neo-microvessels nearly halved by day seven (6.6 (5.1 – 8.8) µm D7 vs 12.2 (9.6 – 17.0)
µm D5, P<0.0001, Figure 4.4 f), and were only slightly enlarged compared to normal
capillaries in native EDL muscle (6.6 [5.1 – 8.8] D7 vs 5.5 [5.1 – 6.0] µm native,
P<0.0001, Figure 4.4 f). Moreover, the 48-hour network transformation entailed a 1.5fold increase in the number of vessel bifurcations (P=0.002, Figure 4.4 g) and a
concomitant tripling of vascular density (P<0.0001, Figure 4.4 h). Together, these
findings reveal that the dilated primordial vessels were, in fact, “mother vessels” (MVs)
that rapidly transformed into an extensive microvascular network.
4.3.4 The Mother Vessel Wall is Comprised of Collectivized Endothelial Cells and
NG2+ Pericytes
To characterize the cellular composition of the MV I double-immunolabeled 100µm thick sections of EDL muscle for the EC marker, CD31, and the mural cell marker,
NG2. I then generated 3-dimensional reconstructions. This revealed that MVs were
comprised of collectivized CD31+ ECs (Figure 4.5 b). However, in contrast to native
EDL muscle capillaries that are comprised of single elongated ECs positioned in series
along the vessel length, the circumference of MVs at a given site was typically comprised
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Figure 4.4 Transformation of mother vessels into an extensive microvasculature
over 48 hours
A. Hematoxylin and eosin-stained section of EDL muscle seven days following
surgery showing newly formed muscle fibers with central nuclei (arrows).
B. Fluorescence micrograph of EDL muscle immunostained for CD31 (green) on
day seven following surgery showing smaller caliber microvessels (arrows)
surrounding newly formed muscle fibers (asterisk). Nuclei are visualized with
DAPI.
C-E. RBC transit maps of EDL muscle on days five (C), six (D), and seven (E)
following surgery showing the transformation of mother vessels into a widely
distributed microvasculature over 48 hours. Hatched lines denote EDL muscle
borders.
F. Graph depicting box and whisker (10-90 percentile) plot of microvessel lumen
diameter, evaluated as indicated below the growth (n=3-5 EDL muscles for each
time point). *p<0.0001.
G. Graph depicting branching density of EDL muscle microvascular networks
(n=3-5 EDL muscles for each time point). *p=0.001, **p=0.002.
H. Graph depicting vascular density of EDL muscle microvascular networks
(n=3-5 EDL muscles for each time point). *p<0.0001.
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Figure 4.5 Mother vessel wall structure and composition
A-B. Confocal micrographs of projected optical sections of a native EDL muscle
capillary (A) and a mother vessel on day five following surgery (B)
immunolabeled for CD31 (green) and TO-PRO-3 (blue).
C. Left: Higher magnification confocal micrograph of projected optical sections
of a mother vessel on day five following surgery. Shown are two EC nuclei
(arrows, hatched lines denote edges of nuclei) that comprise the circumference of
the MV at the same location along the vessel segment length. Right: Fluorescence
micrographs of native and day five EDL muscle cross-sections immunostained for
CD31 (green) showing a single EC nucleus in a normal capillary (top, arrow) and
three EC nuclei in a mother vessel (bottom, arrows).
D. Confocal micrographs of projected optical sections of the mother vessel shown
in Figure 4.5 b immunolabeled for NG2 (red) and TO-PRO-3 (blue). On the right,
the CD31 (green) channel is overlaid.
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of more than one EC (Figure 4.5 a-c). Interestingly, MVs were also extensively invested
with NG2+ pericytes, whereas native capillaries were only sparsely invested with
pericytes that did not fully wrap the circumference of the vessel (Figure 4.5 d). Thus,
MVs are a structurally unique conduit in skeletal muscle.
4.3.5 Mother Vessels Have Profoundly Slow Blood Flow and Low Wall Shear Rate
I next evaluated the RBC transit dynamics within MVs. To do this, I performed
real-time microscopy to image RBCs in transit over seven days following surgery. This
revealed that, on day five, RBCs within MVs transited with a velocity (VRBC) of 87.6
(54.1-177.4) µm/s (median (IQR)) (Figure 4.6 a). This was only 17% of that in native
EDL muscle capillaries (P<0.0001, Figure 4.6 a). Moreover, MVs had strikingly high
hematocrit, with up to 7 RBCs identified across the vessel segment diameter (Figure 4.6
c). This was in contrast to the single-file RBC transit that is characteristic of native
capillaries (Fig. 4.6 b). Furthermore, although MV lumens contained an abundance of
RBCs and were of similar caliber to skeletal muscle feeder arterioles, RBC transit
dynamics were non-arteriolar as they did not exhibit the parabolic radial VRBC profile that
is characteristic of skeletal muscle arterioles (Al-Khazraji et al., 2016). Instead, the radial
VRBC profile was blunted and venous-like, with the vessel centerline VRBC being similar
to VRBC at the vessel wall (data not shown).
I also assessed RBC transit dynamics during the transformation of MVs into an
arborized microvasculature. RBC transit velocity nearly doubled to 164.9 (121.0-236.1)
µm/s by day seven following the transformation of network architecture (P<0.0001,
Figure 4.6 a). Moreover, fewer RBCs were identified across vessel segment lumens on
day seven as a consequence of reduced diameter. Single-file RBC transit was identified in
capillary-like neovessels, although this was not widespread at this time. As well, RBC
transit remained slow compared to the native EDL microvasculature (P<0.0001, Figure
4.6 a).
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Figure 4.6 Mother vessel RBC transit dynamics
A. Box and whisker (10-90) percentile plot of red blood cell velocities (VRBC) in
individual microvessels within native and regenerated EDL muscle evaluated on
the designated days following surgery. Values were obtained from a total of 307
microvessels. Each value is derived from RBC velocities, averaged over a 15second imaging time frame, within each microvessel. *p<0.0001, **p=0.004,
†p=0.002.
B. Video still frame depicting single-file RBC transit in native capillaries.
Hatched lines denote capillary lumens.
C. Video still frames depicting non-single file RBC transit in MVs with high
hematocrit. Hatched lines denote MV lumens.
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I next evaluated vessel wall shear rate using a recently published strategy (AlKhazraji et al., 2016). MV wall shear rate within 48 MVs with a mean diameter of 19.6 ±
8 µm was calculated to be 89.5 (26.4-161.8) sec-1 (median (IQR)) and ranged from 7.1 to
606.4 sec-1 (Figure 4.7). This is ~11-fold lower than the calculated wall shear rate in a
typical native capillary (1028 sec-1). Moreover, there was an inverse relationship between
the diameter of MVs and wall shear rate (r2 = 0.177, P=0.003, Figure 4.7). These findings
reveal profoundly low shear forces on the ECs of MVs.
4.3.6 Mother Vessels Contain Micro-Obstructions to RBC Transit
I next asked how MVs transformed into an arborized neo-microvasculature. To
study this, I inspected RBC transit maps of MVs at high resolution on days five and six
for evidence of active microvascular growth. Surprisingly, I discovered that there were
micro-obstructions to RBC transit within the flowing MV lumens. Micro-obstructions
revealed themselves along the length of MV segments and near MV bifurcations as
punctate dots or circular entities, 2-8 µm in diameter, that were devoid of RBC transit
signal (Figure 4.8). Complementary real-time microscopy video sequences confirmed
that “dead-zones” were bona fide micro-regions of no flow. Individual RBCs were seen
to deflect in transit around the dead zones, indicating that they were intraluminal microobstructions. In addition, cell-free blood plasma “streams” of ~5 µm in length were
observed immediately downstream of the micro-obstructions. Consistent with this, the
RBC transit map “dead-zones” appeared larger than the actual micro-obstruction
identified in the video sequence, indicating there was a region downstream of the microobstruction where no RBCs were flowing.
In addition, I also identified MV micro-divisions that were larger than microobstructions. Micro-divisions were identified in RBC transit maps as ellipsoid “deadzone” entities deficient of any RBC motion (Figure 4.9). Micro-divisions were 3-10 µm
in width and 5-50 µm in length. Real-time microscopy video sequences confirmed that
these regions were devoid of blood flow. Moreover, I identified MVs wherein the lumen
had effectively divided and “split” the long axis of the vessel (Figure 4.10). The MV
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Figure 4.7 Mother vessel wall shear rate
Scatter plot with regression line depicting inverse relationship between mother
vessel wall shear rate and lumen diameter on day five following surgery. (n=48
microvessels from 5 EDL muscles on day 5 following surgery, r2=0.177, *p=0.0002).
Data points represent individual vessels.
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Figure 4.8 RBC transit maps of micro-obstructions to RBC transit
RBC transit maps of circular “dead-zone” entities (micro-obstructions, arrows)
devoid of RBC transit signal within flowing MV lumens. Images are from 5 EDL
muscles on day 5 following surgery. Multiple images are presented to depict the variety
of sizes and shapes of micro-obstructions, the location of micro-obstructions within either
straight regions of MVs or at branch points, and the presence of both isolated and
adjacent micro-obstructions. To note, micro-obstructions were often identified at a
bulbous site of locally expanded MV diameter.
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Figure 4.9 RBC transit maps of mother vessel micro-divisions
RBC transit maps showing ellipsoid “dead-zone” entities (micro-divisions,
arrows) devoid of RBC transit signal within the flowing mother vessel lumen. Images are
from 5 EDL muscles on day 5 following surgery. Multiple images are presented to show
that micro-divisions can be isolated or adjacent to one or more similar divisions. To note,
like punctate micro-obstructions, micro-divisions tend to be at an expanded site of the
primitive vessel.
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Figure 4.10 RBC transit maps of mother vessel splits
A. RBC transit maps showing mother vessel splits (arrows), wherein RBCs are
diverted into two daughter vessel segments that are spread apart from one another
and reconverge into a single mother vessel lumen downstream.
B. RBC transit map showing a mother vessel that has asymmetrically split (arrow)
into a capillary-caliber daughter vessel (arrowhead) and a residual mother vessel.
C. RBC transit maps showing multiple obstructions to RBC transit in series along
the length of individual mother vessels (arrows).
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splits were larger than the identified micro-divisions and up to 200 µm in length. This
entailed the diversion of RBCs into two distinct and smaller daughter vessel segments
that were spread apart from one another, and a downstream reconvergence of the RBCs
into a single MV lumen and flow path (Figure 4.10 a). Remarkably, MVs were also found
to split into daughter vessels of capillary caliber (Figure 4.10 b). Furthermore, multiple
micro-obstructions, micro-divisions, and vessel splits were found positioned in series
along the length of individual MVs (Fig 4.10 c). Collectively, these findings point to a
series of events that is initiated by a micro-obstruction that grows and rapidly doubles
vessel content through splitting.
4.3.7 Micro-Obstructions to RBC Transit are Identified in Mother Vessels with
Ultra-Low Shear
I next determined if the presence of a micro-obstruction or micro-division within
a MV lumen was associated with the size of the vessel. To evaluate this, I quantified the
maximum lumen diameter at the site of local MV expansion that contained these specific
entities. This revealed that, at the site of micro-obstructions and micro-divisions, MVs
had exceptionally large lumen diameters (micro-obstructions: 24.7 ± 1.8 µm, microdivisions: 21.4±2.1 µm, Figure 4.11 a). Interestingly, the maximum lumen diameter of
daughter vessels between sites of MV divergence and reconvergence was found to be
47% narrower than that of MVs at the site of micro-obstructions (P=0.0001, Figure
4.11a) and 39% narrower than that of MVs at the site of micro-divisions (P=0.007, Figure
4.11 a).
In addition, I determined if the presence of a micro-obstruction or micro-division
with a MV lumen was associated with specific RBC transit dynamics. To evaluate this, I
quantified the vessel wall shear rate at the site of local MV expansion that specifically
contained these entities. This revealed that at the site of micro-obstructions, MVs
exhibited ultra-low vessel wall shear rates (46.4 (23.9-120.4) sec-1, Figure 4.11 b).
Interestingly, the vessel wall shear rate in daughter vessels was 3-fold higher than that in
MVs at the site of micro-obstructions (P=0.027, Figure 4.11 b). Furthermore, micro-
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Figure 4.11 Lumen diameter and wall shear rate of mother vessels at the site of
micro-obstructions and micro-divisions
A. Graph depicting the lumen diameter of mother vessels containing microobstructions, mother vessels containing micro-divisions, and daughter vessels on
either side of a mother vessel split. Values were obtained from a total of 47
vessels in 5 EDL muscles on days five or six following surgery (n=17 microobstructions, n=16 micro-divisions, n=14 daughter vessels). *p=0.0001,
**p=0.007.
B. Box and whisker plot (10-90 percentile) of the wall shear rate in mother vessels
containing micro-obstructions, mother vessels containing micro-divisions, and
daughter vessels on either side of a mother vessel split. Values were obtained
from a total of 47 vessels in 5 EDL muscles on days five or six following surgery
(n=17 micro-obstructions, n=16 micro-division, n=14 daughter vessels). *p=0.027
C. RBC flux heat-map showing the identification of a micro-obstruction (arrow)
located in a large mother vessel with low blood flow, the identification of a microdivision in a large mother vessel with low blood flow (arrowhead), and the
absence of a RBC transit micro-obstruction in the smaller mother vessel with
faster flow on the left (asterisk).
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obstructions or micro-divisions to RBC transit were not identified within daughter
vessels.
As shown in the RBC flux heat-map in Figure 4.11c, micro-obstructions and
micro-divisions were identified in large caliber MV sites with low flow. Moreover, no
micro-obstructions or micro-divisions were identified in relatively smaller microvessels
with faster flow. Collectively, these results indicate that micro-obstructions and microdivisions are harbored within sites of MVs that have particularly enlarged lumens and
ultra-low shear forces.
4.3.8 Intraluminal Micro-Obstruction is a Protruding Endothelial Cell
To identify a structural correlate to the RBC transit-free micro-zones, I crosssectioned through EDL muscle five days following surgery. Hematoxylin and eosin
staining of 5-µm thick cross-sections revealed the presence of translumenal obstacles
within dilated, thin-walled channels (Figure 4.12 a,b). This is consistent with intraluminal
tissue “pillars” within the flowing MV.
To determine the cellular structure of intraluminal pillars, I performed serial semithin tissue sectioning. This entailed generating tissue ribbons of up to 1000, 0.5-µm thick
serial sections from a single tissue block of EDL muscle (Figures 4.13, 4.14, 4.15). Next,
I scrutinized MV sections on a section-by-section basis to identify intraluminal tissue
pillars. This revealed ECs protruding into the MV lumen space (Figure 4.13, 4.14, 4.15).
Two types of EC pillars were identified: 1) thin EC cytoplasmic finger-like
protrusions (Figure 4.13 images 7+12, Figure 4.14 image 9) and 2) thicker protrusions
comprised of the EC body and nucleus (Figure 4.13 image 19, Figure 4.15 image 17).
Protrusions could be seen to emanate from opposing sides of the vessel wall (Figure 4.13,
images 17-19). Translumenal connections could extend along the vessel length as little as
2 µm (Figure 4.14 images 9-13). Furthermore, there could be more than one protrusion at
the same cross-sectional site within a MV (Figure 4.13, Figure 4.15 image 19). I also
observed that the nucleus of the pillar-forming EC was typically enlarged and rounded,
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Figure 4.12 Histology of translumenal obstacles within mother vessels
A-B. Hematoxylin and eosin-stained 5-µm cross-sections of EDL muscle showing
translumenal obstacles to RBC transit within MV lumens (arrows).
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Figure 4.13 Serial semi-thin sections of intraluminal EC protrusions (ribbon 1)
Photomicrographs of serial semi-thin (0.5-µm) sections that show two distinct EC
intraluminal protrusions (arrows). Serial images are numbered sequentially. In images 7
and 12, a thin EC cytoplasmic finger-like protrusion is indicated. In image 19, a thicker
protrusion comprised of the EC body and nucleus is indicated (arrow). In image 17, a
protrusion that emanates from both opposing sides of the vessel is indicated (arrows).
RBCs can be seen within the MV lumen.
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Figure 4.14 Serial semi-thin sections of intraluminal EC protrusions (ribbon 2)
Photomicrographs of serial semi-thin (0.5-µm) sections depicting an EC
intraluminal protrusion (arrows). Serial images are numbered sequentially. Images 1-20
show a thin EC cytoplasmic protrusion that spans the lumen of the MV (arrows). Two
sectioned RBCs can also be seen within the lumen.
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Figure 4.15 Serial semi-thin sections of intraluminal EC protrusions (ribbon 3)
Photomicrographs of serial semi-thin (0.5-µm) sections depicting multiple EC
intraluminal protrusions (arrows). Serial images are numbered sequentially. Images 1-20
show a thin EC cytoplasmic protrusion that spans the lumen of the MV. RBCs can be
seen within the lumen. In image 17, a thicker protrusion comprised of an EC body and
nucleus is indicated (arrow). In image 19, two EC protrusions are indicated at the same
site within the MV (arrows). RBCs can be seen within the lumen.
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instead of the flat and elongated nucleus characteristic of ECs aligned to the direction of
blood flow (Levesque et al., 1985) (Figure 4.12 a, Figure 4.14).
4.3.9 Pillar Cells Express CD31, Endomucin, and VE-Cadherin
To confirm and characterize the EC identity of the pillars, I immunostained the
EDL muscle on day five using a panel of distinct EC markers. This revealed that the
intraluminal pillars stained positively for CD31, endomucin, and VE-Cadherin (Figure
4.16 a-c). Interestingly, immunoreactivity for CD31 and VE-Cadherin within the pillar
appeared more intense than the surrounding MV wall endothelium. As well, CD31 and
VE-Cadherin were broadly co-localized (Figure 4.16 c). I did not identify filopodia on
the protrusions by immunostaining for endomucin, which labels the filopodia on
sprouting endothelial tip cells (Gianni-Barrera et al., 2013) (Figure 4.16 b).
4.3.10 Endothelial Cell Intraluminal Protrusions Have Low and Lateralized
VEGFR2 Activation
VEGF-VEGFR2 signaling is fundamental to sprouting angiogenesis. In addition,
endothelial tip cell selection is based on relatively heightened VEGFR2 activation
(Gerhardt et al., 2003). Thus, I sought to probe for VEGFR2 expression and activity in
EC pillars. To do this, I performed immunostaining and generated 3-dimensional
confocal reconstructions. Specifically, I double-immunostained for an EC marker and
phosphorylated

VEGFR2

(pVEGFR2)

at

tyrosine

residues

1054

and

1059.

Autophosphorylation of these tyrosine residues, located in the intracellular tyrosine
kinase activation loop, is necessary for VEGFR2 signaling and maximal kinase activity
(Claesson-Welsh, 2003, Kendall et al., 1999, Simons, 2012, Dougher et al., 1999,
Lanahan et al., 2010). Moreover, phosphorylation of these residues is required for VEGFinduced sprouting angiogenesis (Kawamura et al., 2008).
I first immunostained the neonatal mouse retina on P5 for isolectin-B4 and
pVEGFR2 as a positive control. Generation of 3-dimensional reconstructions of the
developing retina microvasculature revealed a focal enrichment of pVEGFR2 at
endothelial sprouting tips and on cell filopodia (Figure 4.17). In contrast, pVEGFR2 was
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Figure 4.16 Endothelial cell identity of intraluminal protrusions
A-C. Photomicrographs of mother vessels and translumenal endothelial pillars
(arrows) immunostained for CD31 (A,C), endomucin (B), and VE-Cadherin (C), as
indicated by the respective arrows. 5-µm thick immunostained sections were imaged by
brightfield or widefield fluorescence microscopy. Nuclei are visualized with DAPI.
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Figure 4.17 VEGFR2 activation in mouse retina sprouting tip cells
Confocal micrographs of projected optical sections of sprouting endothelial tip
cells within the developing mouse retina on P5 immunolabeled for isolectin-b4 (green)
and pVEGFR2 y1054+1059 (red). Hatched lines denote sprouting tip and arrows point to
focal enrichment of pVEGFR2 at sprout tip. Non-endothelial background pVEGFR2
signal likely is VEGFR2 activity in retinal microglia, astrocytes, and resident
macrophages (Gerhardt et al., 2003)

208

Isolectin-B4
pVEGFR2

10 µm

10 µm

209
reduced at sites distant to the tip.
Double immunostaining for an EC marker and pVEGFR2 in EDL muscle 5-µm
thick cross-sections, as well as 100-µm thick longitudinal sections, revealed no
pVEGFR2 signal in native capillaries. (Figure 4.18 a,c). In contrast, the MV wall
endothelium exhibited widespread and intense immunoreactivity for pVEGFR2. This was
apparent both within EC cytoplasm and at EC-EC junctions (Figure 4.18 a,b,d,e). Some
non-endothelial interstitial cells within the complex EDL microenvironment on day five
were intensely positive for pVEGFR2 immunoreactivity (Figure 4.18 b).
In 3-dimensional confocal reconstructions of the long axis of MVs, ECs
protrusions and pillars appeared as CD31-intense circular structures within the lumen
(Figure 4.18 e, arrowhead). Remarkably, although widespread pVEGFR2 signal was
evident within the MV wall EC population, optical sectioning through the intraluminal
EC protrusions and pillars revealed low pVEGFR2 signal in these structures (Figure 4.19
a-c). Interestingly, intraluminal protrusions and pillars were not entirely devoid of
VEGFR2 activation and highly focal pVEGFR2 signal could be identified (Figure 4.19
a,b, arrowheads). This finding is arguably paradoxical because sprouting angiogenesis
exhibits the reverse pattern - the protruding tip is high in pVEGFR2 signal.
I also determined that 93% of EC protrusions and 83% of translumenal EC pillars
had focal pVEGFR2 signal lateralized to one side of the structure (Figure 4.20 b-e). The
remainder had pVEGFR2 signal localized on both sides of the translumenal structure.
Lateralized VEGFR2 activation may have been induced by ligand-independent VEGFR2
phosphorylation by shear stress, given that there is no matrix-bound VEGF gradient in
the blood. Regardless, these results indicate that intraluminal EC protrusion initiation is
associated with differential VEGFR2 signaling among MV ECs, including reduced and
localized VEGFR2 activation in protrusions and pillars.
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Figure 4.18 Widespread VEGFR2 activation in mother vessel wall endothelium
A-B. Photomicrographs of native and day five injured EDL muscle doubleimmunostained for endomucin (green) and pVEGFR2 1054+1059 (red). Nuclei
are visualized with DAPI. Arrows point to native capillaries with no pVEGFR2
signal (A, left) and mother vessels with widespread intense, immunoreactivity for
pVEGFR2 (A right, B). Asterisk in B indicates EDL interstitial cells positive for
pVEGFR2 immunoreactivity.
C. Confocal micrograph of projected optical sections of a native EDL muscle
capillary immunostained for CD31 (green), pVEGFR2 1054+1059 (red), and TOPRO-3 (blue).
D-E. Confocal micrographs of projected optical sections of mother vessels
immunostained for CD31 (green), pVEGFR2 1054+1059 (red), and TO-PRO-3
(blue). Widespread pVEGFR2 immunoreactivity is shown in the MV wall
endothelium (arrows) and a CD31-intense circular-appearing structure consistent
with an intraluminal protrusion is shown in E (arrowhead).
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Figure 4.19 Reduced and highly localized VEGFR2 activation in EC protrusions
and pillars
A. Confocal orthogonal XZ-axis optical projections of MVs showing CD31-high
pVEGFR2-low intraluminal EC protrusions, relative to surrounding MV wall
endothelium. Arrows indicate intraluminal protrusions, arrowheads indicate
focal pVEGFR2 signal.
B. Confocal orthogonal YZ-axis optical projections of MVs showing CD31-high
pVEGFR2-low intraluminal EC protrusions relative to surrounding MV wall
endothelium. Arrows indicate intraluminal protrusions, arrowheads indicate
focal pVEGFR2 signal.
C. Confocal z-axis optical sections of MVs showing CD31-high pVEGFR2-low
intraluminal EC protrusions relative to surrounding MV wall endothelium.
Arrows indicate intraluminal protrusions.

213

A CD31 pVEGFR2 TOPRO-3

10 µm

XZ

XZ

10 µm

XZ

10 µm

B

C

YZ

10 µm

YZ

10 µm

YZ

10 µm

Z-Slice

10 µm

Z-Slice

10 µm

214

Figure 4.20 Lateralized pVEGFR2 signal on intraluminal protrusions
A. 3-dimensional schematic of a mother vessel containing an intraluminal EC
pillar (blue = nucleus, green = pillar cytoplasm, red = lateralized pVEGFR2)
showing the specific location of confocal z-sections presented in (B).
B. Confocal z-axis optical sections of a mother vessel containing an intraluminal
EC pillar with pVEGFR2 signal lateralized to one side of the translumenal pillar
(arrows).
C. Confocal orthogonal XZ-axis optical projections of the mother vessel
presented in (B) showing the face of the translumenal pillar with lateralized
pVEGFR2 signal (arrow).
D. Confocal z-axis optical section of a mother vessel containing an intraluminal
EC pillar with pVEGFR2 signal lateralized to one side of the “hollow”
translumenal pillar (arrow). Pillar is outlined by hatched line.
E. Pie charts showing the proportion of intraluminal protrusions (n=14), and
translumenal pillars (n=21) exhibiting lateralized pVEGFR2 signal.
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4.3.11 Intussusceptive Angiogenesis Increases Upon Inhibition of VEGFR2
Signaling In Vivo
Because I identified that intraluminal protrusions were associated with reduced
pVEGFR2 signal, I next asked if blockade of VEGFR2 signaling in MVs would impact
IA. To study this, I injected mice intraperitoneally with a VEGFR2-selective tyrosine
kinase chemical inhibitor on day 4.5 following surgery and assessed the microvasculature
by immunostaining and real-time microscopy 16 hours later (5 days after femoral artery
excision). Immunostaining revealed that injection of the VEGFR2-selective tyrosine
kinase inhibitor, Apatinib (60 mg/kg), on day 4.5 resulted in reduced pVEGFR2
immunoreactivity throughout the EDL muscle and neo-vasculature on day 5 (Figure 4.21
a). However, the formation of MVs was not abolished (Figure 4.21 a). Real-time
microscopy of the EDL muscle on day five revealed that Apatinib induced a modest
reduction in EDL surface zone vascularity (P=0.002, Figure 4.21 c), but the resulting
network was similar in vascular and branching density compared to that of mice injected
with vehicle control (Figure 4.21 d,e).
However, analysis of RBC transit maps revealed that Apatinib delivery resulted in
distinctive MV crowding and increased branching complexity of MVs (Figure 4.21 b).
Remarkably, I also identified increased pillar content and increased vessel splitting
density (Figure 4.21 f,g). Apatinib induced a 2.6-fold increase in the network density of
intraluminal pillars (P=0.0003, Figure 4.21 f) and a 2.5-fold increase in the network
density of vessel splits (P<0.0001, Figure 4.21 g), relative to that of mice injected with
vehicle.
To ascertain if the network-level increase in IA was a result of VEGFR2 signaling
blockade versus off-target effects of Apatinib, I repeated the experiment using either a
more potent VEGFR2 tyrosine kinase inhibitor (Cabozantinib) or a more selective
VEGFR2 tyrosine kinase inhibitor (ZM323881 HCl) (Yakes et al., 2011, Whittles et al.,
2002). Analysis of RBC transit maps revealed that short-term delivery of Cabozantinib or
ZM323881 HCl induced a 2.2-fold and 2.7-fold increase in the network density of pillars,
respectively (P=0.018, P=0.005, Figure 4.22 a-c) and 1.7-fold and 2.0-fold increase in
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Figure 4.21 Histology and RBC transit maps of mother vessels following inhibition
of VEGFR2 signaling by Apatinib delivery
A. Photomicrographs of 5-µm thick EDL muscle sections on day five
immunostained for endomucin (green) and pVEGFR2 y1054+1059 (red)
following intraperitoneal injection of Apatinib or vehicle control on day 4.5.
Nuclei are visualized with DAPI.
B. RBC transit maps of the EDL muscle neovasculature on day five following
intraperitoneal injection of Apatinib or vehicle control on day 4.5. Arrows point
to sites of mother vessel intraluminal pillars or splits.
C-E. Graphs depicting total microvasculature length (C), vascular density (D),
and branching density of EDL muscle microvascular networks. (n=5 vehicle
control EDL muscles, n=3 Apatinib EDL muscles) (*p=0.002).
F-G. Graphs depicting the numerical density of pillars (F) and splits (G)
normalized to total microvasculature length. (n=5 vehicle control EDL muscles,
n=3 Apatinib EDL muscles) (*p=0.0003, **p<0.0001).
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Figure 4.22 RBC transit maps of mother vessels following inhibition of VEGFR2
signaling by Cabozantinib, ZM323881 HCl, and DC101 delivery
A-B. RBC transit maps of the EDL muscle neovasculature on day five following
intraperitoneal injection of Cabozantinib (A), ZM323881 HCl (B), or vehicle
control on day 4.5. Arrows point to sites of mother vessel intraluminal pillars or
splits.
C-D. Graphs depicting the numerical density of pillars (C) and splits (D)
normalized to total microvasculature length. (n=3 vehicle control EDL muscles,
n=3 Cabozantinib EDL muscles, n=2 ZM323881 HCl EDL muscles)
(*p=0.0003, **p<0.0001) (†p=0.017).
E. RBC transit maps of the EDL muscle neovasculature on day five following
intraperitoneal injection of DC101 or HRPN antibody control on day 4.5.
Arrows point to sites of mother vessel intraluminal pillars or splits.
F-G. Graphs depicting the numerical density of pillars (C) and splits (D)
normalized to total microvasculature length. (n=2 DC101 EDL muscles, n=2
HRPN EDL muscles) (*p=0.0003, **p<0.0001) (†p=0.017).
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the network density of vessel splits, respectively (P=0.017, Figure 4.22 a,b,d), relative to
that of mice injected with vehicle.
I also blocked VEGF-VEGFR2 signaling by delivering the anti-VEGFR2
antibody DC101 (Fontanella et al., 2014). In contrast to inhibition of VEGFR2 signaling
by tyrosine kinase chemical inhibitors, delivery of DC101 induced only a modest and
non-significant increase in the network density of pillars, relative to that of mice injected
with IgG HRPN antibody control (Figure 4.22 e,f). Moreover, the network density of
vessel splits was not different following DC101 delivery (Figure 4.22 g).
Therefore, blockade of intracellular VEGFR2 signaling with selective tyrosine
kinase chemical inhibitors resulted in increased pillar formation and intussusceptive
angiogenesis.
4.3.12 Downregulation of VEGFR2 Expression Induces Endothelial Cell
Rounding, Decreases Cell Spreading, and Enables EC Protrusive Behaviour in EC
Monolayer In Vitro
The foregoing studies suggested that relatively low VEGFR2 signaling enabled
pillar formation and IA. In this context, it is noteworthy that depletion of VEGFR2 in
culture has been found to inhibit the alignment of HUVECs to the direction of laminar
flow and shear stress (Coon et al., 2015, van der Meer et al., 2010). Thus, I next tested if
differential EC VEGFR2 expression impacted EC morphology within an EC monolayer.
For this, I co-cultured HUVECs with baseline VEGFR2 expression and reduced
VEGFR2 expression, at a 10:1 ratio. The HUVECs were transfected before co-culture
with either control siRNA or VEGFR2 siRNA, and also transduced with RFP or GFP
adenovirus, respectively. VEGFR2 mRNA knockdown in HUVECs was confirmed by
qRT-PCR (Figure 4.23 a). Next, I examined the co-cultured monolayers by laser
scanning confocal microscopy and generated 3-dimensional reconstructions of optical
sections. This revealed that ECs with VEGFR2 knockdown were less spread and had a
smaller planar surface area (Figure 4.23 b,c).
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Figure 4.23 Reduction of cell spreading following targeted VEGFR2 reduction
A. Graph depicting relative mRNA abundance of VEGFR2 in HUVEC cultures
transfected with control (n=3) or VEGFR2 (n=3) siRNA (*p=0.005).
B. Box and whisker plot (10-90 percentile) depicting the surface area of HUVECs
transfected with control (n=174) or VEGFR2 (n=34) siRNA (*p=0.006).
C. Confocal micrographs of projected optical sections of HUVEC monolayers
transfected with control (red) or VEGFR2 (green) siRNA showing reduced cell
spreading and surface area in HUVECS with reduced VEGFR2 expression.
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Figure 4.24 Cell rounding following targeted VEGFR2 reduction
A. Box and whisker plot (10-90 percentile) depicting the maximum cell body
thickness of HUVECS transfected with control siRNA (n=149) or VEGFR2
siRNA (n=36) (*p<0.0001). Control ECs were transduced with RFP and
VEGFR2-knockdown ECS with GFP.
B. Orthogonal confocal projections of HUVEC monolayers transfected with
control siRNA (red) or VEGFR2 siRNA (green) showing cell bulging and
increased thickness of HUVECS with reduced VEGFR2 expression (arrows).
C. Orthogonal confocal projections of HUVEC monolayers, with reversed
fluorophore adenoviral transduction, and transfected with control siRNA (green)
or VEGFR2 siRNA (red) showing cell bulging and increased thickness of
HUVECS with reduced VEGFR2 expression (arrows).
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To search for protrusive EC behaviour, I evaluated orthogonal optical sections of
the monolayers. This revealed that VEGFR2 knockdown induced cell rounding and
thickening in the z-axis (Figure 4.24 a,b). The VEGFR2-knockdown HUVECs were often
positioned at a different vertical plane relative to the surrounding monolayer. To confirm
that the increased thickening was not imaging artifact introduced by GFP, I reversed the
adenovirus fluorescent labeling. This revealed that RFP-labeled VEGFR2 knockdown
HUVECs were also rounder and thicker in the z-axis. (Figure 4.24 c). To further assess
for protrusive capacity in VEGFR2-low ECs, I treated the monolayer with sphingosine-1phosphate (S1P) (1 µM, 3 minutes). This exacerbated the morphologic heterogeneity of
co-cultured HUVECs, and induced striking EC protrusions (Figure 4.25 a). Lamellipodial
protrusions in VEGFR2-low ECs formed and were seen to spread on the surface of
adjacent ECs. This contrasted with the normal contact-inhibited behaviour of VEGFR2normal ECs in a monolayer (Figure 4.25 a). As well, the S1P-stimulated VEGFR2knockdown cells were small (P=0.0006, Figure 4.25 a,c), rounded (P=0.007, Figure 4.25
b,d), and bulged in the vertical direction. Thus, the overall appearance of VEGFR2-low
ECs was that of “rogue” cells that are capable of protruding out of the EC collective.

4.4 Discussion
Using high-resolution real-time imaging of RBCs in transit, I have identified
architectural and cellular events by which a new microvascular network forms following
ischemic injury in skeletal muscle. These events are: 1) the abrupt emergence of
metastable primordial microvessels that are subjected to ultra-low blood flow and shear
forces, and 2) the rapid transformation of these MVs into an extensive and hierarchical
microvasculature. This later event proceeds by pillar formation and vessel spitting and is
enabled by heterogeneous activation of VEGFR2.
Intussusceptive Angiogenesis in Ischemic Skeletal Muscle
Studies have attributed the neovascularization response in ischemic skeletal
muscle to sprouting angiogenesis (Hershey et al., 2001, Madeddu, 2005, Limbourg et al.,
2009, Al Haj Zen et al., 2010). Sprouting endothelial tip cells are known to generate a
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Figure 4.25 Non-contact inhibited cellular protrusions in VEGFR2-low ECs induced
by S1P
A-B. Confocal micrographs of projected (A) and orthogonal (B) optical sections
of HUVEC monolayers transfected with control siRNA (red) or VEGFR2
siRNA (green) and treated with 1 µM S1P for 3 minutes showing bizarre cellular
protrusions (A, arrows) and exaggerated cell thickening (B, arrow).
C. Graph depicting the surface area of HUVECs transfected with control (n=93)
or VEGFR2 (n=17) siRNA and treated with 1 µM S1P for 3 minutes
(*p=0.0006).
D. Graph depicting the maximum cell body thickness of HUVECs transfected
with control (n=65) or VEGFR2 (n=15) siRNA and treated with 1 µM S1P for 3
minutes (*p=0.007).
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web-like meshwork of microvessels and capillaries (Gerhardt et al., 2003). However, the
parallel and long-running (200-500 µm in length) capillaries in skeletal muscle bear little
similarity to this patten. Interestingly, the EDL microvasculature regenerated over 48
hours, whereas it takes eight to ten days to generate a complete microvasculature in the
mouse retina via sprouting (Gerhardt et al., 2003). I have demonstrated that the neomicrocirculation in skeletal muscle is reconstructed following ischemic injury via the
formation of translumenal pillars - the hallmark of IA, not sprouting angiogenesis.
Intussusceptive, or splitting, angiogenesis is less understood than sprouting
angiogenesis. Only recently is IA becoming recognized as a more general mechanism of
blood vessel growth during development and postnatal growth (De Spiegelaere et al.,
2012). This is the first study to have identified IA during neovascularization in ischemic
and regenerating skeletal muscle. My findings do not exclude concurrent sprouting
angiogenesis although, at least in muscle zones where the native microvasculature is
obliterated, IA appears dominant. Immunostaining for CD31 and endomucin, the latter of
which homogeneously stains ECs including the filopodia on sprouting tip cells (GianniBarrera et al., 2013), did not reveal endothelial tip cells emanating from the MV wall.
Moreover, semi-thin sectioning showed no evidence for the degradation of MV basement
membrane, which is a requirement for sprouting angiogenesis (Carmeliet et al., 2011). As
well, filopodia were not identified on the “inward” EC protrusions. Together with realtime microscopy data, these results indicate that the transformation of MVs into an
extensive microvasculature occurred by splitting angiogenesis and not by sprouting.
The Mother Vessel
My discovery of primordial and slow-flowing channels within the obliterated
skeletal muscle was surprising. I termed these dilated channels MVs as they are
reminiscent of the transient, very enlarged, and thin-walled “mother vessels” found as the
first new vessels that form in tumors (Chang et al., 2009). A potentially similar structure
has been noted in skin and muscle in pre-existing microvessels that dilate in response to
substantial local VEGF delivery (Pettersson et al., 2000). However, in the regenerating
EDL muscle MVs were de-novo vascular structures, as we have shown that the pre-
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existing microvasculature is lost following femoral artery excision (Arpino et al., 2017).
Thus, MVs in infarcted and regenerating skeletal muscle are previously undescribed
vascular structures that generate daughter vessels by IA.
The rapidity with which the MV transformed into an extensive microvasculature
was remarkable. This entailed the formation of translumenal EC pillars and subsequent
division of MVs into smaller conduits. This process doubled the local vascular density
and generated bifurcations. This organ-wide reconstruction of a neo-microvasculature
over 48 hours reveals the efficiency of pillar formation and IA for regenerative
angiogenesis. The result was to the prompt restoration of vascular and branching density
in the EDL seven days following its obliteration.
Mother Vessel Blood Flow and Pillar Formation
The wide caliber of MVs and slow RBC transit suggest profoundly nonphysiological perfusion. Furthermore, real-time microscopy revealed that EC pillars were
located in MVs with particularly large diameters and particularly low blood flow.
Interestingly in the chick chorioallantoic membrane (CAM), pillars have also been found
to form in vessels with widened lumens or circumference irregularities (Lee et al., 2010).
These findings raise the possibility that perturbed shear forces may be related to pillar
formation. My findings support this. Quantitative analysis established that MVs had
ultra-low vessel wall shear rates. The average wall shear rate in MVs was only 4%
compared to that of small arterioles (21 µm diameter) in the rat gluteus maximus muscle
(Al-Khazraji et al., 2016) and 5% of that of arterioles in rat cremaster muscle (Koller et
al., 1991). In fact, MV wall shear rates were lower than that of a healthy venous
circulation, where the lowest shear rates in the microcirculation are normally found. For
example, shear rates have been reported to be ~400 sec-1 in cat mesentery venules (25 µm
diameter) (Lipowsky et al., 1978) and ~600 sec-1 in rat mesentery venules (Pearson et al.,
2000). I also observed RBC aggregations (rouleaux), a phenomenon seen under
conditions of low blood flow shear (Shiga et al., 1983).
I propose that the low MV wall shear rate was permissive for pillar development.
This is consistent with computational simulations of the CAM vasculature (Lee et al.,
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2010) and calculation of low shear rates (100 sec-1) in tumor vessels undergoing IA
(Kamoun et al., 2010). Moreover, my finding pillars in series is supported by a
computational model which predicted that new pillars would form downstream of preexisting pillars, at sites of low shear stress (Lee et al., 2010). This suggests that shear rate
gradients guide the insertion and growth of pillars. The process of MV splitting may also
serve to increase and normalize vessel wall shear rate.
Paradoxically, the low blood flow and low shear forces that I found during IA
contrasts with what others have observed associated with IA in healthy skeletal muscle.
Zhou et al. and Milkiewicz et al. demonstrated that delivering prazosin to rats increased
the shear forces within native EDL muscle capillaries and that this intraluminal stimulus
induced IA (Zhou et al., 1998a, Milkiewicz et al., 2001, Egginton et al., 2001).
Reconciling high shear- versus low shear-induced IA warrants further study.
Molecular Regulation of Intussusceptive Angiogenesis: VEGFR2 Signaling
Using an antibody targeting phosphorylated VEGFR2 intracellular tyrosine
residues 1054 and 1059, residues critical for the maximal kinase activity of VEGFR2
(Dougher et al., 1999), I identified low and highly localized VEGFR2 activation in the
EC comprising an intraluminal protrusion or pillar. In contrast, there was extensive
VEGFR2 activation in the ECs comprising the rest of the lining of the MV wall. This
finding is opposite that found during sprouting angiogenesis. For sprouting angiogenesis,
the VEGF-VEGFR2 signaling axis is the master controller of tip cell formation and
guidance (Olsson et al., 2006, Gerhardt et al., 2003). ECs with the greatest activation of
VEGFR2 become a sprouting tip cell (Gerhardt et al., 2003, Jakobsson et al., 2010).
Therefore although from a structural standpoint, IA appears as an “outside-in” form of
sprouting angiogenesis, the signaling events appear to be regulated quite differently.
Both VEGF (Dougher and Terman, 1999, Simons, 2012, Harper and Bates, 2008,
Dellinger and Brekken, 2011) and blood flow shear forces (Jin et al., 2003, Tzima et al.,
2005, Chen et al., 1999) can induce the phosphorylation of VEGFR2 1054 and 1059. My
finding of lateralized pVEGFR2 signal on one side of translumenal EC pillars raises the
possibility of flow-related, ligand-independent activation of the receptor. ECs detect
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blood flow shear forces via an EC-specific mechanosensory complex. This
mechanosensory complex is comprised of CD31, VE-Cadherin, and VEGFR2 (Tzima et
al., 2005). This complex is required for the alignment of ECs in the direction of blood
flow and entails phosphorylation of VEGFR2 at tyrosine residue 1054 (Tzima et al.,
2005). Although I do not know whether the activated VEGFR2 was on the upstream or
downstream side of the pillar, it is reasonable to expect the former. In fact, this is
supported by computational simulations (Filipovic et al., 2009). I also cannot rule out the
possibility that circulating VEGF is binding to and phosphorylating VEGFR2 on the
pillar.
I did not study the signaling pathways downstream of VEGFR2 activation that
may be implicated in pillar formation. It is likely that EC cytoskeletal rearrangements and
migratory behaviour are required to generate an intraluminal protrusion. In this regard,
phosphorylation of VEGFR2 intracellular tyrosine residues 951, 1175, and 1214 are
implicated in EC cytoskeletal and shape control and warrant further study in IA (Coon et
al., 2015, Koch et al., 2011, Holmqvist et al., 2004, Olsson et al., 2006, Sun et al., 2012).
Augmentation of IA During Regenerative Angiogenesis by Inhibiting VEGFR2 Activity
Acute blockade of intracellular VEGFR2 signaling using three different selective
tyrosine kinase chemical inhibitors, remarkably, increased network-level pillar formation
and IA. This suggests that low VEGFR2 signaling, in itself, is a driver of pillar formation
and IA. The in vivo blocking findings are consistent with a study of gene expression in
the developing porcine glomerulus, which demonstrated that VEGFR2 is downregulated
during late glomerular development where IA predominates over sprouting angiogenesis
(De Spiegelaere et al., 2010). Moreover, another study demonstrated that during
glomerular repair following injury, IA was not halted following delivery of the VEGFR2
and PDGFRβ tyrosine kinase inhibitor PTK787/ZK222584 (Wnuk et al., 2011).
Interestingly, blocking VEGF-induced VEGFR2 dimerization and activation via
acute delivery of DC101 did not significantly impact the formation of pillars and IA. In
contrast to the chemical inhibitors, DC101 binds the extracellular domain of VEGFR2
(Fontanella et al., 2014). Whether this extracellular-targeted VEGFR2 blockade strategy
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could also block ligand-independent activation of VEGFR2 is not completely understood.
However, assuming it does not, my results support the importance of ligand-independent
activation of VEGFR2 in MVs and the heterogeneity of this response in pillar formation
and IA.
I did not observe a substantial reduction in the overall vascularity of the
regenerated EDL muscle surface zone following VEGFR2 blockade. This may be
explained by the fact that I delivered only a single dose of VEGFR2 inhibitor and
evaluated the network ~16 hours later. This is in contrast to the reduction of vascularity
observed in tumors following delivery of VEGFR2 inhibitors over several weeks
(Ackermann et al., 2012, Tong et al., 2004, Goel et al., 2011, Chung et al., 2010).
Protrusive Behaviour of VEGFR2-Low Endothelial Cells
ECs normally elongate in response to physiological shear stress, with their long
axis oriented in the direction of flow (Dewey et al., 1981, Krueger et al., 1971).
Importantly, VEGFR2 knockdown has been shown to decrease the alignment of ECs in
the direction of laminar shear stress (Coon et al., 2015, van der Meer et al., 2010). I
propose that those pVEGFR2-low ECs in MVs are relatively insensitive to shear stressinduced EC alignment, priming these particular ECs to protrude into the MV lumen. This
was supported by my in vitro model of VEGFR2 knockdown. This demonstrated that
HUVECs with reduced VEGFR2 expression were less spread and thicker relative to their
control cell neighbours. VEGFR2 knockdown also induced the overlapping of cell bodies
and the sending of cytoplasmic projections over or under neighbouring control cells.
Accordingly, I speculate that reduction of VEGFR2 signaling activity induced amoeboid,
non-contact inhibitable protrusive behaviour in ECs.
These “amoeboid-like” phenomena were exaggerated when the VEGFR2
knockdown HUVEC actin cytoskeleton was acutely triggered to reorganize by delivery
of S1P. S1P is a soluble sphingolipid that normally stimulates EC spreading and
migration and stabilizes the cortical actin network (Vouret-Craviari et al., 2002,
Yamaoka-Tojo et al., 2004). S1P is also a negative regulator of sprouting angiogenesis
and inhibits VEGF-VEGFR2 signaling (Gaengel et al., 2012). Interestingly, epithelial cell
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extrusion in response to overcrowding requires the S1P receptor 2 pathway (Gu et al.,
2011). Together, these findings further suggest that pillar-forming ECs are a phenotypic
subset of ECs in the MV that are relatively undifferentiated and prone to extrusion.
Finally, I propose that pillar-forming ECs in the regenerating skeletal muscle
exhibit “flow-seeking” behaviour. Positioning a cellular protrusion or pillar into the
flowing lumen might be a strategy for an EC to increase the shear forces that it
encounters, by making more contact with flowing RBCs. This flow-seeking cellular
strategy might be particularly important if the EC had an underdeveloped VEGFR2
activation machinery. Moreover, this might serve to help differentiate the pillar-forming
EC into a more mature microvascular EC phenotype.
In summary, early-stage vascular regeneration following skeletal muscle
infarction entails the emergence of metastable, primordial microvessels with ultra-low
blood flow. These primordial microvessels subsequently transform into a neomicrovascular network via inward EC protrusion and IA. This non-sprouting
angiogenesis cascade was determined by differential VEGFR2 activation in ECs.
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CHAPTER 5
General Discussion and Conclusions
The findings presented in this thesis provide several new insights into the
microvasculature that forms upon angiogenesis in adult ischemic tissues. As a
methodological centerpiece, I developed an intravital microscopy-based strategy for
interrogating the architecture, hierarchy, perfusion attributes, and vasoreactivity of the
newly formed microcirculation in adult mouse tissues. I then used this strategy to uncover
five new phenomena. First, I identified multiple microcirculatory defects within
malignant renal tumors. Second, I discovered that FGF9 can productively reconfigure and
“normalize” the architecture and otherwise abnormal hierarchy of the tumor
microvasculature and also impart vasoreactivity. Third, I discovered a range of defects in
the regenerated microvasculature that forms in skeletal muscle following ischemic injury.
These architectural and functional abnormalities established that the microcirculation was
ill-suited for effective O2 delivery. Fourth, I uncovered a non-sprouting form of
angiogenesis by which the early microvascular network forms following skeletal muscle
infarction. This entailed inward endothelial cell protrusion and intussusceptive
angiogenesis. Finally, I discovered that intussusceptive angiogenesis in regenerating
skeletal muscle was based on differential VEGFR2 activation.
5.1 Development of a Novel Strategy for Interrogating Microvascular Architecture
and Perfusion in Tissues
The approach I developed for interrogating newly formed microvessels entailed
real-time epifluorescence intravital microscopy. I was thus able to image RBCs in transit
and ascertain flow-based assessments of the microcirculation. This included quantifying
RBC velocity and flux in individual microvessels and interrogating microvascular
vasoreactivity. The latter was enabled by developing chamber devices that were
integrated into the microscope stage for locally delivering vasoactive agents, or
perturbing local O2 content in the tissues while simultaneously tracking RBC motion.
Together, these methodological developments advanced the field by enabling an
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assessment of the regenerated microvasculature by integrating network microstructure
with real-time tracking of RBC transit.
5.2 Novel Insights into the Structure, Function, and “Normalization” of Renal
Tumor Microcirculation
Tumors recruit a vascular network to sustain their growth. The resulting vessels
are generally understood to be tortuous with abnormally large diameters (Nagy et al.,
2009, Fukumura et al., 2010). My findings add several new insights into the renal tumor
vascular biology. RBC transit analysis revealed not only densely packed and tortuous
microvessels, but abnormalities in network hierarchy and vasoreactivity. I found that
network hierarchy was essentially missing and that flow appeared venous-like
throughout. I also found that vasoreactivity was minimal. These abnormalities constitute
important reasons for impaired O2 delivery in the tumor.
I also discovered that delivery of FGF9 productively normalizes the renal tumor
microcirculation. This intervention generated hierarchical arteriole-capillary-venule
microcirculatory units and feeder vessels with vasomotor competence. Together, these
normalized RBC transit and improved blood flow within the renal tumor. The attainment
of a physiologically advanced microvasculature with the ability to dynamically regulate
blood flow is, to my knowledge, new in the field of tumor biology.
These findings have implications for tumor therapy. The perfusion anomalies
arising from an absence of network hierarchy and vasomotor control would impair the
delivery of chemotherapeutic drugs. Likewise, the associated hypoxia is likely to blunt
the response to radiation therapy (Jain, 2005, De Bock et al., 2011). In this regard, FGF9mediated normalization of the tumor microvascular network architecture and function has
the potential to enhance the delivery of chemotherapeutics and improve the effectiveness
of radiation therapy.
5.3 Future Directions in Tumor Angiogenesis and Vascular Normalization Studies
Whether the FGF9-exposed tumor can regulate blood flow in response to local O2
content remains unknown. I found that FGF-exposed tumors had functional α-adrenergic
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and nitric oxide signaling. Establishing whether the feeder vessels can also regulate flow
in response to a local hypoxia “challenge” would clarify the idea that FGF9 delivery can
normalize microvascular responsiveness, with implications for increasing tumor
sensitivity to radiation therapy (De Bock et al., 2011, Goel et al., 2011).
I studied the FGF9-exposed renal tumor 10 days following implantation of Renca
cells. However, a daily microscopy-based investigation via an abdominal window
chamber could reveal powerful insights into the processes of tumor angiogenesis and
FGF9-induced normalization (Ritsma et al., 2013). A window chamber strategy might,
for example, elucidate the relative contributions of sprouting versus intussusceptive
angiogenesis in the generation of the renal tumor microvasculature (Patan et al., 1996,
Nico et al., 2010).
The current paradigm of tumor vessel normalization is to balance the chronic proangiogenesis drive in tumors with anti-angiogenesis and vascular destroying drugs (Goel
et al., 2011). Importantly, I showed that delivery of a growth factor (FGF9) normalizes
the vasculature and blood flow in tumors and also avoids vascular destruction. These
findings could be translatable to a clinical setting. First, however, whether normalization
of network hierarchy and restoration of vasoreactivity augments delivery of
chemotherapeutic drugs should be directly tested in vivo. One could test if the
“normalized” network effectively distributes chemotherapeutics throughout a large tumor
volume and leads to tumor shrinkage. A similar pre-clinical study of radiation could also
be employed.
5.4 The Regenerated Skeletal Muscle Microvasculature is Profoundly Flawed and
Ill-Suited for Oxygen Delivery
I determined the physiological attributes of the regenerated microcirculation that
forms in the mouse hindlimb EDL muscle following femoral artery excision. I discovered
that, despite extensive regeneration of the previously obliterated microvasculature, the
neo-microvasculature was highly flawed. I found abnormalities in network-level
architecture, supernumerary branching, violations of arteriole-capillary-venule geometry
and hierarchy, slow and monotonous RBC transit, a blunted hyperemic response to
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hypoxia, and aberrant smooth muscle cell wrapping architecture. Moreover, these flawed
attributes were largely permanent. Associated with this, hypoxia persisted in the
regenerated skeletal muscle (Figure 5.1). These newly identified pathologies would be
effectively hidden using current strategies for assessing microvascular perfusion
(Limbourg et al., 2009, Simons et al., 2015, Arpino et al., 2017).
Notably, this is the first study to assess regenerative angiogenesis in ischemic
skeletal muscle at the microcirculatory network level and at the individual capillary level
where gas and nutrient exchange occurs. The remarkable discordance between the
microvascular restoration process and the functionality of the O2 delivery system
indicates that capillary density and bulk flow are inadequate indicators of functional
angiogenesis. Accordingly, I propose that strategies beyond stimulating angiogenesis in
ischemic muscle are required, including normalizing microcirculatory physiology.
5.5 Future Directions in Regenerative Angiogenesis Studies
Following femoral artery excision in the C57Bl/6 mouse strain, the entire EDL
muscle was destroyed and all subsequently identified microvessels were new vascular
structures. However, this raises the consideration as to how does the nature of the injury
determine the functional outcome of the angiogenic stimulus? Little is known about the
angiogenesis process in muscle following minor ischemia, i.e. without extensive tissue
infarction. Likewise, the response to traumatic injury or chemical damage is not well
understood. Importantly, the limb damage can be more restricted and focal in these latter
settings and upstream blood flow is not halted. Thus, the resulting networks might be
comprised of a mix of pre-existing and new microvessels. It is also not known if the
natural angiogenesis program in response to exercise produces a healthier and more
functional network compared to a regenerated network in muscle (Egginton et al., 2001,
Olfert et al., 2010). These questions could be addressed using the high-resolution
strategies employed in this thesis.
In the big picture, my studies have identified targets within the microvascular
regeneration program that must be improved or “normalized” in order to advance
therapeutic strategies for treating ischemic disease in patients. Some of the identified
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Figure 5.1 The regenerated microcirculation in ischemic skeletal muscle Is flawed
and ineffective at delivering oxygen
Schematic of the network and cellular architecture of the proximal (feeder) end of
microcirculatory units in normal skeletal muscle microcirculation (top) and regenerated
skeletal muscle microcirculation (bottom). In the healthy skeletal muscle microcirculation
(top), arteries and arterioles are tightly invested with circumferentially wrapped SMCs
and SMC processes. In the regenerated skeletal muscle microcirculation (bottom), there
are substantial gaps in coverage between individual SMCs and SMC processes (arrows).
As well, some SMC processes are not oriented perpendicularly to the axis of the
underlying endothelial channel (arrowhead). These wrapping abnormalities, together with
downstream arterio-venous shunts and hyper-dense capillary beds, impair appropriate
delivery of O2 and produce a hypoxic tissue environment.
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defects, such as the aberrant SMC wrapping, represent a component of the faulty neomicrovasculature that could be modulatable. Co-delivery of the growth factor FGF9 with
pro-angiogenesis growth factors has the potential to improve and reinforce the wrapping
of neo-terminal arterioles with SMCs (Frontini et al., 2011, Yin et al., 2015, Said et al.,
2013). This would be expected to impart the reconstructed microvasculature with
improved vasomotor control and better delivery of RBCs and O2 in response to demand.
The development of drug or growth factor delivery platforms for individuals with
peripheral vascular disease thus remains a potentially important therapeutic context for
this study.
Furthermore, the development of minimally invasive and high-resolution imaging
strategies to be used in patient tissues could substantially enhance the understanding of
angiogenesis and microcirculatory pathophysiology in the clinical setting. As such
technology is developed, my findings could serve as an important framework for
identifying microvascular health versus pathology.
5.6. Discovery of a Non-Sprouting Form of Angiogenesis Following Skeletal Muscle
Infarction
I discovered that early-stage vascular regeneration following skeletal muscle
infarction entails the emergence of primordial, large-caliber vessels that subsequently
transform into a neo-microvascular network. This transformation proceeds via
intraluminal EC protrusion and IA. This is the first study to have identified the process of
IA during neovascularization in ischemic skeletal muscle. Sprouting angiogenesis was
not identified during this early-stage process even though the neovascularization response
in ischemic skeletal muscle has been attributed to sprouting angiogenesis (Hershey et al.,
2001, Madeddu, 2005, Limbourg et al., 2009, Al Haj Zen et al., 2010). Moreover, current
therapeutic angiogenesis strategies for ischemic muscle target pathways controlling
sprouting angiogenesis (Annex, 2013, Said et al., 2013). However, therapeutically driven
neovascularization in the ischemic skeletal muscle has been ineffective at improving
perfusion (Annex, 2013, Simons et al., 2003). My findings provide novel information in
this regard and prompt the reconsideration of current angiogenesis paradigms and
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associated therapeutic strategies for ischemic disease.
I discovered that IA generated a neo-microvascular network at an incredibly rapid
pace following skeletal muscle infarction. As well, I found that IA generated
neocapillaries in a parallel arrangement - a hallmark of healthy skeletal muscle
microvascular architecture. In addition to these favorable characteristics, IA has several
critical advantages over sprouting angiogenesis. These include that 1) IA does not require
the breakdown of basement membrane, 2) new vessels formed by IA are inherently
perfused and thus are not required to lumenize, and 3) IA is an energy-efficient and nonproliferative process (Burri et al., 2002, Styp-Rekowska et al., 2011, Mentzer et al.,
2014). Collectively, these findings suggest that optimizing IA should be exploited as a
more effective and non-disruptive alternative to sprouting for rapidly re-establishing a
functioning microvasculature in infarcted muscle.
5.7 Intussusceptive Angiogenesis In Ischemic Skeletal Muscle Is Based On
Differential VEGFR2 Activation
The molecular divers and pathways regulating IA and pillar cell selection are
poorly understood. My studies identified that VEGFR2 signaling is a regulator of the IA
process during regenerative angiogenesis following skeletal muscle infarction. I
identified that pillar cell selection is based on low VEGFR2 activation relative to the
surrounding ECs comprising the MV wall. These findings were supported by my
observation that blockade of VEGFR2 signaling in vivo increased the formation of pillars
and IA in the early-stage microvasculature. In contrast, during sprouting angiogenesis, tip
cell selection requires VEGF-VEGFR2 signaling wherein the EC with the highest level of
VEGFR2 activation is chosen to lead the sprout (Gerhardt et al., 2003, Hellstrom et al.,
2007). These findings suggest that EC intraluminal protrusion is effectively “inverse”
sprouting, both structurally and with respect to the VEGF signaling axis (Figure 5.2).
I also uncovered a permissive role for ultra-low blood flow and shear forces in the
formation of intraluminal pillars. This is consistent with the prediction that pillars form in
local minimums of shear stress within the CAM vasculature (Lee et al., 2010). As well,
my in vitro and in vivo findings indicate that ECs with low VEGFR2 activation are
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Figure 5.2 Proposed model of EC inward protrusion and differential VEGFR2
activation
Top: Schematic of the cellular architecture of the mother vessel wall. Pillarforming ECs exhibit reduced and highly focalized activation of VEGFR2
(pVEGFR2) relative to the ECs that comprise the mother vessel wall. I propose
that focalized activation of VEGFR2 is present on the flow-facing side of the
intraluminal protrusion or pillar. Pillar-forming ECs paradoxically sprout inwards.
Bottom: Summary and image depicting the two phenotypes of ECs found within
MVs. Show in the image are two pillar-forming ECs (Type 1) on the left, and two
mother vessel wall ECs (Type 2) on the right.
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unaligned to the direction of flow and I propose that they exhibit “shear-seeking”
behaviour by protruding into the lumen (Figure 5.2). The goal of this would likely be to
increase ligand-independent activation of VEGFR2 by blood flow shear forces. These
findings arguably provide a new paradigm for the delicate interplay between the
molecular and mechanical regulators of neovascularization.
5.8 Synthesis of Regenerative Angiogenesis (Chapter 3) and IA (Chapter 4)
Studies
Although I discovered that IA is an effective means to rapidly generate a
functioning microvasculature in ischemic skeletal muscle, I also identified that the
structure of the end-stage regenerated microcirculation is highly flawed. This raises the
consideration as to whether these phenomena are functionally related. IA is a high
precision-process and very well proceeds imperfectly during regenerative angiogenesis in
ischemic skeletal muscle. For example, primordial vessels with relatively higher shear
and VEGFR2 activation in the early phases may not adequately split into a capillary
mesh. If this is the case they could instead develop into AV shunts (Figure 5.3). On the
other hand, other primordial vessels might split excessively and form too many
capillaries. This would be consistent with the increased capillary density and branching
density in the end-stage regenerated microvasculature and could be a basis for mismatch
between RBC delivery and demand (Figure 5.3). Therefore, further work is warranted to
understand what is required for successful regenerative angiogenesis via IA.
5.9 Future Directions in the Investigation of Intussusceptive Angiogenesis
My studies revealed a role for low VEGFR2 activation in the selection of pillar
forming ECs. However, compared to the plethora of sprouting tip cell markers, the pillarforming EC cell is not well characterized and there are no reliable immunohistochemical
markers for pillars (Konerding et al., 2010). This warrants further study into the
expression profile and surface markers of pillar cells that distinguish them from ECs that
line the primordial vessel wall.
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Figure 5.3 Steps of microvascular regeneration following skeletal muscle injury
Schematic of a healthy skeletal muscle microcirculation (top left), the loss of
microvessels following femoral artery excision and muscle infarction (top right), the
emergence of primordial mother vessels containing intraluminal pillars and splits (bottom
left), and the end-stage and flawed regenerated microcirculation (bottom right).
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The origin of pillar-forming cells could also be explored. Transplantation of bone
marrow-derived GFP-expressing cells following ischemic injury could reveal whether
pillar-forming cells are circulating cells or locally-derived cells within the ischemic
muscle. In addition, a “rainbow” fluorescent reporter mouse strategy could be used to
assess for EC heterogeneity within primordial vessels, and for investigating whether
pillar-forming ECs and MV wall ECs are distinct.
It is not understood how intraluminal pillars grow and extend down the long axis
of a vessel. In this regard, an in vivo time-lapse microscopy strategy could be used to test
if GFP-expressing circulating cells hone to the pillar and play a structural role in pillar
expansion. Moreover, using an in vivo time-lapse microscopy strategy could reveal novel
architectural cascades associated with the splitting process and potential fusion of
neighbouring pillars.
EC mechanosensory pathways other than the CD31/VE-Cadherin/VEGFR2
mechanosensory complex may play a role in pillar initiation during low shear conditions.
Possibilities include VEGFR3, primary cilia, caveolae, ion channels, adhesion molecules,
glycocalyx, and the cytoskeleton (Coon et al., 2015, Ando et al, 2015). Establishment of
an in vitro model of EC monolayers exposed to low shear forces could potentially reveal
new insights into how ECs sense that they are in a low-shear environment, and how this
leads to the generation of non-contact inhibitable protrusions.
Finally, my studies raise the consideration as to whether the IA process occurs in
ischemic human tissues. Histological studies of patient samples, for example after
amputation for peripheral vascular disease, could be performed to screen for intraluminal
protrusions and pillars in microvessels.
5.10 Summary
Angiogenesis is critical for restoring perfusion to tissues that are attempting to
regenerate following ischemic injury. For a neo-microvascular network to function
properly it must be exquisitely organized, hierarchical, and have the ability to
dynamically regulate O2 delivery in order to match local metabolic requirements. As
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described in this thesis, the networks that form during angiogenesis in ischemic adult
tissues do not fully acquire these critical attributes. This is the case in renal tumors and in
skeletal muscle following ischemic injury. Furthermore, the processes by which a neomicrovascular network regenerates in ischemic skeletal muscle occurs by the emergence
of primordial vascular structures and subsequent non-sprouting intussusceptive
angiogenesis and differential VEGFR2 activation. Collectively, the findings in this thesis
provide novel insights into an understanding of adult angiogenesis at both a network and
functional level. These novel findings prompt the reconsideration of angiogenesis
paradigms and therapeutic strategies for treating ischemic disease, with the goal of
generating highly functional microcirculations that reverse hypoxia.
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Appendix B: Ethics Approval for Animal Use

AUP Number: 2010-244
PI Name: Pickering, Geoffrey
AUP Title: Smooth Muscle Cells and Vascular Disease
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-244 has been approved.
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS
office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this
protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional
safety standards and have received all necessary approvals. Please consult directly with your
institutional safety officers.
Submitted by: Thompson, Sharla H
on behalf of the Animal Use Subcommittee
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Appendix C: Legends For Chapter 3 Video Files
Online Video 3.1: RBC transit in the native EDL muscle microvasculature visualized by
blue light epi-illumination real-time video microscopy. RBCs are seen in relief against
the bright plasma that has been labeled with high molecular-weight FITC-labeled
dextran.
Online Video 3.2: Real-time video microscopy sequence showing no RBC transit in the
EDL muscle one day following femoral artery excision.
Online Video 3.3: Real-time video microscopy sequence showing RBC transit signal in
the early (10 day) regenerated EDL muscle microvasculature.
Online Video 3.4: Real-time video microscopy sequence showing RBC transit in the
regenerated EDL muscle microvasculature 28 days after femoral artery excision.
Online Video 3.5: Real-time video microscopy sequence showing RBC transit in the
regenerated EDL muscle microvasculature 56 days after femoral artery excision.
Online Video 3.6: Real-time video microscopy sequence showing RBC transit in the
regenerated EDL muscle microvasculature 120 days after femoral artery excision.
Online Video 3.7: Real-time video microscopy sequence showing a neo-arteriole (top of
field) in the late-stage regenerated EDL muscle microvasculature that bifurcates into
daughter vessels with strikingly unequal lumen diameters.
Online Video 3.8: Real-time microscopy sequence of the microvasculature 28 days after
femoral artery excision showing halted RBC transit.
Online Video 3.9: Real-time video microscopy sequence showing RBC transit
(demarcated

by

FITC-labeled

dextran)

through

an

arteriole-capillary-venule

microcirculatory unit in the native EDL muscle. A normal microvascular hierarchy is
evident with divergence of an arteriole into discrete capillary meshes that drain into
venules.
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Online Video 3.10: Real-time video microscopy sequence showing RBC transit through
an aberrant microcirculatory unit in the regenerated (28 day) EDL muscle
microvasculature. An arteriolar-venular malformation (AV-connection) with high RBC
flux can be seen to directly connect the neo-arteriole to a venule, bypassing a capillary
mesh.
Online Video 3.11: Real-time video microscopy sequence showing RBC transit through
an AV-connection in the 28-day regenerated EDL muscle microvasculature, visualized
by ultraviolet light epi-illumination. A direct connection between the neo-arteriole and a
venule is present.
Online Video 3.12: Real-time video microscopy sequence of a native EDL
microvasculature showing an increase in RBC velocity and supply rate in response to a
local hyperoxia challenge. The video sequence displays the identical field of interest
during hyperoxia (12% O2) and 120 seconds after converting to hypoxia (2% O2).
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